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A thorough understanding of drug-target relationships is essential in preclinical
and clinical translation studies. However, there is a gap of knowledge in the quan-
titative understanding of dose-response relationships at the target site. To fill that
gap, a particularly promising approach is quantitative systems pharmacology (QSP)
where, mechanistic and hence comprehensive models of dose-effect relationships
are used to guide the design of clinical and translational studies.
In this thesis, I present for the first time a QSP approach for a therapeutic protein, in-
terferon alpha (IFN-α), by coupling physiologically based pharmacokinetic (PBPK)
models at the whole-body level with intracellular models of signal transduction in
the liver. Whole-body distribution models of an injected dose of IFN-α calibrated to
quantitative measurements of the plasma concentration are established for humans
and mice. They are then coupled to mechanistic intracellular models of the triggered
JAK/STAT signalling cascade that describes the dynamic response in the expression
of the antiviral mRNAc of IRF9 for humans and antiviral protein Mx2 for mice on
the cellular scale. By doing so, I am able to establish the quantitative dose-effect re-
lationship of the injected IFN-α dose to the responding interferon stimulated genes
(ISGs) triggered at the target site, the liver.
The established multi-scale physiologically based pharmacokinetic/pharmacody-
namic (PBPK/PD) model of human predict a reduced response of IRF9 mRNAc
to IFN-α under physiological in vivo conditions as compared to in vitro. The QSP
model also elicits the large impact of the IFN-receptors on the clearance of IFN-α in
the liver, thus, not only providing mechanistic insights into the pharmacodynamic
(PD) response but also elucidating the influence of receptor variability on the re-
sponse.
Although IFN-α is specifically used in humans, in preclinical studies, it is also tested
in mice for understanding the medical impact of IFN-α for other diseases. Therefore,
I elaborate an analogous QSP model for the IFN-α response in mice to illustrate pos-
sibilities of model-based cross species translation. Like the human model, a whole
body PBPK/PD mouse model was also established to follow the response of antivi-
ral protein Mx2. The model clarified the differences between the pharmacokinetics
of human and murine IFN-α injection in mice and will support quantitative cross-
species extrapolation in the future.
Finally, as heterogeneity in ISGs reflects inter-cell variability in response to IFN-α, I
study the impact of sources of this heterogeneity by implementing the mechanistic
stochastic model of the JAK/STAT signalling pathway. The model was developed
on the basis of time-resolved flow cytometry data of two ISGs, MxA and IFIT1, in
Huh7.5 cells. The model analysed intrinsic variability in the concentration of the
molecules of the pathway and generated a graded response of MxA and IFIT1 in-
stead of an all-or-none response. Ultimately, the model concludes that the stochas-
ticity in the initiation of the signalling pathway, i.e., at the receptor level, can be
buffered by the system and a more robust response of ISGs, MxA and IFIT1 is in-
duced.
Zusammenfassung
Vernetzung von pharmakokinetischen und intrazellula¨ren Modellen der
Interferonverabreichung und der darauffolgenden induzierten Antwort
by Priyata KALRA
Ein umfassendes Versta¨ndnis der Wechselwirkung zwischen einem Arzneimittel
und seinem Zielmoleku¨l bildet die Grundlage pra¨klinischer Studien im Rahmen der
Translationsmedizin. Aufgrund der Systemdynamik des menschlichen Ko¨rpers ist
eine quantitative Beschreibung zwischen verabreichter Dosis und Wirkung jedoch
erschwert. Die quantitative Systempharmakologie (QSP) setzt an diesem Punkt an
und beschreibt die Verteilung eines Arzneimittels im Ko¨rper sowie seine Wirkweise
am Zielort mithilfe komplexer mechanistischer Modelle.
In der vorliegenden Arbeit wird zum ersten Mal ein QSP-Ansatz fu¨r ein ther-
apeutisches Protein - IFN-α - entwickelt. Hierfu¨r wird ein Physiologie-basiertes
pharmakokinetisches Modell (PBPK-Modelle) der Ganzko¨rperverteilung von IFN-
α mit einem intrazellula¨ren Modell der Signaltransduktion in der Leber gekoppelt.
Das Modell der Ganzko¨rperverteilung wird fu¨r Mensch und Maus getrennt erstellt
und mit quantitativen Messungen der Plasmakonzentration von IFNa nach Injektion
kalibriert. Anschließend wird das Ganzko¨rpermodell an ein intrazellula¨res Mod-
ell des JAK/STAT-Signalwegs gekoppelt, das die dynamische Antwort einer antivi-
ralen RNA - IRF9 im Mensch und Mx2 in der Maus – auf zellula¨rer Ebene beschreibt.
Somit la¨sst sich die Expression Interferon-stimulierter Gene (ISGs) am Zielort der
Leber in Abha¨ngigkeit der verabreichten IFN-α-Dosis quantitativ beschreiben.
Modellsimulationen des menschlichen QSP-Modells sagen vorher, dass phys-
iologische Bedingungen die Antwort der IRF9 mRNAc auf IFN-α-Stimulation im
Vergleich zu in vitro-Bedingungen reduzieren. Weitere Analysen des Modells legen
außerdem einen hohen Einfluss der IFN-Rezeptordichte auf die Clearance in der
Leber dar. Dementsprechend ermo¨glicht das QSP-Modell nicht nur mechanistische
Einsichten in die pharmakodynamische Antwort, sondern zeigt auch den Einfluss
der Rezeptorvariabilita¨t auf die physiologische Antwort auf.
Wenngleich IFN-α in erster Linie als Arzneimittel fu¨r den Menschen dient, wird
sein Potential zur Behandlung weiterer Krankheiten in pra¨klinischen Studien an
Ma¨usen untersucht. Um Forschungsergebnisse, die an Ma¨usen erhoben wurden,
auf den Menschen zu u¨bertragen, wird im zweiten Teil der vorliegenden Arbeit
ein QSP-Modell fu¨r die Maus erarbeitet. Dem murinen QSP-Modell unterliegt im
Wesentlichen die Struktur des humanen Modells; allerdings dient im murinen Mod-
ell die Expression des antiviralen Proteins Mx2 als Surrogat fu¨r die IFN-α-Antwort.
Mithilfe des murinen QSP-Modells lassen sich Unterschiede zwischen der Phar-
makokinetik in Mensch und Maus aufkla¨ren und somit quantitative Studien an Ma¨usen
auf den Menschen u¨bertragen.
Heterogene Expression von ISGs spiegelt die interzellula¨re Variabilita¨t der IFN-
α-Antwort wider. Der dritte Teil der vorliegenden Arbeit untersucht die Ursache
dieser Heterogenita¨t anhand eines stochastischen Modells des JAK/STAT-Signalwegs.
Das Modell beruht auf zeitaufgelo¨sten Daten zweier ISGs, MxA und IFIT1, die mit
Durchflusszytometrie in Huh7.5 Zellen erhoben wurden. Aufgrund der intrinsis-
chen Variabilita¨t in der Konzentration der Signalwegmoleku¨le legt das Modell statt
einer Alles-oder-nichts-Reaktion eine graduelle Antwort von MxA und IFIT1 auf
IFN-α-Stimulierung nahe. Im Gegensatz dazu kann das System die Stochastizita¨t
auf Rezeptorebene, die zu Fluktuationen in der Signalwegaktivierung fu¨hrt, puffern
und ermo¨glicht somit eine robuste Antwort der ISGs MxA und IFIT1.
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1Chapter 1
Introduction
1.1 Chapter Summary
The work in this thesis describes the study of Interferon-α (IFN-α) as a therapeutic
protein using a combination of modelling, experimental approaches and the grow-
ing domain of quantitative systems pharmacology. The work explores not only IFN-
α drug distribution in the body, but also the effects on the downstream JAK/STAT
signalling pathway and the intricacies of the response at the target site. From a
methodological point of view, the thesis tackles the integration of theoretical and
modelling frameworks from two different domains: Systems pharmacology and
systems biology. In summary, this thesis describes the establishment of molecular
pathway models at the cellular level and physiology-based pharmacokinetic (PBPK)
models at organism scale by using experimental data from both scales. These mod-
els are later combined to quantify the available therapeutic dose at the liver and the
triggered cellular response for the same.
In this chapter, I provide a brief introduction to various biological aspects of
IFN-α as a therapeutic, as well as an introduction to the methods, focusing on the
modelling approaches. This chapter covers the elementary background that will
inform the discussions throughout the thesis.
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1.2 General introduction to cytokines
Cytokines
(noun)
Etymology: κύτος meaning cavity or cell and κίνησις meaning movement.
Proposed by Cohen et al. in 1974 [1]
1. The cytokine protein super-family encompasses immunological proteins that
regulate a wide range of biological functions, including immunity, hematopoiesis,
inflammation & proliferation and repair. They are primarily large molecules (around
80 kDa in size).
In the last decades, much light has been thrown on the role of various cytokines
in our body. They are thereby aptly called immunomodulators, due to their ability
regulate the defence mechanisms in our body. In the current times, cytokine research
is being actively developed by biotechnology and pharmaceutical companies to aid
in the treatment and prevention of various diseases.
1.3 Medical relevance of cytokines
Cytokines are secreted by a large variety of cells and function in both paracrine and
autocrine fashion. They have been successfully utilised to treat immune-mediated
inflammatory diseases (IMID), chronic obstructive pulmonary disease (COPD), asthma,
cancer, multiple sclerosis (MS), and various viral infections (HCV, HIV, Influenza,
etc.) [2]. Some examples of well-studied cytokines include interleukins (IL1-10), tu-
mor necrosis factors (TNF-α, TNF-β), granulocyte-colony stimulating factor (G-CSF)
and interferons (IFN-α, IFN-β, IFN-λ). For atleast two decades, these molecules
have been probed as potential therapeutics for various infections or immunomod-
ulatory diseases, leading to a number of successful clinical therapies involving cy-
tokine modulation. For example, TNF-α blocking agents are used in rheumatic dis-
eases and asthma [3]–[5], IFNs are used as antivirals, ILs are extremely efficient in
few cancer therapies [6] and IFN-β is used for MS therapy [7].
To be able to use immunomodulators to target diseases showing inadequate im-
mune response is an exciting possibility. Nevertheless, their full potential against
diseases is an ongoing investigation. Hence, many endeavours are pursued on un-
derstanding efficacy, specificity and toxicity of cytokines. These have led to two
very different strategies towards using cytokines as therapeutics. In several treat-
ment strategies, the purified recombinant cytokine is administered, e.g., interferon
in viral diseases. Alternatively, therapeutic approaches can also target endogenously
up-regulated cytokines as in the case of cancer.
Due to the large size of cytokines and their ability to be therapeutic proteins, they
are classified as drugs and are commonly addressed as biologics or biopharmaceuticals
in the pharmaceutical industry. These can be produced via protein engineering (e.g.
recombinant technology) and are optimised copies of the endogenous proteins e.g.,
pegylated-interferon alpha 2b (peg-IFN-α). Cytokines usually bind to a very specific
receptor, especially when applied in cancer therapy and therefore, have lesser side
effects compared to chemotherapy. In the next section, I shall discuss in detail, the
type I interferons- a large subclass of cytokines.
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1.4 The biology of type I interferons
IFNs are are polypeptides that influence the development of humoral and cell-based
immune responses. They were discovered in 1957, as proteins which interfere viral
replication [8]. They are known to exhibit multiple biological properties such as
antiviral, anti-proliferative and immunomodulatory effects [9], [10]. Once produced,
they bind to IFN-α/β receptors, which induce the cell’s intrinsic antimicrobial state
leading to controlled transcription of various interferon stimulated genes (ISGs).
Type-I IFNs constitutes the largest class of IFNs. In humans, this class comprises
IFN-α, IFN-β, IFN-ω, IFN-κ, IFN-e, IFN-ζ and IFN-δ whose genes are located on
chromosome 9 [11], [12]. All of these genes, except for IFN-e, are transcribed towards
the direction of the telomere in the chromosome (in plus direction). Type I IFNs
exhibit high homology in their sequence and protein structure (75-99%) [13]. Also,
all of them bind to the ubiquitously expressed IFN-α receptors (IFNAR) but have
distinct biological activities.
IFN-α has multiple subtypes which are expressed by 14 genes, two of which are
pseudogenes. The remaining 12 subtypes share a homology of ¿ 75% . In vitro studies
have shown that the antiviral potential (measured in U/mg of protein) amongst IFN-α
subtypes can vary upto 100 fold while the anti-proliferative response varies around
20 fold, hence, establishing no correlations among the activities [14]–[16].
Although various subspecies of IFN-α are produced for therapeutic interven-
tions, IFN-α2 (subspecies 2a and 2b) is predominantly used [17], [18]. However,
varied levels of responsiveness to IFN-α2 have been observed in different cell lines,
e.g., ∼ difference of antiviral potency of IFN-α2 on human fibrosarcoma cell lines to
human hepatoma cell lines [19]–[21]. Another study by Wolber et al. [22] elaborates
upon the strong variance of response to IFN-α2 treatment in different human hep-
atic cell lines [22]. Because of this difference, which is presumably associated with
receptor recognition and kinetics, IFN-α2 has been subject to pre-clinical and clinical
studies.
Having briefly introduced the class of type I interferons, I will now focus on
IFN-α, the biologic (i.e., the biological compound) of this thesis.
1.5 IFN-α as immunotherapeutic protein
Over the years, proteins have been gaining a lot of attention as a therapeutic to treat
various diseases. All three classes of IFNs ( α, β, λ) have therapeutic scopes as antivi-
rals or anti-proliferatives and/or immunomodulators. Since 20 years, particularly
IFN-α has been approved by the FDA to be clinically effective as an antiviral and
antineoplastic therapeutic protein. However therapeutic proteins are traditionally
administered intravenously, which proves to be both inconvenient and expensive
for the patients. This shortcoming has led to evolving the chemical structure of the
drug compound from being a native protein (eg. IFN-α, IFN-β) to a biotherapeutic
version, e.g., using conjugates of polyehtylene glycol (PEG) (PEG-IFN-α, RBV-IFN-α)
or albumin (albIFN) to increase the half-life of the compound in the blood plasma.
These changes in the chemical structure of the proteins as drugs have introduced
new challenges in the understanding of their metabolism and elimination from the
body. Due to their vast applications in diseases, there are newly engineered variants
of IFN-α that are often being introduced in the pharmaceutical market.
To design effective dosing schedules (toxicology studies, best efficacy and safety
formulations of the drug), an understanding of the pharmacokinetics is of paramount
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importance. Hence, in the next section, I shall discuss the present-day knowledge of
the pharmacology and pharmacokinetics of IFN-α.
1.5.1 Pharmacology of IFN-α
Studies have shown that IFN-α is secreted by fibroblasts, T cells, macrophages, plas-
macytoid monocytes, natural killer cells (NK) and dendritic cells (DCs) [23]–[25].
The current working hypothesis is that the ”professional” IFN-α secreting cells are
the CD4+CD11c-type 2 precursors (pDC2s) [26], [27]. DCs are important producers
of IFN-α, and since DCs are the part of the local immune responses, this implies in-
direct involvement of IFN-α in the regulation of local immune responses [28]. This
highlights an important aspect of IFN biology: The IFN-α therapy dose and adminis-
tration schedule determine the regulation of patients innate and adaptive immunity,
consequently, the systemic administration of IFN-α at low-doses leads to priming
of the immune response and governs the induction of interferon stimulated genes
(ISGs) [29]–[31]. It has observed that a low-dose IFN-α treatment in patients resem-
bles the endogenous response of IFN-α [32]. High doses, on the other hand, are
poorly tolerated by the patients [33]. Additionally, undesirable side effects have
been seen in patients injected with pure IFN-α, some of which are nausea, anorexia,
psychomotor slowing, bone marrow depression, hair loss and fatigue.
The choice of dosage and regimes are devised and optimised by pharmacokinetic
(PK) studies where the movement of the drug through the body is evaluated. Once
approved, the doses are tested with clinical trials. To gain insights into the effect
of the body on the drug, the drugs’ absorption, distribution, metabolism, and elimination
(ADME) properties are required. The ADME parameters are quantified descriptors
of the drug. They provide information on the (A)bsorption of the drug in organs and
tissues from the plasma, the (D)istribution at the site of action of the drug and the
mechanism of metabolism and elimination (ME) or clearance (such as by urine) with
systemic distribution of the drug.
In the 1970s - 1980s, several fundamental pharmacokinetic studies were per-
formed for IFN-α. In the following subsection, I review the studies that led to a
coherent understanding of the IFN-α PK.
Fundamental PK of IFN-α
Several pharmacokinetic and tissue distribution studies with different doses of IFN-
α have been performed on rats [34]–[37], mice [38]–[42], rabbits [41], [43], [44] and
monkeys [36], [41], [45]. Additionally, some pharmacokinetic studies have also been
carried out on humans. However, no work has been reported on the investigation
of the tissue distribution of recombinant (r)IFN-α in humans. Currently, (r)IFN-α-
2a and -2b are manufactured by recombinant DNA technology using a genetically
engineered Escherichia coli bacterium (approximate molecular weight (MW): 20,000
daltons).
1. Absorption
As stated previously, oral doses of IFN-α were found to be poorly absorbed in
the gastro-intestinal tract (GI) due to its natural proteolytic digestion . Thus,
other administration sites were explored and measures for IFN-α, such as, in-
travenous (i.v.), subcutaneous (s.c.), and intramuscular (i.m.) absorption of
IFN-α was measured [46]. i.v., i.m. and s.c. doses for rIFN-α were accessed in
various studies [47]–[52] and the systemic absorption for all other sites were
remarkably good. In the case of IFN-α dose administered IV, the maximum
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plasma concentrations (Cmax) of IFN-α occur around 0.6-1 hour (Tmax) after
administration, while for IM and SC the Tmax is 7-10 hours, along with rela-
tively low detectable rIFN-α in the plasma [47], [50]–[52]. Type I interferons are
poorly absorbed by gastrointestinal tracts and hence work best as parenteral
(a dose which bypasses the GI tract, such as an injection) dose. The general
routes of IFN-α administration are: intravenous infusion and subcutaneous in-
jections. Usually the therapies have a schedule and range from a period of 6
months to 2 years.
2. Distribution and metabolism
Different dosage regimes and frequencies have been tested for rIFN-α, rang-
ing from daily to intermittent administration. It is noted that the plasma con-
centration rapidly declines in a bi-exponential manner after IV administration
[47]–[52]. rIFN-α plasma concentrations can be measured for 24 hours after
the injection to follow the bi-exponential behaviour. The volume of distribu-
tion ranges from 12 to 40L in different studies stated above.
3. Elimination
Terminal elimination half-life of rIFN-α range from 4 to 16 hours depending
on the routes of administration, the fastest being IV administration. There has
been no work reported on the catabolism of rIFN-α in humans. The work per-
formed thus far on animal models suggests that major clearance/catabolism
takes place in the kidney and the liver [39], [40], [42].
In a review by Bocci [42], IFN-α half-life values have a considerable variability.
This can be partially explained because of the strength of various doses, i.e., a larger
dose has a longer half-life than a smaller one. Moreover, past work [53], [54] has
shown that repetitive daily doses tend not to differ in effect, which suggests that
saturation and down-regulation of cell receptors play a role in this phenomenon.
There is a strong relationship between the pharmacokinetics-pharmacodynamics
(PK/PD) and ADME processes of IFN-α, where the ADME properties influence
the observed PK. Properties like molecular mass, charge, glycosylation and protein
modification, size and target-mediated binding can heavily influence the ADME
profile of IFN-α. One particularly important example in this regard is that target
binding (at the receptors) has a profound effect on IFN-α ADME. This phenomenon
is known as target-mediated drug disposition (TMDD) and has been successfully
modelled to account for various IFN-α PK distributions [55]–[57]. The TMDD is si-
multaneously linked to the IFN-α signal transaction, as the activation of the receptors
in turn activates various genes that are a nexus for the innate-to-adaptive transition
of immune response.
1.5.2 Mechanism of action: IFN-α signalling
As shown in the following Figure 1.1, the ligand binding induces the JAK/STAT sig-
nalling pathway. Upon ligand binding, the receptors move to closer proximity and
lead to auto/trans phosphorylation of Janus kinase (JAK). The phosphorylated form
of JAK is the activated form and it induces the activation of the downstream sig-
nalling pathway. Once JAKs are activated, they phosphorylate the members of sig-
nal transducers and activators of transcription (STAT) family [58], [59]. The STAT1
and STAT2 bind to the src homology domain (SH2) of the receptors where they are
activated individually and dimerise, either independently or with each other. The
activated dimer either independently translocates to the nucleus or interacts with
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Interferon regulatory factor 9 (IRF9) to form the interferon-stimulated gene factor 3
(ISGF3) complex and translocates in the nucleus [60]. In the nucleus, ISGF3 binds
to various palindromic sequences called IFN-stimulated response elements (ISREs)
which lead to expression of several hundred IFN-stimulated genes (ISGs). Of these,
some ISGs are now used as gold-standard genomic biomarkers for example, IFIT1
(a.k.a. ISG56) for glioblastoma [61], ISG15 for tumor detection [62], [63] and Aicardi-
Goutie`res syndrome (AGS) [64], [65]. As the response ISGs, IFIT1 (ISG56) and MxA
are commonly used biomarker to follow IFN treatment response along with under-
standing the antiviral activity of IFN against various viruses like Paramyxoviridae,
Orthomyxoviridae and many others [66]–[72]. Many of the ISGs activated as the
response to IFN are classified as cell restriction factors (CRF), responsible for the
establishment of an antiviral state [73].
At every step, the JAK/STAT pathway is fine-tuned by many regulatory mecha-
nisms to restrain the amplitude and duration of the signal. These negative regulators
control the cytokine effects and suppress the activity associated with disease state.
There are three key regulatory modules, two of which act on the level of receptors
and one on the level of gene transcription. On the receptor level there are many
phosphotyrosine phosphatases (PTPs) which dephosphorylate the JAKs [74]. The
second module on the receptor level is the suppressor of cytokine signalling (SOCS)
[75] proteins, which in turn act as negative regulators in the circuit. The third module
involves the protein inhibitors of activated STATs (PIAS) which conceal STAT-driven
gene transcription by various mechanisms in the nucleus.
Presumably, because IFN-α regulates the transcription of numerous genes, the
effect of IFN-α treatment is described as pleomorphic. In addition, the regulation of
various cytokines adds to the complexity in identifying the IFN-α-specific response.
Furthermore, the JAK/STAT pathway is used by many other signalling molecules
and these complexities add to variability in inter-cell response of a population of
cells.
A part of heterogeneity of IFN-α pleomorphic response difference in inter-cell
of a population can be explained by i) cell-extrinsic factors (like the different viral
infections) or ii) cell-intrinsic noise, which can be understood by exploring the cell
to cell response variability to the IFN-α treatment.
1.5.3 The noise in the interferon signalling pathway
At the single cell level, the IFN response system is dedicated to processing and trans-
ducing information about the environment provided by the extracellular immune
stimuli ( e.g., viruses). The task of relaying this information into the cell becomes
challenging when the normal cellular molecular processes also add to the determi-
nation of the response. These processes include diffusion, chemical reaction (like
association, dissociation and conversion of molecules), range of molecular numbers
of involved molecules (the infrequency of molecular events because of small num-
bers of molecules) and gene expression (variation due to mutations, from cell-cycle
progression or random environmental differences). We use the term ”noise” to refer
to inter-cellular response variation to IFN-α stimulus regardless of source, within
a supposedly identical cell population [76]. Noise can be divided into two compo-
nents: intrinsic noise and extrinsic noise. Intrinsic noise is a result of randomness in
the molecular processes, e.g., in the process of gene expression, the promoter bind-
ing to translation of mRNA to the protein synthesis and degradation will manifest
the intrinsic noise [77]. Extrinsic noise, on the other hand, is caused by cell to cell
variation or by variations in the cell components, e.g., differences due to the local
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FIGURE 1.1: IFN binds to the heterodimeric complex of the IFNAR1
and IFNAR2 to activate the signal transduction from the JAK/STAT
pathway. STAT1 and STAT2 are phosphorylated in the cytoplasm
where they form a heterodimer (dimer STAT). This dimer interacts
with IRF9 to form the ISGF3 complex which translocates in the nu-
cleus and binds to the ISREs to transcribe various ISGs. This leads
to the production of IRF9 as positive feedback and SOCS1 as nega-
tive feedback. PTPs act on the receptor level and dephosphorylate
the JAKs to lead to another negative feedback, which are called SHPs
(SH2 domain-containing protein tyrosine phosphatase). The nuclear
negative feedback is exerted by PIAS [58], [59], [73].
environment in the cells of the population or differences in the concentration or ac-
tivity of any of the molecules that effect the gene expression [78]. Recently, it has
been shown that the information transduced in cellular signalling pathways is af-
fected by noise [79], but little is known about its effect on the signalling response
[80]. Noise in cellular signalling pathways is conceptually different from the noise
resulting from stochastic fluctuations of low-abundance genetic regulators. In cellu-
lar signalling pathways, noise can consist of low levels of enzyme activity through
random transient interactions of receptors, binding of ligands to receptors in non-
functional complexes, and background interactions along the pathway [80].
Noise plays an important role in IFN responses. It has been observed in popula-
tions of nearly identical cells, that not all cells that are infected by a virus or that not
all cells stimulated by IFN express ISGs [81]–[84]. In all these cases, the suggested
mechanisms behind this heterogeneity have been related to stochastic events along
the JAK/STAT signalling pathway.
However, since the initiation of IFN-α signalling is initiated by highly specific
ligand-receptor interaction, part of the heterogeneity can be unwound by under-
standing the interaction between IFN-α and IFNARs. The stochastic induction of
inter-cellular IFN-α response leads to large heterogeneity in the response at onset
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of the infection, consequentially leading to variability in the bound receptors which
transmit this variability further in the induced JAK/STAT pathway. By understand-
ing what happens at the level of the interaction of IFN-α with IFNARs, we can get
insights on the impact of heterogeneity on autocrine and paracrine signalling of IFN-
α in a collection of cell populations [85].
1.5.4 IFN-α receptors
A substantial deal of non-redundancy in the JAK/STAT pathway activation is driven
by the IFNARs which have functional plasticity for all type I IFN ligands. Thus, sig-
nal activation is refined by the subtle interplay of the affinity of the receptors to the
different ligands, the stability of the ternary complex and the number of receptors
presented on the cell’s surface [86]–[88]. The receptors have two subunits which
come together to form a heterodimer: IFNAR1 and IFNAR2, which belong to the
family of class II helical cytokine receptors [89]. When IFNAR1 and IFNAR2 interact
with the ligand they form a ternary complex. The two receptors differ substantially
in their binding affinities towards different IFNs. IFNAR1 is a low affinity receptor
with binding affinity in micromolar range whereas IFNAR2 is a high affinity recep-
tor with binding affinity in nanomolar range [90], [91]. Activation of both receptors
is necessary to activate the downstream signalling. The current hypothesis on ligand
receptor binding is that IFN-α binds to IFNAR2 which then interacts with IFNAR1
to form the heterodimeric complex. The stability of this complex is determined by
the affinity of the receptors to the ligand. The receptor distribution and abundancy
per cell also varies depending on the cell-type. For example, there are 3300 bind-
ing sites/cell for AU937 (human monocytoid cells) or approximately 2500 binding
sites/cell for MBDK bovine cells and 12700 binding sites/cell for Daudi lymphoblas-
toids [92], [93].
Near a cell population, the secreted IFN-α diffuses and binds to the IFNARs
which activate the signalling. Therefore, this step is one major component that in-
duces the noise in the signalling pathway in individual cells. The noise can propagate
or deplete depending on the threshold fraction of bound and unbound receptors per
cell, their affinity to the temporally fluctuating presence of IFN-α near the cell surface
area and their spatial distribution on the cell surface.
Once IFN-α activates the JAK/STAT pathway, the effects are very heterogenous,
even within cell-type. For example, in liver, the JAK/STAT pathway can promote
liver damage or provide hepato-protection. The next section discusses the immuno-
biology of IFN-α in the liver and the hepatocytes.
1.6 The role of liver and hepatocytes in interferon signalling
The liver serves as a buffer between the gut and systemic circulation: 80% of the hep-
atic blood is delivered from the gut via the portal vein [94]. The venous blood in the
hepatic environment mixes with oxygen-laden blood of the artery at the hepatic si-
nusoids, through plates of hepatocytes. The sinusoids have three non-paranchymal
resident populations: Specialised liver sinusoidal endothelial cells (LSEC) that line
the sinusoids, the liver resident macrophages (known as Kupffer cells (KC)) in the
sinusoids, and hepatic stellate cells (HSCs) found in the space of Disse in the liver mi-
croanatomy [95], as seen in Figure 1.2. It is the richest source of of the gamma/delta
T cell subpopulation [96].
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FIGURE 1.2: Liver anatomy: The hepatic arteriole and the portal
venule circulate blood into the liver sinusiodal space, which is carried
away by the central vein. The liver sinusoidal space is lined with non-
parenchymal cells: Kupffer cells (liver macrophage), LSEC (endothe-
lial cells) and Stellate cells (source of extracellular matrix proteins).
The plasma components from the blood seep through the LSECs and
the space of Disse (the interstitial space between the LSECs and hep-
atocytes) towards hepatocytes. The hepatocytes are organised in the
form of plates.
The hepatic micro-environment is also influenced by dietary fats and carbohy-
drates in the hepatic blood supply. The carbohydrates are taken up by the hepa-
tocytes. Hepatocytes make up 70-85% of the liver volume [97]. They are pivotal
for metabolism, protein synthesis, and detoxification. Hepatocytes take up carbohy-
drates from the hepatic micro-environment, which are provided by the blood supply.
Additionally, hepatocytes also receive pathogenic and inflammatory signals, and re-
spond by releasing acute phase proteins in the blood [98]. They also contribute to T
cell activation [99]. Hepatocytes are well studied for their innate immune response
via the expression of a variety of pattern recognition receptors for major pathogens,
such as, HCV [100]. Therefore, hepatocytes have a vital role in producing innate
immunity proteins and controlling bacterial infection and chronic liver disease, es-
pecially cirrhosis. As mentioned in subsection 1.5.1, the liver is the predominant site
for elimination of IFN-α. Consequently, hepatocytes are a key element of study for
translational experiments, to understand the interaction of immunity with bacterial
infections and how theses are combated with the production of ISGs.
In the above sections I have covered the biological aspects of IFN-α as a protein
therapeutic and the importance of the liver and hepatocytes in the generation of
immune response via JAK/STAT pathway. In the following sections, I will introduce
the concepts of mathematical modelling applied in this work in order to understand
the mechanistic details of the JAK/STAT pathway activated by IFN-α.
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1.7 Mathematical models in biology
At the turn of 21st century, modelling was vastly accepted as a tool for analysing
and explaining biological systems and has since become an integral part of drug dis-
covery pipelines. However, the reliability and the explanatory power of the models
depends on the chosen modelling approaches and level of details that are included in
the model. With respect to quantitative biology and pharmacology, modelling helps
to validate hypotheses which are supported by experimental data. In addition, it has
lent its hand to experimental predictions and contributing positively towards good
experimental/ clinical study-design. Over time, impressive cases of models have
been published which have provided fresh perspective towards biological/clinical
studies due to the holistic approach of such models.
Existing modelling techniques employed in biology can be grouped in various
classes. In the following sections, I will cover two approaches commonly used in
this work: Deterministic modelling applied in systems biology and physiologically-
based pharmacokinetic (PBPK) modelling utilised in systems pharmacology.
1.7.1 Quantitative models for signalling dynamics
On one hand, with the advent of high-throughput technology and the associated cost
reduction (microarrays and flow cytometry etc.), has led to the literature filled with
what it’s known as a ”data iceberg”. On the other, the signalling pathways are com-
plex and the effect of single players is not easy to understand without the surround-
ing context. Computational modelling allows the integration of various datasets
(the ”data iceberg”) to help understand the big picture. This kind of systems think-
ing is of increasing importance in biology, because of the high inter-connectivity and
high interdependence of of molecules, at cell-level, following to tissue and finally to
body level. Computational modelling is a tool through which we can make sense of
such quantitative data. On the cellular scale, one can have simple ordinary differ-
ential equations (ODEs) models, stochastic (SDEs) models and spatial models. The
ODEs and SDE represent change of species over time ( ∂[Species]∂t ), while the partial
differential equations (PDE) represent the change of species in geometric state space
( ∂[Species]∂x ).
ODE-based models are generally used to describe population dynamics and are
often termed as deterministic models. In deterministic systems, no randomness is
involved in calculating the interaction of existing molecules with future molecules,
thus, when simulated multiple times, such models always produce the same result
when triggered [101]–[104]. Experimentally, such dynamics can be measured by
techniques like western immuno-blots, PCR or microarray to detect concentration
changes over time for the particular protein or mRNAc, and the model is therefore
based on these quantitative experimental datasets. In reality, the repeated measure-
ments of such experiments result to time-course dynamics which look similar but
have slight variations in them. These variations are largely driven by stochastic pro-
cesses which are subject to random external perturbations, hence in every repeat of
the experimental procedure, it is impossible to yield the exact same result. These
random effects occur at the microscopic scale where the stochastic motion of the
molecules are characterised by two properties: i) their random occurrence in time
and ii) no correlation between successive interaction. The consequences of such ran-
dom processes can be investigated and analysed by the development of SDE-based
models [101], [105], [106].
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In the case of dynamical deterministic modelling of cellular signal transduction,
systems biology has made considerable advances [107]–[109]. For the JAK/STAT
pathway activated by IFN-α, the quantitative mechanistic models predict the be-
haviour of the system over time and track the dynamical changes for a set of pro-
teins in the pathway, helping explain the complexity, dynamics and specificity of
the activated response. The first computational model to describe the JAK/STAT
pathway via Epo signalling was established in the work of Swameye et al. [110]
where the model revealed that the pathway is non-linear and that the nucleus plays
a major role in regulating STAT5. This model has been used as the base model for
further works and has been expanded by the inclusion of more complex molecular
events of cytoplasmic shuttling, along with time series data [111]–[113]. In parallel,
the first ODE-based model of activation of the JAK/STAT pathway by IFN-γ was
developed by Yamada et al. [114], where they analysed the control ofthe feedback
by the SOCS1 molecule on the pathway. Other dynamic mathematical modelling
describing the pathway in the context of interferon were done by Smeija et al. [115]
and Maiwald et al. [116]. Finally, Rybin´ski et al. [117] have analysed various models
of the JAK/STAT receptor activation and laid emphasis on model selection methods
for the same, when the model is evaluated and analysed without sufficient data. In
the studies by Sharma et al., Papin et al. and Heinrich et al. [118]–[120] large scale
JAK/STAT signalling models including the feedback on the pathway were recon-
structed and analysed for descriptive insight on the fundamental system properties
of the pathway.
Nevertheless, all the deterministic efforts lack an exhaustive and systematic anal-
ysis of the influence of the randomness introduced by stochastic fluctuations in the
molecular reactions among the molecules involved in the pathway. Experimentally,
the individual mechanisms behind the heterogeneity in isogenic cell populations
have been related to stochastic events in the JAK/STAT pathway responsible for elic-
iting the antiviral response have been well documented [81], [82], [84], [87], [121].
Development of stochastic counterparts of these using modelling still remains an
open topic [122]. However, there have been some endeavours for stochastic models
for JAK/STAT pathway, where the pathway is activated by different IFN types. For
example, Auguilera et al. [123] studied the stochastic model of JAK/STAT pathway
response to IFN-β and analysed the control of positive and negative feedback on the
bistable response of IRF7. Zhang et al. [124] developed a small model of the IFN-β
induced activation of IRF7 and ISG56 response to the virus and analysed the con-
trol of the negative feedback of ISG56 in the stochastic expression of IFN-β. Finally,
a recent study by Czerkies et al. [125] has analysed the stochastic effect of IFN-β
pre-stimulation on responses to poly(I:C) which replicates the viral stimulation.
In conclusion, such systems biology models of the activated JAK/STAT path-
way by IFN-α can offer insights into complex decisions made by this pathway for
immunity. In order to understand the cellular processes that contribute to drug de-
velopment, it is crucial to model the signalling system which includes the sufficient
details of the complexity: The feedback and -forward loops. In the past few years,
systems biology has served as a complementary tool to the preclinical and clinical
drug development pipeline and is slowly finding its way into clinical pharmacology
modelling approaches.
1.7.2 Pharmacokinetic/Pharmacodynamic modelling
In the drug development pipeline, computational models are implemented in the
form of pharmacokinetic and pharmacodynamic (PK/PD) models. These models
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describe the relationship between the body and the drug in complementary ways:
PK how the body processes and clears the drug, whereas the PD describes how the drug
makes the body respond [126]. Only with a PK/PD model is it possible to assess the
clinical significance of differences in PK under various circumstances. With the
growing importance of preclinical understanding of drug discovery processes, em-
pirical PK models and mechanistic PK/PD models [127], [128] can provide strong
insights into clinical outcomes. In many cases, these models are ”minimal” where
two or three-compartment (where the compartments mimic the physiological or-
gans of the body) models are used to describe the distribution profile of the drug
into the organs of the body by using zero, first or second order rates as absorption
rates between the different organs.
In the past, the virus effects on the animals and later humans were measured for
the effect of the virus on the IFN-α PK [129]–[132]. Mathematical models were de-
veloped to analyse IFN-α PK and understand the effects of HCV RNA decay and to
access the effectiveness of the therapy [133]–[135]. On the other hand, classical one-
compartment PK models were developed to describe IFN-α distribution of different
routes of administration, e.g., in a study by Chatelut et al. [136], effect of a subcuta-
neous dose on IFN-α PK was analysed. Similarly, a simple model of absorption and
elimination could describe the pharmacokinetics for subcutaneous doses of pegIFN-
α and ribavarin in HCV-HIV co-infected patients, published by Powers et al. [137].
Jeon et al. [138] developed a one-compartment model with first order elimination
and turnover and a transit compartment to model PKPD of a sustained release of
IFN-α PK and neopterin PD in healthy human volunteers. There have been models
to understand the toxicology and dosing regime of IFN-α on animals because such
studies and their validation serve an important role in pre-clinical assessment [139]–
[141]. For example, a minimal two-compartment PKPD model of IFN-α distribution
in mice was developed in the study by Benson et al. [134]. A two-compartment
receptor-mediated pharmacokinetic model for IFN-β in monkeys was developed by
Mager et al. [55] and by Abraham et al. [142]. Additionally, some models were
developed to describe interspecies scaling of IFN-α doses. Furthermore, it is nec-
essary to rely on PBPK in vitro in vivo extrapolation (IVIVE) or scaling of animal
data to humans in regards to prediction of absorption and clearance of IFN-α doses
[143], [144]. To scale from animal data to humans, the earliest model was developed
by Lave et al. [145] where they used published PK data of IFN-α in animals and
observed underestimation by allometric scaling on the prediction of parameters in
man. Kagan et al. [146] developed two-compartment PKPD models for IFN-α and
IFN-β where they described interspecies scaling of target-mediated drug disposition
(TMDD) of pharmacokinetics for rodents, monkeys and humans. They were able to
conclude that classical allometric scaling performed well in case of type-I interferons
and described the TMDD at the liver.
1.7.3 PBPK methodology
As mentioned in the previous section, PK/PD models do not represent human phys-
iology in detail. PBPK modelling aims for a detailed representation of human or an-
imal physiology at the whole-body level in which prior information available on the
biological system and on the drug are combined together to predict a priori the ex-
pected pharmacokinetics. These models mimic the physiology of an organism. The
anatomical compartments of the PBPK model are coupled to each other via ODEs.
The organs (anatomical compartments) are linked by the circulatory system. These
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compartments replicate the most important organs of the body that contribute to the
drug ADME profile [147]–[149].
Parameters in PBPK models are, on the one hand, based on large-scale collec-
tions of physiological parameters such as organ volumes or blood flows which build
up the physiological database or organism properties for different species such as
mouse, rat, dog or human. On the other hand, physicochemical properties of the
drug such as lipophilicity and molecular weight are used to parametrise the distri-
bution model describing the steady state tissue concentrations as well as the corre-
sponding permeation rates. Hence, even though PBPK models may comprise sev-
eral hundreds of ordinary differential equations, the number of independent model
parameters is usually small (less than 5 per compound in most cases), due to the
large degree of prior physiological information contained in the models. Each organ
in a PBPK model is characterised by an associated blood flow rate, organ volume,
permeability and tissue partition coefficient linked together by arterial and venous
blood compartments ( see Figure 1.3). These parameters are obtained from the liter-
ature.
FIGURE 1.3: Figure adapted from Kuepfer et al. 2016 [144]. The rep-
resentation of a whole body PBPK model containing all the important
organs required to simulate the ADME of a compound. The organs
are linked to the arterial and venous blood compartment with par-
tition coefficients, permeability, blood-flow rates and volumes. The
PBPK models typically consists of building blocks which are either
organism properties or drug compound properties and both of them
can be combined to simulate different drug-dose scenarios.
1.8 Quantitative Systems Pharmacology (QSP)
More recently, QSP has evolved from systems pharmacology where the integration
of two levels of complexity is achieved. On the whole body level, the drug distri-
bution (in the form of ADME profile) is modelled and on the intracellular level, the
biochemical/signalling cascade are included from approaches of systems biology.
Thus, this field aims to have a perspective on the system as a whole, as reviewed
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in the literature [150]–[152]. Hence, multi-scale physiologically based pharmacoki-
netic and pharmacodynamic (PBPK/PD) modelling [144], [153], [154] is advocated
for its holistic approach of modelling towards clinical decision making of a pharma-
ceutical molecule. Furthermore, these models are integrated in animal and human
physiology along with in vitro experiments and allow translation of experimental re-
sults from pre-clinical research to clinical development and contribute to an efficient
design of cost-effective animal studies too.
For the design of QSP models, one has to cautiously consider the granularity of
the model. Granularity is the detail level to which the molecular and pharmacologi-
cal processes are represented and associated such that the model has higher predic-
tive power and flexibility to follow more than one molecule. But inclusion of such
details comes with a penalty, which is the difficulty of building, running, integrating
and maintaining a model with a vast number of molecular species and parameters.
This can be summarised as complexity in the approach of QSP. The sine qua non for
detailed PBPK/PD models is quantitative data on each scale, i.e., molecular, cellular
and organ level (as detailed in the Figure 1.4).
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FIGURE 1.4: The relationship between Pharmacokinetic (PK) ADME
and the immune response to the treatment of a therapeutic protein
can be modelled by combining the mechanistically detailed pathway
described by systems biology (SB) approach with PK modelling, giv-
ing the opportunity to explore the cross-species extrapolation, indi-
vidual inter-variability and dosing regimes through quantitative sys-
tems pharmacology (QSP). Exposure profiles of the PK and the bio-
logical activity induced by it as dose-response relationship describe
the balance between the induced response and the tolerance of the
biological system to a certain biologic. Inter-dependencies on the im-
pact of the biological activity on the PK can lend better insights on
TMDD and ADME profiles. To help infer the inter-dependencies, as-
says can be used to check and infer the established model at various
stages resulting into an iterative cycle for data interpretation and es-
tablishing a clear PK-PD relationship.
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PBPK/PD models help understand translation. As stated earlier, pharmacolog-
ical aspect is focused on human application. The wealth of information that lies in
the data on a molecular scale and in animals is important to give insights into the
early-stage drug discovery, biological implications and in vitro assay design. Such
models help to bridge the understanding of biological, metabolic and physiological
differences on a molecular and animal scales such as cell culture vs in vivo animal
models vs in vivo human conditions. Thus, they characterise the longitudinal and
physiologically varied effects of drug intervention. Hence, building such models re-
quires integration of the scientific network (wet-lab biologists, systems biology mod-
ellers) and drug discovery experts. Such strong collaborations imply standardised
modelling language and quantitative validation sets for model verification.
In the case of biologics, PBPK/PD models are of increasing importance as they
not only help to decide whether the dose regimen should be adjusted accordingly,
but give clear understanding into the biomarker of choice for therapies of immuno-
oncology interest.
1.9 This thesis in context
This thesis is an endeavour to implement the state-of-art quantitative systems phar-
macology (QSP) approach to determine a quantitative understanding of the action
of injected dose of the therapeutic protein, IFN-α. This work combines whole-body
physiologically-based pharmacokinetic models (PBPK) with mechanistic intracellu-
lar signalling models (PD) for humans and mice. The resulting PBPK/PD aids to
analyse the liver response to IFN-α injection.
In chapter 2, I will introduce the data and software used to establish the PBPK/PD
model. I will also elaborate on the single-cell data which laid the basis for the side
project on cell to cell variability with respect to IFN-α response in the hepatic cell
culture. In particular, I will detail the methodology of preparing cellular and PBPK
models for IFN-α in humans and mice. Moreover, I will discuss the current under-
standing and availability of experimental and PK data in the context of IFN-α drug
action and cellular response, respectively. During the course of this dissertation, the
establishment of such models led to collaborative effort on this topic, which will be
discussed in this chapter. I contributed to the experimental design of the experi-
ments produced by our collaborators.
In chapter 3, I will elaborate upon the PBPK/PD model for IFN-α in human where
I describe the establishment and analysis of the model. In this chapter, I further
examine the multi-scale target-mediated drug disposition (TMDD) as the primary
clearance process of IFN-α from blood plasma. Finally, I characterise the quantifiable
differences between in vitro-in vivo situations of IFN-α responses. I simultaneously
investigate the differences in temporal dose-response relationship between IFN-α
and antiviral response of IRF9 mRNAc. I also consider the strength of PBPK models
where large number of compartments (depicting organs) describe the physiology of
the organism and predict the the tissue concentration–time profiles of IFN-α distri-
bution following i.v. administration.
In chapter 4, I will focus on preclinical translation. Mice have been extensively used
in preclinical research as their genes are closely related to that of humans (reviewed
in Emes et al. [155]). Animal studies serve as intermediate step between in vitro and
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in vivo studies. The development of computational models for animals help contex-
tualise the research on them. Thereby, in this chapter, I will elaborate on the set-up
of the whole-body PBPK/PD model for the mouse to simulate the effect of the in-
jected murine IFN-α. I will explore the difference in the plasma concentration profile
(ADME distribution) of murine IFN-α and human IFN-α in mice and its implication
in species-specific response to the aforementioned IFN-α subtypes. Further, as most
tissue distribution studies are conducted on animals, I will compare the simulated
PBPK tissue concentration–time profiles of murine IFN-α distribution following i.v.
administration in mice with the available experimental data.
Chapter 5 is a side-project for this dissertation. The work in this chapter is moti-
vated from the variability in the JAK/STAT pathway response to IFN-α which has
been reported in the literature [85]. The molecules of the signalling pathway have
inherent variability in their endogenous abundance which determines the fate and
strength of the response to the stimuli. Therefore, the work of this chapter describes
the cell to cell variablity in response of the JAK/STAT pathway to the trigger of IFN-
α in human hepatic cell lines (Huh7.5). The chapter encompasses the development
of a mechanistically detailed stochastic model of the JAK/STAT pathway using flow
cytometry data provided by our collaborators as the basis of the model analysis to
aid in understanding the impact of biochemical noise (intrinsic and extrinsic) on the
pathway. The stochastic model described in this chapter is by far the most detailed
stochastic model for the activation of JAK/STAT pathway in response to IFN-α.
As a final note, despite over 70 years of research, relevant new findings are still being
uncovered about surprisingly fundamental aspects of the immune response when
triggered with IFN-α. In general, as a therapeutic protein, IFN-α is outdated with
regards to protection against the global burden of HCV, but it is still an important
therapeutic for other viral infections and for different cancer treatments. Besides,
in the past years, great attention is being brought on the aspect of humane animal
testing in clinical drug discovery pipelines. In the light of this topic, many attempts
are drawn towards the principles of 3Rs (reduction, refinement and replacement)
(reviewed in Ranganatha et al. [156]). In this regards, the computational simulations
can be a method to replace the animal experiments in the future. In the last decades,
mathematical models have expanded to be potential support in biomedical research.
Therefore, it is of increasing importance to implement translational mathematical
models to be able to explore the relationship of drug action to the induced response
of IFN-α in a model organism by implementing QSP approaches.
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Chapter 2
The building blocks of PBPK/PD
modelling: Data and software
2.1 Chapter summary
In the fields of systems biology and pharmacology, an iterative process is now es-
tablished where experimental data is used as a knowledge base to created computa-
tional models. The scope of this work is to deal with models for two species, namely,
human and mice. To be able to establish and analyse multi-scale PBPK/PD models,
quantitative experiments are a must. In this chapter, I will detail the extensive ex-
perimental research which was the basis of the PBPK model development and pre-
diction for humans and mice. For the QSP approach, system biology models serve
complementary to PBPK models. Therefore, I will detail on experimental data used
to establish the two models respectively. I will elaborate the data used to establish
PBPK models where the injected i.v. IFN-α dose in humans and mice were used and
also on the data used to establish systems biology models of JAK/STAT pathway.
The systems biology models are based on data of various molecules in the signal
trasduction pathway obtained in primary human and mouse hepatocytes. Most im-
portantly, I will describe on the experimental data that was a result of collaborations
established during the course of this work and to a great extent drive the fruitfulness
and analysis of this work. This chapter also contains the details of single cell exper-
iments that were performed to implement and validate the mechanistic stochastic
model which is used to analyse the cellular response variability to IFN-α treatment
on human hepatic cell-line.
Furthermore, this chapter covers the software and methods used to establish
whole body models as well as the cellular scale for the respective species. The
methodology which focused on the integration of the two scales is also discussed
such that in the later chapters a clear understanding of the methodology of the es-
tablishment of the models and their results is achieved.
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2.2 Experimental data
This work focuses on the models of humans and mice. For the models developed on
humans, a large amount of experimental data has been procured from the literature.
In the case of the mouse model, the experimental data used was taken from the
literature and data obtained in collaboratory effort. In the following subsections, I
describe the different datasets used for the PBPK/PD model and for the inter-cellular
stochastic model of the JAK/STAT pathway.
2.2.1 Pharmacokinetic blood plasma measurement of IFN-α for humans
Four datasets of IFN-α plasma concentrations were obtained from three publications
for the PBPK modelling. These data were divided into two sets: One dataset was
used for parameter estimation to establish the model and the rest were the basis
of the validation of the established model. The data from the publication Wills et
al. (1984) [50] was used for the model prediction and the remaining two datasets
from Shah et al.(1984) [48] and Radwanski et al(1987) [49] were available for model
validation.
The first pharmacokinetic profile of recombinant leukocyte IFN-α (rIFN-α) was
extracted from Wills et al. (1984) [50]. In this work, a dose of 36 × 106 U rIFN-α
was administered as an intravenous infusion to a group of 6 human subjects for 40
mins. rIFN-α is a water soluble protein with a molecular weight of 19500Da. The
activity of rIFN-α is commonly expressed in terms of units (U) where 1 mg of rIFN-
α protein corresponded to 1.7× 108 U. The publication multiplied the dose with a
factor of 6 to convert it into picograms (pg). This information was used to calculate
the dose in milligrams (mg). The blood plasma concentrations were measured over
a period of 24 hours in this study. This data was retrieved, digitised and converted
into concentrations using a global unit for specific activity of rIFN-α specified in the
publication. This concentration data was used for fitting the human PBPK model.
Two plasma pharmacokinetic profiles of rIFN-α-2 were extracted from Shah et al.
(1984) [48]. A group of seven patients were administered intravenous rIFN-α-2 doses
of 30× 106 U and 60× 106 U over a period of 30 mins. The specific activity of rIFN-
α-2 was taken from the NIH standard. Although the plasma concentration samples
were collected for 48 hours, the samples for a period of 8 hours were available in the
research paper.
The final plasma profile of rIFN-α-2b was taken from Radwanski et al. (1987) [49].
In this study, a group of four healthy volunteers was administered an intravenous
dose of 5× 106 U/m2 body surface area rIFN-α-2b over 30 mins. The reported inter-
feron specific cativity was 2.2× 108 U/mg. The serum concentration was plotted for
a period of 6 hours in this study.
The doses were calculated in mg for all the publications using the formula de-
picted in 2.1
Dose in mg =
Dose in IU
Speci f ic Activity in
IU
mg
(2.1)
The pharmacokinetic data from all the literature were digitised and the concen-
trations were calculated as in 2.2.
Concentration in
µmol
l
=
Concentration in
IU
ml
Molecular Weight × Speci f ic Activity (2.2)
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This concentration data was used to validate the model.
2.2.2 Pharmacokinetic blood plasma measurement of IFN-α for mice
To model the mouse pharmacokinetics, three plasma concentrations of murine IFN-
α (mu-IFN-α) were used in total, out of which two datasets were used for validation.
The first was taken from Bohoslawec [39] where the mice were injected with a bo-
lus intravenous injection of mu-IFN-α (subtype unknown). The dose was 8.7× 105U.
For each measurement time point, 3 mice were killed to yield the average of the data.
mu-IFN-α concentrations were quantified by an antiviral assay and this concentra-
tion data was used in the parameter estimation of the PBPK model.
The second dataset was provided by our collaborator Dr. Mario Ko¨ster1. This
dataset was published in 2010 by Pulverer et al. (2010) [157]. C57BL/6 Mx2-Luc
transgenic mice were injected with an intravenous bolus dose of 5000U mu-IFN-α-4.
Before sacrificing the mice were injected with luciferin so that the Mx2-Luciferace ac-
tivity in the liver could be measured. They were then sacrificed and Mx2-Luciferase
activity was measured by light emission from the organs of the mouse body. De-
tails can be found in the publication [157]. The residual plasma mu-IFN-α-4 in the
serum was measured for 20 mins and the sample concentration was determined by
ELISA. The specific activity of mu-IFN-α-4 was 1.4108 U/mg; the conversion of the
IU to concentrations are described in the aforementioned equations 2.1 and 2.2. This
dataset was used in preliminary analysis as it was for a short-time scale of 20 min-
utes. It has to be noted that Pulverer et al. [157] measured a fraction of less than 10
% of the injected mu-IFN-α 4 dose in the serum and this was scaled to 100% in the
publication.
The third dataset was digitised from Rosztoczy et al. (1986) [158] where an i.v.
bolus dose of 2000 IU/g of mu-IFN-α was injected into male CFP mice with weight
20± 1 gram. The specific activity of mu-IFN-α used in this publication was 1.2× 107
U/mg. Data (an average of a set of six mice) was collected over a time period of 12
hours post injection.
For validation, the first dataset was extracted and digitised from the publication
Kiuchi et al. (1983) [159]. In this work, mu-IFN-α was injected in male CDF1 mice
as i.v. dose of 1× 105 IU/mouse. Plasma volume was estimated as one tenth of the
body weight and serum volume as 50 % of the plasma volume. The specific activity
of the mu-IFN-α used was 3× 10 7 IU/mg. Each data-point was a measurement of
pooled sera of three mice and the measurements were taken for 3 hours.
The second dataset was extracted from Koyanagi et al. (1997) [160]. In this study
an i.v. dose of 10 MIU/kg human IFN-α (hu-IFN-α) was injected in mice. Here, two
measurements were reported: From the light and dark cycles (one measurement
done after the injection at 5 a.m. and the other after the injection at 5 p.m.). The
serum samples were collected at the time points: 0.167, 0.5, 1.0, 2.0, 3.0, and 4.0 hr
post injection, and each data-point represented a mean of six mice.
Further calculations of all the datasets into proper dose of mg/kg and the plasma
concentrations of nmol/ml are described in the Appendix A in Table A.2 and Ap-
pendix C, Table C.1 .
1Department of Gene Regulation and Differentiation, HZI – Helmholtz Centre for Infection Re-
search, Inhoffenstr. 7, 38124, Braunschweig, Germany.
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2.2.3 Human hepatocyte data
The intracellular measurements of the JAK/STAT pathway were used to parame-
terise the intracellular signalling model. The time course data for molecules after
IFN-α stimuli on Huh7.5 were taken from Maiwald et al. (2010) [116] for 0, 1, 2, 3,
4 and 6 hours. Huh7.5 and primary human hepatocytes (PHH) were treated with
500 U/ml of human leukocyte IFN-α and the abundance of the induced intracellu-
lar molecules was measured. These datasets encompass the measurements of pJAK,
pSTAT1, pSTAT2, SOCS and IRF9. The proteins were monitored using quantitative
immunoblotting. The publication also had measurements of wildtype Huh 7.5 cells
and IRF9 over-expressing Huh7.5 for IRF9 mRNAc expression using quantitative
PCR and microarray analysis. Furthermore, dose-response measurements of pJAK,
pSTAT1 and pSTAT2 for the doses 500 U/ml and 1000 U/ml leukocyte IFN-α were
performed on primary human hepatocytes. The specific activity of human leukocyte
IFN-α was 1× 106 U/mg which was then converted to the model units as used by
Maiwald et al. [116], further explained in Appendix A, section A.1.
The second validation dataset was obtained from Bolen et al. (2014) [161], kindly
provided by Christopher R. Bolen , Michael D. Robek and Steven H. Kleinstein from
Yale University. The dataset represented long-term (24 hours) time course data to
support the model prediction A.3. In this work, the measurements were performed
on human Huh 7 and PHH. The cells were treated with 500 U/ml of IFN-α and data
was collected at time points 0.5, 1, 2, 4, 6, 12 and 24 hours post-treatment. Total RNA
was collected and analysed by microarray and quantitative PCR. Huh 7 cells were
treated with 10 U/ml, 100 U/ml, 500 U/ml and 2500 U/ml IFN-α and IRF9 mRNAc
was analysed using RT-qPCR at time points 1, 4, 6, 12 and 24 hours after stimulation.
The third validation dataset was digitised from Jilg et al. (2014) [162]. In this
publication, the Huh7.5 cells and PHH from three donors were used. PHH recieved
the stimulus of 0.21 ng/ml pegylated IFN-α (peg-IFN-α) (equivalent to 6.91 × 10
-6 nmol/ml or 15 U/ml). Huh7.5 were stimulated with 0.43 ng/ml (1.38 × 10-5
nmol/ml or 30 U/ml) (IFN − α). They identified differential effects of (IFN − α)
and IL28B on hepatocytes using transcriptomic microarray and followed the tempo-
ral dynamics of IRF9 gene expression at 4,8 and 24 hour respectively by isolating the
RNA. Gene induction was determined by expression microarrays.
2.2.4 Mice hepatocyte data
Primary mouse hepatocytes (PMH) isolated from transgenic mice were treated with
different doses of mu-IFN-α-4 by our collaboration partner, Dr. Mario Ko¨ster. He
quantified the luciferase activity by measurement of the emitted light intensity of
the luciferin-luciferase reactions for the reporter gene expression (Mx2) [157]. The
response of Mx2-Luc light intensity was measured for mu-IFN-α-4 doses of 1 U/ml,
10 U/ml, 100 U/ml, 500 U/ml, and 2500 U/ml at 18 hours or 24 hours. Two repeats
for doses 5 U/ml and 500 U/ml mu-IFN-α-4 were performed at time points 0, 4,
8, 12, 19, 23, 27, and 34.5 hours. The specific activity of mu-IFN-α-4 was 1.4× 108
U/mg.
2.2.5 Flow cytometry data for stochastic modelling
For the establishment of intracellular stochastic model, the datasets were provided
by our collaborator, Dr. Marco Binder2. The experiments were kindly performed
2Research Group ”Dynamics of early viral infection and the innate antiviral response”, Division
Virus-associated carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
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by Pascal Mutz and Christopher Daechert. Human IFN-α-2a with a specific activ-
ity of 3.91× 10 8 U/mg was used in this study. Human Huh7.5 cells harboured a
bacterial artificial chromosome (BAC) containing destabilised enhanced fused green
fluorescent protein (GFP) mxa and ifit1. 1.5 × 105 cells were seeded per well and
were treated with IFN-α doses 10 U, 100 U, 500 U and 1000 U, 24 hours after seed-
ing. The time course measurements were taken at 8, 12, 16, 20 and 32 hours after
treatment with IFN-α doses and the cells were harvested at the above mentioned
measured time points. Further protein expression was inhibited by treating the cells
with 2 % paraformaldehyde. The cells were then washed with phosphate-buffered
saline (PBS) and measurements were performed with flow cytometry.
2.2.6 Databases accessed for parameter values
The assumptions and reasons for using certain values for kinetic parameters, initial
concentration of the molecules present in the cell/body for modelling are based on
the data from various databases. In particular, I used information from the BioN-
umbers database [163] to find the molecular numbers of the proteins present in the
cell and compute the initial concentrations for the same. BLAST [164] was used
for evaluating the differences in protein structure identities and homology between
mouse and human molecules (e.g. receptors, JAKs, STATs etc.), See Appendix C, Ta-
ble C.7. Drugbank [165] was accessed to find the values of the lipophilicitiy, molec-
ular weight and other compound-specific information needed for the PK model of
IFN-α (see Appendix A.2, Table A.4). Information on the transcription factor binding
sites was obtained from ENCODE [166].
2.3 The modelling resources
In this section, I cover the software used to achieve the multi-scale integration of
experimental data to ”learn” and ”predict” the behaviour of the system, to answer
the questions asked in this work. The whole-body plasma distribution models were
developed in the software, PK-Sim and the intracellular models were developed
in the software, COPASI. The integration of the models was executed in MoBi. This
step-wise procedure helped in effectively integrating the experimental data at multi-
scale level into the PBPK/PD model which aids in predictions.
2.3.1 Physiologically-based pharmacokinetic model
Model setup
Open Systems Pharmacology Suite (OSPsuite) was used to estbish the PBPK/PD
model of IFN-α drug action. The OSPsuite includes two software tools: PK-Sim and
MoBi which were formerly commercially available [167], [168]. Since January 2017,
it is a freeware under the license GPLv2. The software suite is publicly available at
Github3.
PK-Sim is a software for physiologically based pharmacokinetic modelling. The
software has database of relevant expression information of the protein binding part-
ners for human and common animal models. The software has a user-friendly in-
terface and allows for integrating information on the organism, the compound and
the administration protocol with the formulation of the compound. Independently,
3https://github.com/Open-Systems-Pharmacology
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PK-Sim enables the simulation of pharmacokinetics (drug distribution ADME pro-
cesses) resulting from single or multiple dosing regimes through all routes of ad-
ministration. It enables the modelling of small (size < 900 daltons) via three sub-
compartment as well as large molecules (size> 900 daltons) via four sub-compartment
(large molecules) per organ. The mentioned three sub-compartmental structures
differentiate the separation between plasma/interstitial space, thus defining instan-
taneous permeation (without interstitial compartment; for small molecules). The
four compartment model represents high permeation barrier between plasma and
interstitium thus describing non-instantaneous equilibrium between plasma/inter-
stitium concentrations (with interstitial compartment; for large molecules that are
highly bound to plasma). Once set-up, the models from PK-Sim can be linked to
the intracellular pharmacodynamics in MoBi. Furthermore, the software tool MoBi
is available for multi-scale physiological modelling and allows the user to access,
manipulate and extend the models developed in PK-Sim. MoBi can also be used
to develop systems pharmacology models from scratch. It is a tool for develop-
ing mechanistic dynamical models of biological processes and is complementary to
PK-Sim. In this work, all models were created with PK-Sim, exported to MoBi and
extended with pharmacodynamic interactions in MoBi.
The PK-Sim (Version 7.0; OSPsuite) software tool was used to model the PK IFN-
α-2 in humans and mu-IFN-α-4 in mice (PK-Sim Version 7.2; OSPsuite) using the
PBPK approach. The organism details of healthy human and mouse were integrated
with physico-chemical information of IFN-α to parameterise the IFN-α PBPK model.
In PK-Sim, the biometrics of the average individual species were described. The
software has building blocks which can be later compiled into a simulation. Please
note, in the upcoming explanation, the words which are italicised are the components
of the software PK-Sim where the model components are set up. In a nutshell, the
compound building block carried the information on physico-chemical properties of
IFN-α. Since IFN-α is a therapeutic protein, it is depicted as a large molecule in the
compound building block. The information of renal clearance from the kidney along
with the specific binding values (Koff, KD) of the protein binding partners was estab-
lished in the ADME subsection of the compound. The gene expression of receptors
were queried in the internal database. The database described the expression values
of the receptors in all organs collected from micro-array experiments. The health-
state of the individual was chosen as normal hence the expression is not governed
by a diseased state. In the Administration Protocol building block, the intravenous
dose given for human and mouse was inputted respectively for each model. In the
Observed Data building block, the data for fitting and validation were loaded and
assigned to the venous plasma concentration of IFN-α such that they could be used
in the simulation later on. Finally, all building blocks were combined to simulate the
PBPK model for the respective species. In the model settings, model for large proteins
and molecules was chosen.
MoBi The simulation was exported from PK-Sim to MoBi as pkml format. Here,
the drug-receptor binding reactions were restructured to mimic the physiological
conditions. The IFN-α PBPK model was coupled with the IFN-α intracellular model
in MoBi (version 7.2; OSPsuite).
Reactions and rate laws Most reactions were modelled as mass action kinetics
(2.3).
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vi = ki × [Substrate1]× [Substrate2]− 1keqi × [Product] (2.3)
Here, the velocity of the reaction is determined by the ki and keqi and the transi-
tion concentration of Substrate1, Substrate2, and the Product.
Parameter estimation
Model parameterisation and identification was done in MoBi and MoBi Toolbox for
MATLAB (product of Matworks Inc., USA; version R2014b). The toolbox function
‘generateMatlabCodeForXML’ was used to export the XML from MoBi to MATLAB
and custom scripts were created for plotting. Parameter scans for various parame-
ters were executed in MoBi and MATLAB.
The IFN-α models for human and mouse were fitted in MoBi. The human IFN-α
model fitting was performed using the Levenberg-Marquadt algorithm (Maximum
number of iterations 200; Initial step-bound factor 100; multiple optimisation runs
of 500). The Monte Carlo method was time-consuming and did not perform as well
as Levenberg-Marquadt. The mouse IFN-α model fitting was performed using two
algorithms: Levenberg-Marquadt algorithm (Maximum number of iterations 200;
initial step bound factor 100; multiple optimisation runs of 500) and Monte Carlo
method (Break condition for error improvement: 0.001; alpha: 30; multiple optimi-
sation runs of 50). Both the algorithms rendered similar solutions. Since there were
more iterations performed with Levenberg-Marquadt, the values from the fit were
used for further analysis. Further simulations and analysis of the models were exe-
cuted using MATLAB.
time course, sensitivities and parameter scan
The time course was simulated in MoBi using ODERHS function written in MAT-
LAB. The MATLAB code for differential equations can be accessed by exporting the
simulation.
The sensitivity analysis was performed in MoBi using the sensitivity analysis
section. For advanced sensitivity analysis, the simulation was exported as xml into
MATLAB and custom scripts were written for the same.
The model was exported as xml and the parameter scan was performed using
custom scripts written in MATLAB.
2.3.2 Hepatocyte model
Model setup
The JAK/STAT pathway model (referred in the text as hepatocyte model/petridish
model/pharmacodynamic model) was modelled using COmplex PAthway SImulator
[169] (COPASI). COPASI is open source software for mathematical modelling of bio-
logical processes. The software can be found at COPASI website4 and is maintained
by international collaborators from University of Manchester, UK; Virginia Bioinfor-
matics Institute, USA and University of Heidelberg, Germany. The software allows
simulations for stochastic as well as deterministic kinetics on time course or steady
state data. The simulations can be evaluated using the feature of parameter scan
for parameter sampling and by creating multiple simulations simultaneously. Fur-
thermore, it provides various features for analysing the developed models such as
4http://copasi.org/
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metabolic flux analysis, time scale separation, optimisation to name a few. COPASI
allows for SBML export/import which supports inter-operability of the model files
in different modelling environments.
The human hepatocyte model developed by Tim Maiwald [116] was altered in
COPASI version 4.16.104. Over the course of time the COPASI version 4.22 Build
170 was used to do the analysis. The human hepatocyte model was extended to
include the reactions for Mx2 transcription, translation and degradation to establish
the mouse model. The mouse hepatocyte model was established in COPASI version
4.22 Build 170.
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Reactions and rate laws The hepatocyte models consists of 2 compartments. The
substrates and the product of each reaction are indicated in COPASI. The reversible,
irreversible and multi-compartment reactions are indicated in COPASI as = ,→/←
and X Multi Compartment, respectively. Most of the reactions are described using
mass action kinetics (2.4 and 2.5) [170], [171].
vi = ki × [Substrate] (2.4)
vi = ki × [Substrate]− 1keq × [Product] (2.5)
Here, vi is the velocity of the reaction which is defined by ki or keq and the tran-
sient concentration of the substrate or product.
Parameter estimation
Due to the large size of the model, all the parameters could not be determined exper-
imentally. The human hepatocyte model was fitted and validated with the published
data detailed in Section 2.2.3. The mouse model was fitted and validated using the
data detailed in Section 2.2.4. The model fits for both the models were performed on
the cluster using command line interface COPASI SE 4.19.140.
The models were optimised using Particle Swarm which is a global method on
the cluster. The obtained top models were further optimised on the local machine
using local algorithm, hooke and jeeves. The resulting models were analysed to find
the top 20 models using a script written in MATLAB.
Time course, sensitivities and parameter scan
The time courses of the models were simulated using the LSODA algorithm [172].
For both models, the scaled sensitivities were calculated using the the subtask
Time Series in COPASI and the option Single Object was chosen in COPASI to deter-
mine the control of the single parameter on the system. The scaled sensitivities were
used because they are normalised and hence allow for comparability of parameters
within the model.
Parameter scan was applied to aid in the further analysis of the models. The
parameter scans were performed using the task Time Course and object Initial Con-
centration/Kinetic Value Of Species in COPASI.
The data visualisation was performed by extracting the report files as text files
from COPASI and were plotted in MATLAB by custom-made scripts.
2.4 Integrated PBPK/PD model
The PK models for hu-IFN-α and mu-IFN-α were set up using PK-Sim. They were
then exported, fitted and validated in MoBi. The hepatocyte models using human
and mouse cell culture data were set up, fitted and validated in COPASI. Up to
this point, the models existed separately in the two different software. After that
the integration was executed in MoBi as described in chapter 3 section 3.5. Further
analysis was done in MATLAB by using custom-made scripts.
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2.5 Stochastic intracellular model
The stochastic model of the JAK/STAT signalling pathway was set up using CO-
PASI. A special version of COPASI was provided by Dr. Frank Bergmann. This
version allowed to export the model to MATLAB where the algorithm developed by
Aguilera et al. [123] was used to fit the model to the single cell data. The Intrin-
sic noise was introduced by solving the model using Gillespie algorithm in COPASI
4.21. Extrinsic noise was simulated as suggested by Shahrezaei et al. [173] where
the extrinsic noise is introduced on the SSA as a time varying parameter and can
simultaneously execute on many parameters of the model. This work focuses on
introduction of extrinsic noise only on the molecular count of the molecules in the
pathway where the noise is normally distributed over the following three values of
three values of σ: 0, 0.3, 0.6.
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Chapter 3
Multi-scale PBPK/PD model of
IFN-α dose in humans
3.1 Chapter summary
The work in this chapter is motivated from the key issue that there is no intra-cellular
in vivo data for biological processes available on humans except that of the PK for
IFN-α. Ultimately, we need to be able to scale the animal in vivo or human in vitro
data to human in vivo scenarios. Thus, to make the most of pre-clinical to clinical
translation of IFN-α we must rely on either animal in vivo data or human in vitro
data. To achieve this with the present knowledge on IFN-α, the use pf PBPK/PD
approach is a powerful strategy.
In this chapter, I elaborate the establishment of such PBPK/PD model, describing
the role of IFN-α dose on human body using the methodology described in chapter
2.
This chapter will cover establishment of the cellular model using time course ex-
perimental data for the JAK/STAT pathway obtained in PHH and Huh7 cell lines.
I will detail the model structure, the parameter identification and the resulting in-
tracellular model containing the cytoplasm and the nuclear compartment of a hep-
atocyte. I will further discuss how the model is calibrated with dose-response data.
Then, I will cover the establishment of the pharmacokinetic model for the IFN-α in-
travenous injection on humans along with validation of the fit. Finally, the chapter
will focus on the establishment and the analysis of a multi-scale PBPK/PD model in
human body. Here, I use the mRNAc of IRF9 as a biomarker to compare the IFN-α
response in vivo vs. in vitro. The results highlight the quantitative differences of in
vitro-in vivo response of the biomarker IRF9 mRNAc for this study.
The text of some subsections and discussion is taken from Kalra et al. 2018 (in
preparation) [174] and has been originally written by myself. Most Figures used in
this chapter are adapted from Kalra et al. [174] and were originally produced by
myself. The experimental data used in this chapter is described in chapter 2, section
2.2; subsections 2.2.1 and 2.2.3 respectively.
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3.2 Motivation and open questions
Pharmacokinetics (PK) and pharmacodynamics (PD) play an important role in un-
derstanding the relationship between the temporal changes of induced signalling
cascades in the cell and the drug distribution in the body [175]. Thus, unfurling the
PK-PD relationship contributes to the pre-clinical to clinical translation of doses of
the drug. Although IFN-α was first used as antiviral, there is growing evidence for
broader clinical applications of IFN-α. IFN-α is extremely potent. It interacts with
specific receptors and drives the expression of ∼ 300 genes whose products mediate
antiviral or anti-proliferative responses. Even though, there is clear understanding
on the pharmacokinetics (ADME profile) of IFN-α [44], [50], [176], there is a gap of
knowledge towards understanding the dynamics of the response of IFN-α with its
receptor at the target site (in this case, the liver) [177]. In addition, the association
between the association between gene expression of a variety of genes to the clinical
response have not been clearly established [178], [179]. The efficacy of IFN-α in vitro
remains enigmatic as the work on understanding the antiviral response of IFN-α at
the cellular level is ongoing [180], [181].
Classical pharmacokinetic modelling has been employed for decades to under-
stand the distribution of pharmaceuticals in the body [147]. Of late, mechanistic
PBPK models have been successfully used as tools for predicting dose recommen-
dations and selecting drug candidates [182]. However, these approaches are limited
to the description of the fate of biologics in the blood and do not consider any bio-
chemical consequences [183]. However, in the recent years, kinetic models have been
used to understand the biochemical processes in detail [114], [116]. So far, the two
modelling techniques exist in isolation. To achieve a systems level understanding of
a drug’s effect, an integration of both modelling techniques is necessary [144].
The coupling of the PBPK model with the intracellular model will help to anal-
yse IFN-α drug effects in a holistic way - advocating effective treatment methods as
different proteins and molecules can be simulated simultaneously. Predominantly,
such a PBPK/PD model allows for studying processes that are not accessible by ex-
perimental procedures and analysing the IFN-α drug-response interaction at the tar-
get site (namely, the liver) in a time resolved manner. Hence, the motivation behind
the work described in this chapter is to have a better understanding of the temporal
dose-effect relationship at the target site.
In this chapter, I detail on the development a human whole body distribution
model of IFN-α and its integration with adjusted detailed intracellular model of the
JAK/STAT signalling cascade localised in the liver. Finally, I infer effective concen-
trations of IFNα arriving in the liver after intravenous injection. This approach opens
the opportunity to study the impact of in-vivo drug dose on the signalling behaviour
in the liver, taking into account the effective dose at the target site..
3.3 IFN-α PBPK model
To represent the distribution of IFN-α at the whole body level and to quantify the
exposure on the liver, a protein PBPK model of IFN-α was established. The corre-
sponding model comprises more than one hundred ODEs. However, the a posteriori
physiological knowledge constrains the number of independent parameters in the
PBPK model which need to be identified. The clear separation of physiological and
drug-specific parameters also allow for the separated inference of the parameters on
the ADME profile.
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For the human PBPK model of IFN-α, the weight, height and BMI of an aver-
age European individual were selected as individual biometrics (Appendix A B.1).
Physico-chemical information of IFN-α was obtained from the literature (Appendix
A, Table A.4).
There are two ways IFN-α gets eliminated from the plasma: By binding to the
receptors present in the liver (TMDD) and by pand via excretion through the kid-
neys. These modes of clearance were included in the PBPK model. The TMDD was
accounted by relative tissue-specific distribution of IFANR1/2 that was taken from
the gene expression database within PK-Sim [184]. This allows for the estimation of
in vivo receptor abundancies in the liver and other organs. The clearance parameter
was inserted from [50], where the elimination of IFN-α by the GFR were described.
The receptor kinetics and binding values were implemented in the model according
to the established kinetic mechanisms described in previous studies [185]–[187].
3.3.1 Human PBPK model overview
The following text is taken from the publication Kalra et al. [174] and has been written by
myself.
”The clinical profile of IFN-α was modelled as zero order input rate and first
order elimination rate. All the parameters for the pharmacokinetic modelling are
listed in Table 3.2. For modelling purposes, the liver was simplified as one big cell
with keeping the hepato-cellularity number to calculate the cell content and con-
centrations of the receptors [188], [189]. The liver was divided into three compart-
ments: the interstitial, the cytoplasm and the nucleus. The defined volumes of each
compartment are described in Appendix B, Table B.3. As seen in Figure 3.1 the IFN
receptor dynamics were modelled in the interstitial compartment and consist of a de-
tailed representation of the receptor binding and turnover. Here, the IFN-α arriving
to interstitial compartment binds to IFNAR2 to form a dimeric ligand-receptor com-
plex (IFNA-IFNAR2 Complex) (M1). The ligand-receptor complex (IFNA-IFNAR2
Complex) binds to IFNAR1 to form the hetero-trimeric ligand receptor complex (Ac-
tivated Receptor Complex) (M2). The hetero-trimeric ligand receptor complex was
internalised and degraded (M5). Finally, IFNAR1 and IFNAR2 undergo a turnover
process under basal conditions (M3 and M4). ”
The parameterisation of the PBPK model was derived on the basis of the ob-
served plasma concentration after intravenous application of recombinant leukocyte-
A of 0.22 mg on human subjects as reported by Wills et al. (1984) [50]. These data
served as a basis to estimate parameters like receptor abundancy, binding affinity
and internalisation (details in Appendix B, Table B.2).
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IFN-α
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IFNAR2 M3
IFNA-IFNAR2 Complex IFNAR1 M4
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Activated Receptor Complex
Internalized Complex
M5
FIGURE 3.1: The structure of the kinetic model of the IFNα drug in-
teraction in the liver of the whole-body model. For the model an
i.v.injected dose of 0.22 mg (36 U) was assumed. The clearance was
modelled by taking into account renal (GFR; not depicted in this Fig-
ure) and hepatic clearance (Receptor binding partners). The basal re-
ceptor (IFNAR1 and IFNAR2) turnover in the absence of the drug
is included in the whole-body model. The dose arriving in the liver
binds to the receptors which are activated, followed by internalisation
and degradation of the drug-receptor complex.
The range of biologically valid concentration values for IFNAR2 and IFNAR1
as used in parameter estimation was calculated as in subsection 3.3.2. Remain-
ing downstream reactions were compartmentalised as presented in the cellular sig-
nalling model section 3.4, model overview 3.4.1.
Reactions and rate laws used for the PBPK model IFN-α first binds to the IFNAR2
subunit and then recruits the IFNAR1 subunit on the membrane surface to form a
heterodimeric complex [90], [91], [185]–[187]. Most model reactions are described by
mass action kinetics. This reaction is depicted by the following equation 3.1.
vi = ki × [Substrate1]× [Substrate2]− 1keqi × [Product] (3.1)
Here, the velocity of the reaction is determined by the ki and keqi which are the
kinetic constants and the transient concentration of the Substrate1, Substrate2 and the
Product.
The basal receptor turnover of IFNAR1 and IFNAR2 were modelled as:
vi = rel norm exp× [S re f erence conc]× K turnover− [S conc]× K turnover (3.2)
Here, the velocity of the turnover was determined by the parameter K turnover,
the reference concentration of the receptors ([S reference conc]), the normalised rel-
ative expression of each receptor in different organs (rel norm exp) along with the
transition concentration of the receptors in the liver [S conc].
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3.3.2 Calculations for the PBPK model
Calculation of receptor concentration A mean receptor density was taken as ap-
proximately 0.55 molecules/µm2 based on [190], which corresponds to 500-1000
binding sites per cell [191]–[193]. The number of hepatocytes per gram of human
liver has been estimated as 139 × 106 cells/g liver [188]. The average liver volume
was previously determined to be 1.6 L [194]. With this information, the total receptor
(including IFNAR1 and IFNAR2) concentration in liver was calculated:
Number o f cells in liver = (Liver weight× ( Cells
g liver
)) = 2.085× 1011 (3.3)
Receptors per liver = number o f cells× receptors per cell
= 2.085× 1011 × 1000 receptors per cell
= 2.085× 1015 receptors
(3.4)
RecAmount Liver = (
number o f receptors
avogadro constant
) = (
2.085× 1015
6.02× 1023 ) = 3.46× 10
−9mol (3.5)
Receptor amount = 3.88× 10−4µmol (3.6)
From this amount, the total receptor concentration (IFNAR1 and IFNAR2) in the
liver was calculated as:
Receptor Concentration Liver = Receptor density per cell×
Human hepatocellularity number× liver density (3.7)
Recexp(
Receptor
ml
) = 1000(
Receptor
cell
)× 139× 106( Cells
g liver
)× 1.05( g liver
ml
) (3.8)
Recconc(
mol
ml
) =
14595× 107(Receptorml )
6.02× 1023 = 2.424× 10
−13(
mol
ml
) (3.9)
RecconcLiver = 0.242nmol/l (3.10)
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3.3.3 Parameter estimation strategy for the human PBPK model
The simulated venous blood plasma concentrations of human IFN-α were fitted to
the observed average venous blood plasma concentration of 20 volunteers (data
from Wills et al. [50]). The parameters used for the estimation were:
• Reference concentrations of the individual receptors
• Individual receptor binding kinetic constants (Koff and KD)
• Receptor complex binding kinetic constants
• Endocytosis of the receptor complex into the cells
• Glomerular filteration of IFN-α from the kidneys
150 randomised parameter-sets of the established human PBPK model were ob-
tained by using the Levenberg-Marquardt algorithm. The above mentioned param-
eters were randomised in parameter identification for the PBPK model. The renal
clearance is a very well defined parameter (0.0002 - 0.0003 ml/min/kg). The ref-
erence concentrations of IFN-α receptors were in 20% range from the reported re-
ceptor values in the literature [90]. The mean squared error (measure of the differ-
ences between values predicted by the PBPK model and the values observed in the
dataset) for the top 5 fits was 0.7. Most parameters estimation results spanned 2
orders in magnitude as seen in Table B.4. It can be seen in Figure B.1 that the top
models exhibit a similar fit and the parameter-sets of these fits have similar values.
For all top 5 fits, the correlation of the plasma clearance is high with the receptor
keq of the receptors. The basal turnover of each receptor is highly correlated to the
concentrations of the individual receptors. This was an indication that the differ-
ent PBPK model paramterisations do not differ with regards to the IFN-α venous
plasma concentrations, hence, fit 1 (seen in Figure 3.2, a.k.a Fit 1 in Table B.4 and
Figure B.1. The fitted values of the parameters are found in Table B.2) was a good
representation of the pharmacokinetics of IFN-α venous plasma concentrations and
was chosen for further evaluation. The chosen simulation is able to describe the bi-
phasic IFN-α plasma ADME. It exhibits the rapid distribution phase IFN-α from the
venous plasma in the starting 4-6 hours after the injection and the shallower elimi-
nation phase for the later hours. The simulated IFN-α half life was 5.5 hours, which
is consistent with the measured range of 3.7 - 8.5 hours (mean t1/2: 5.1 hours). The
simulation represents the total body clearance of 3.14 ml/min/kg which lies in the
range of the reported total body clearance ( 2.14 - 3.62 ml/min/kg) [50]. The IFN-α
pharmacokinetics of the chosen simulation is consistent with the published data.
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FIGURE 3.2: The Physiologically based pharmacokinetic (PBPK)
model simulation (line) and experimental blood plasma profile of
Wills et al. [50] (circles) of IFN-α in humans is plotted in the above
plot. The y-axis for the larger semi-logarithmic plot represents the ve-
nous blood plasma concentration of IFN-α and the x-axis represents
a time course of 24 hours. The goodness of fit is plotted on the upper
right (small plot). In this plot the mean squared error (RMSE) and the
R2 values are depicted. For the goodness of fit plotted in the smaller
box, the y-axis represent the Predicted values at the time-pints cor-
responding to the observed values in the dataset by Wills et al. [50]
which are represented on the x-axis.
3.3.4 Validation of the human PBPK model
The above chosen simulation was validated to different doses of intravenous IFN-α
profiles for human injection. The validation was performed on published datasets
using varying doses of intravenously applied IFN-α (doses of 0.136 mg and 0.27
mg by Shah et al.(1984) [48] and 0.045 mg by Radwanski et al. (1987). [49]) in hu-
mans (see Figure 3.3). The chosen parameter-set for the PBPK model of IFN-α ve-
nous blood plasma concentration was able to fit the IFN-α plasma concentration for
all chosen experimental conditions. The resulting simulation for Radwanski et al.
(1987) [49] displays a biphasic decline of IFN-α plasma concentration. The simula-
tion is able to represent the initial rapid distribution phase. However, it is not able to
describe the last two measurements during the elimination phase of IFN-α plasma
concentration. Nevertheless, the simulation represents similar t1/2 values as that in
Radwanski et al. (1987) [49]. The simulation depicts the t1/2 at 2.3 hours which is in
congurence to the terminal t1/2 values reported in Shah et al. [48] (1.9 - 2.9 hours).
Thus confirming that the same parameterisation can represent different doses of the
IFN-α venous blood plasma concentration.
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FIGURE 3.3: Validation of the physiologically based pharmacokinetic
(PBPK) model to different doses of IFN-α plasma concentrations as
reported in the literature. The experimental (circles) blood plasma
profiles of IFN-α in humans as reported in Radwanski et al. [49] (pur-
ple) and Shah et al. [48] (orange and green) and the corresponding
simulations (lines) are plotted. The goodness of fit is plotted on the
right (small plot). R2 values are provided for reference.
3.3.5 Analysis of the human PBPK model
Human PBPK models can help predict the tissue distribution of a drug. After IFN-α
injection, understanding its tissue distribution is a key element to predict the effi-
cacy of IFN-α, as the target sites of immune responses are not commonly found in
the blood plasma itself [195]. For example, comprehending the pharmacokinetics in
plasma alone does not suffice, for example, to understand the antiviral response of
IFN-α at the infected site. In literature, tissue distribution profiles of IFN-α in mice
and monkeys have been obtained [36], [39]–[41]. These studies indicate that the
highest amount of IFN-α can be found in the spleen, liver, kidney and lung. While
it has already been possible to obtain useful information about IFN-α pharmacoki-
netics by studying blood levels in patients, tissue distribution of IFN-α was so far
only measured in animal models, as experiments in humans are not ethically feasi-
ble. However, the model created in this thesis provides valuable insights into IFN-α
pharmakokinetics in humans, which can’t yet be obtained experimentally.
From our model, it can be seen (Figure 3.4) that the IFN-α concentration in the
highly perfused tissues, such as lung, liver, spleen or kidney is close to the plasma
concentration. The low perfused tissue such as the fat or muscle show a lower con-
centration of IFN-α. Over time the concentration of IFN-α decreases more rapidly in
highly perfused tissues than in poorly perfused tissues.
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FIGURE 3.4: Simulated tissue distribution profile of IFNα for the dose
reported by Wills et al. (1984) [50] for 24 hours. The lines represent
the simulated tissue distribution of IFNα in venous blood vs. the dif-
ferent organs. IFNα concentration in the well perfused tissues such
as the liver, spleen or the kidney is close to the plasma concentration.
Initially, the concentration is high, but it decreases more rapidly as in
the poorly perfused tissues.
3.4 IFN-α hepatocyte model
The IFN-α signalling model developed in this work is a reduced model from the one
published by Maiwald et al. [116]. The original model can be retrieved at online
cellular systems modelling database1.
In Maiwald et al. [116] , the authors focused on dynamic changes for short time-
scales (up to 6 hours) in the JAK/STAT pathway and traced the influence of IRF9 on
the pathway activation. In our work, I analysed the response behaviour on longer
time-scales (up to 1 day) without an over-expression of IRF9. To this end, I imple-
mented the 24-hour time course and dose-response datasets of the biomarker IRF9
mRNAc to fit and validate the model. Besides reducing the model, I had to repa-
rameterise it in order to adjust the original model [116] to our study. In the process I
introduced the following changes in the model:
1. The adapted model replicated the receptor concentration and the kinetics of
the surface receptor behaviour predicted by the PBPK model. Furthermore, it
included physiological concentrations of the receptors. The new structure of
the model at the receptor level is depicted in Figure B.5).
2. The initial expression for the STAT and IRF9 molecules were excluded in the
adapted model due to stiffness in the long-time model simulation.
3. The execution of the sensitivity analysis on the adapted model reported less
control of two reactions implemented in the Maiwald et al. [116] model:
(a) Dephosphorylation of the receptors by SHP dephosphatase. This reaction
was removed.
1http://jjj.biochem.sun.ac.za/database/maiwald/index.html
36 Chapter 3. Multi-scale PBPK/PD model of IFN-α dose in humans
(b) Feedback of nuclear phosphatase. This rreaction was added as an extra
mass balance term to the release of each protein transported to the nucleus
(STAT1, STAT2, IRF9 and ISGF3) as an extra mass balance term.
4. The kinetics of SOCS feedback on the receptor is reported as non-competitive
kinetics in the literature [196]. In the adapted model the feedback of SOCS was
changed from simple mass action to catalytic activation.
5. The model integrated the long time course (24 hours) data data representing
the dose-response relationship of IFN-α and IRF9-mRNAc.
6. Finally, the volumes of the cytoplasmic and nuclear compartments of the vir-
tual hepatocyte for human and mouse were calculated from the PK-Sim liver
intracellular volume.
There are two prerequisites for intracellular models which allows the meaningful
integration and conclusions with PBPK models.
• The hepatocyte model should have identical cell surface receptor behaviour to
that of the PK model.
• The hepatocyte model is able to simulate dose-response behaviour for various
doses.
In the following section I will provide the in-depth description of the model
structure and establishment. In the coming sections this model is addressed as the
Hepatocyte model.
3.4.1 Intracellular hepatocyte model overview
the deterministic model developed here encompasses the key molecules and feed-
back mechanisms of the JAK/STAT pathway. The new model comprises 21 molecules
and 20 reactions. The reaction kinetics are mainly modelled by mass action kinetics,
except for 2 reactions: the transcription of IRF9, which follows the Michaelis Menten
kinetics, and the catalytic inhibition described the feedback inhibition of SOCS on
the ternary receptor complex. The model consists of two compartments: the cyto-
plasm and the nucleus. The volume of the cytoplasm corresponds to the volume of
the intracellular space of the liver from the PBPK model. The molecule species exist-
ing in the two compartments have the suffix c when in the cytoplasm and the suffix
n when in the nucleus (see Figure 3.5 for the structural cartoon of the model). The
degradation of IFN−α was modelled (R1) as the IFN−α dose is constant and the half
life of IFN−α is reported in the range of 4 - 8 hours [197], [198], The IFN−α - recep-
tor binding was described step-wise, where first, the free IFN−α (IFN atSite) binds to
IFNAR subunit 2 (IFNAR2) forming a ligand receptor complex (IFNA R2 Complex)
(R2) which then binds to IFNAR subunit 1 (IFNAR1) to form a trimeric complex
( Activated Receptor Complex) (R3). The activated trimeric receptor-ligand complex
associates to the STAT2 (STAT2c) in the cytoplasm to activate the phosphorylated
STAT2c (Rec2) (R5). Then, the union of STAT1c (STAT1c) to STAT2c (STAT2c) was
incorporated to form the heterodimer of STAT1-STAT2 (Rec 21) (R6). Consequently,
binding to IRF9 (IRF9c) to form ISGF3 complex in the cytoplasm (ISGF3c) (R7). Some
species were transported independently into the nucleus, namely, STAT1 (STAT1c/n)
(R14), STAT2 (STAT2c/n) (R15), IRF9 (IRF9c/n) (R16) and ISGF3 (ISGF3c/n) (R17). The
transcription complex (ISGF3n) binds to the promoter sequence on DNA known as
ISRE sites (Open ISGF-3n binding sites) to transcribe (Occupied ISGF-3n binding sites)
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(R18) the mRNA of IRF9 (mRNAc) (R8) and SOCS (mRNAc SOCS) (R10). The lib-
eration of the DNA-bound transcription factor (Occupied ISGF-3n binding sites) by
nuclear phosphatase refurbished the individual molecules and freed the ISRE sites
(IRF9n, STAT1n, STAT2n and Open ISGF-3n binding sites) (R19). The mRNAc of IRF9
and SOCS were translated into the respective proteins (IRF9 and SOCS1) which were
further degraded (R12, R13 & R20). The mRNAc degradation for the IRF9 mRNAc
and SOCS1 mRNAc was included ( R9 & R11). Lastly, the SOCS protein binding is
to the heterotrimeric receptor complex and thus, the exertion of the negative feed-
back resulting in the freed receptor subunit, was incorporated (R4). The details of
the reactions and their kinetic rate laws are summarised in Table 3.2
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IFNA-IFNAR2 Complex IFNAR1
STAT1c
STAT2c
IRF9c
ISGF3cIS 3c
R10
R7
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R5
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FIGURE 3.5: The structure of kinetic model of the IFN-α signalling
pathway in the hepatocyte is drawn here. The JAK/STAT pathway
is modelled by simulating a dose of 500 U IFN-α dose (12.96 nmol/l
model units) which led to the activation of the receptors in the cy-
toplasm. The downstream cytoplasmic and nuclear reactions (black
solid arrows) and degradation reactions (red arrows with φ ) are di-
vided into the respective model compartments (yellow dashed line).
Finally, the feedback reactions are depicted (red solid lines).
Reactions and rate laws The reaction describing the feedback of SOCS on the re-
ceptors is modelled by catalytic activation kinetics. The rest of the reactions are
decribed by mass action kinetics. The receptor kinetics were implemented from the
PBPK model and these reactions are further explained in the section 3.3.
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The feedback inhibition of SOCS on the receptors was modelled as irreversible
catalytic activation on the receptors, hence freeing the individual receptors. This
reaction kinetics is a simple form to describe the inhibition and the term activator in
the below mentioned equation describes the inhibition molecule (SOCS):
vi =
V × [Substrate]× [Activator]
(kms + [Substrate])× (Ka + [Activator]) (3.11)
Here the velocity of the reaction is determined by Kms, V and Ka and the Activator
(in this case the inhibitor) is a modifier to the the Substrate (the receptor complex).
3.4.2 Calculations for the intracellular hepatocyte model
Converting IFN units: From IU/mL to nmol/l Most parameters of the adapted
model were reparameterised by parameter estimation. The kinetic model was fitted
to the data reported by Bolen et al. and Maiwald et al. [116], [161]. In the exper-
imental data, various IFN-α stimuli (IFNexp) were applied on the cells to activate
the signalling pathway. IFNexp doses ranged from 10 IU/mL to 500 IU/mL (1× 104
IU/L to 5× 105 IU/L). The model includes the fold-change ratios between the dif-
ferent IFN-α stimuli, but not the actual protein concentrations. The experimentally
applied stimuli of U/ml was assigned to a model value of 12.96 in all subsequent
analysis. This was based on the following conversions:
The IFN-α doses (IU/L) were converted to molar concentration (M), that is,
IFNexp(M) =
(
IFNexp(IU/L)/IFNsa(IU/g)
)
/IFNw(g/mol), (3.12)
where, IFNsa is the IFN specific activity. IFNsa = 1× 106 IU/g (R&D Systems, Min-
neapolis, MN, USA). IFNw is the IFN molecular weight. IFNw = 19241.0 (g/mol).
TABLE 3.1: From IFN-α (IU/mL) to nmol/l and to model concentra-
tions.
IFN-α (IU/mL) M nmol/l Model Units
500 2.6 ×10−7 25.98 12.96
100 5.19 ×10−9 5.19 2.59
10 5.19 ×10−10 0.519 0.25
It is worth to mention, that those numbers provide an overall idea of the the final
IFN-α concentration at the target cell. However, the numbers can be affected by
various factors, including:
• The storage of IFN-α: Concentrations and activity of IFN-α varies widely due
to vendor-specific characteristics of the IFN-α sample. The activity is affected
by freezing and thawing, which may cause changes to the IFN-α activity over
time, even if the same batch is used. Activity may also be different in different
solvents or cell culture media. For these reasons, there is a significant potential
for variable activity.
• The cells to be studied: It’s hard to compare different cell types; cells react
very differently to IFN-α and some may not react at all (e.g. they lack the
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IFN-α receptor) whereas IFN-α activity varies very much between some cell
types (e.g. tumor cell model vs. primary cells). Therefore, additional variance
might be added by inconsistent use of cell lines, e.g. use of different cell lines,
differences in passage numbers and cell density.
Estimating nuclear binding sites of ISGF3 During re-parameterisation of the model,
the TFBS were estimated. Thereby, I confined the range of the TFBS to physiological
values. A detailed explanation is presented below:
The human genome consists of 3× 109 base-pairs, total DNA content of a 2n cell
is 2× 3× 109 base pairs. A transcription factor binding site (TFBS) consists of more
than one base-pair. In the study done by Whitfield et al. [199], they predicted a
binding site for transcription factor every 5 kb of DNA. Therefore, they calculated
the binding sites per nucleus to be 6*105. The ENCODE [166] bed file of ChIP seq
experiments for STAT1 and STAT2 after IFN-α treatment in the human cell line K562
had 1.36 - 1.74× 105 potential binding sites per nucleus.
In the model published by Maiwald et al. [116] the concentration of the open
binding sites was 5312 nmol/l, which translates to 8.55× 105 binding sites per nu-
cleus (see calculation 3.13 ). This number is extremely high as compared to the num-
ber of base pair in the human genome ≈ 3× 109 bp (6× 109 base-pairs in case of
diploid cells).
Vnucleus =
4
3
× (nuclear diameter× 0.5)3 × piVnucleus = 268µm3 (3.13)
Amount TFBSnucleus = Concentrationbinding sites in the model ×Vnucleus (3.14)
Amount TFBSnucleus = 5312
nmol
l
× 268× 10-15l = 1.42× 10-9nmol (3.15)
Number TFBSnucleus = Amount TFBSnucleus × Avogadro Constant (3.16)
Number TFBSnucleus = 1.42× 10-18mol × 6.022× 1023 1mol (3.17)
Hence, the initial concentration of the TFBS was fitted to more realistic concen-
trations as calculated with the help of the above stated calculations.
Up to now, no crystal structure of ISGF3 is available and hence both, the DNA
binding contacts and the stoichiometry of ISGF3 DNA complex is unclear [200]. The
binding dynamics are are crucial for the model behaviour. The IRF9 promoter con-
tains two putative ISRE binding sites for ISGF3 (as evaluated from sabioscience tran-
scription factor database and ENCODE database (Appendix B, Figure B.3 and Figure
B.4)) and has been indicated to have an overlap with the putative IRF7 binding site
sequence [200], [201] thus potentially allowing cooperativity in the binding. How-
ever, Begitt et al. [202], demonstrated that the cooperative binding of STAT1 is not
important for type I interferon responses, as found by using cooperativity-deficient
STAT1.
Hence, three different kinetics were defined for the binding of ISGF3 to the nu-
clear binding sites as follows: mass action kinetics, Michaelis Menten kinetics and
Hill cooperativity. Mass action kinetics allows for a graded response to the binding,
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while Michaelis Menten allowed saturable response to the binding of ISGF3 to the
DNA, whereas Hill cooperativity encoded switch like behaviour of gene expression.
It turned out that the model version with mass action kinetics for transcription of
IRF9 best described the data during the parameter estimation, The other kinetics
were discarded. The model with mass action kinetics was further evaluated. In the
further steps, the receptor dephosporylation reaction was removed as it was not in-
cluded as part of the receptor activation mechanism in the PK model. Besides, the
receptor dephosporylation reaction had little to no influence on the model due to
the realistic concentrations of the receptors. Furthermore, the nuclear phosphatase
feedback was observed to be too fast and and without control over the model pa-
rameters, hence this reaction was removed from the model structure. This version
of the model (a.k.a. adapted model/ hepatocyte model) was used for investigating
the parameter distribution and further evaluations.
3.4.3 Parameter estimation strategy for the intracellular hepatocyte
model
Mapping of the model variables to the data For the integration of the hepatocyte
model into the PBPK model, I needed to ensure consistency at the receptor kinet-
ics level. Thus, the receptor parameter values and the equation was taken from the
PBPK model into the hepatocyte model (the parameter values can be seen in ap-
pendix B, Table B.7). The datasets included mRNA abundance profiles followed
over time for different IFN-α stimuli. The dataset was split into two parts and one
was used for parameter fitting, while the other was used for validation. The doses
included in the parameter estimation were 10 U and 100 U from Bolen et al. [161].
As the time points were in arbitrary units, the mRNAc species of the model was
mapped to the dataset as follows:
IRF9mRNAc†(ti) = ϕ1 ×
(
IRF9mRNAc(ti)
)
, (3.18)
where ϕ1 is the scaling factor.
Fitting the deterministic model The model was fitted to short time course (up to
6 hours) experimental data obtained for IFN-α stimuli of 500 U and 1000 U. Various
intracellular signalling species (JAK, STAT1, STAT2, IRF9, IRF9 over-expression and
SOCS protein) as reported in Maiwald et al. [116] were measured. The ability to
predict the dose-response data is crucial for this model. Thus, the model has to be
able to estimate the behaviour of IRF9 mRNAc (the key molecule to extrapolate the
comparative behaviour in-vitro vs.in-vivo) when conditioned to low or high doses of
IFN-α. IRF9 has been suggested to play a pivotal role in the dynamics of the sig-
nalling pathway [116]. Studies on hepatic cell-lines indicated that the transcription
of IRF9 mRNA got triggered at a rather low dose of IFN-α, namely between 50U to
100U [21], [22], [161], [162]. Consistently, at doses beyond 500 U IFN-α IRF9 mRNAc
response has been reported to be saturating (see Appendix B Figure B.2).
Based on the model structure and available data, many of the parameters of the
model were not identifiable. To understand the distribution of possible parameter
values for different parameters in the model, a model ensemble of 1000 parameteri-
sations was set up. Each model in this ensemble had identical model structure, but
the parameter estimation started with random parameter values. Due to the com-
plex structure of the model, high number of parameters and presence of different
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time-scales of the reactions, parameter estimation was a time intensive task. To re-
duce the computation time, I analysed and removed the reactions which showed
structural non-identifiablity. The final parameter estimation was then performed
using the implemented particle swarm algorithm in COPASI (iteration Limit: 20000
and swarm size: 60; multiple iterations of 1000 fits; performed on the cluster). All
parameters for which experimental data was available were included in the param-
eter estimation after adding a variance within 20 % of the measured value (see Table
B.5). The rest of the parameter values were varied 50-75 % from the values establised
in Maiwald et al. [116].
The parameter estimation analysis yielded the result (see Figure 3.6) that most
parameters were evidently unidentifiable due to their broad distribution (see Figures
B.6 and B.7)).
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FIGURE 3.6: The parameter values of 1000 fits are represented in the
box plot. The 25-75 % quantiles of the fitted parameter is represented
by the box (green), the full range of the parameter variation is rep-
resented by the dashed line (black) and the median is indicated by a
solid line (black).
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Information on several parameters modelled was sparse or not measured in hu-
man hepatic cell lines. To deal with the model uncertainty and scarcity of the data,
further analysis was based on a model ensemble of 10 models [203]. All ten models
have identical model topology but different parameter values (see Appendix B, Ta-
ble B.6) that described the experimental data equally well and cover the full range
of possible biologically relevant parameter values. The model ensemble consisted
of models that not only fit the experimental data well, but also showed steady state
without IFN-α stimulus and described the dose-response behaviour of IRF9 mRNAc
well.
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FIGURE 3.7: Parameter estimation results of the top ten models in the
ensemble. The experimental time course (dots) and parameter esti-
mation results (solid lines) are plotted. The x-axes of the plots repre-
sent the time scale at which the measurements were taken after the
applied IFN-α stimulus. The measurements of the protein quantities
in arbitrary units are plotted on the y-axes. The protein reaction dy-
namics was measured and published in Maiwald et al. [116] by quan-
titative immuno-blotting in Huh 7.5 cells stimulated with 500 U IFN-
α for the activation of A) cytoplasmic pSTAT, C) cytoplasmic pJAK (
which was mapped to the Act Rec Complex), D) total nuclear IRF9
(IRF9n), E) cytoplasmic SOCS mRNAc and F) cytoplasmic SOCS pro-
tein. The dynamic expression of B) IRF9 mRNA was measured and
published by Bolen et al. [161] by microarray analysis in Huh 7 cells
after the treatment with 10 U IFN-α. Complete fits to all the datasets
are shown in appendix B; Figure B.8.
3.4.4 Validation of the intracellular hepatocyte model
For the validation of the parameter estimation result, I used the datasets for IFN-α
stimuli of 500 U and 2500 U from Bolen et al. [161] and 15 U and 30 U from Jilg et al.
[162]. As the measured biomarker is the same as the one used for model ensemble
training (IRF9 mRNAc), the validation data was well suited for testing the validity
of the trained model ensemble. The datasets arise from different publications and
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are in arbitrary units, they cannot be qualitatively cross compared, although the
normalised relative behaviour of IRF9 mRNAc response over time for the different
doses can be compared. Hence, as stated previously, the datasets were normalised
within the experiments from each publication.
I analysed whether the model ensemble reproduced the temporal dynamics of
the validation datasets for the dose-response time profiles (Figure 3.8). In Figure 3.8
A) and B), the model ensemble is able to achieve the peak amplitude of the IRF9
mRNAc response for 500 U and 2500 U at a similar time scale as the dataset, i.e., at
nearly 360 mins for 500U and at 245 mins for 2500 U. However, for 2500 U the peak
concentrations are under-estimated by the model ensemble (Figure 3.8 B)). In Fig-
ure 3.8 C) and D), the model ensemble is simulated against the datasets of 15 U and
30 U from Jilg et al. [162]. The model ensemble simulates the dynamic behaviour
quantitatively for 15 U, where the peak amplitude of response IRF9 mRNAc is sim-
ulated well, but the model predicts a faster response than the response measured
in the dataset. Also, the amplitude of the response of IRF9 mRNAc and the tempo-
ral dynamics is under-estimated for 30 U. In Figure 3.8 E) and F) the concentration
of IRF9 mRNAc 24 hours after treatment with different concentrations of IFN-α is
shown. ¡the model approaches close to saturation in response to 100 U (hollow cir-
cles depicting the value was used in the parameter estimation) which is close to the
the dose (between 50 U to 100 U) reported in the literature at which the IRF9 mRNAc
response saturates (Table B.2).
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FIGURE 3.8: In the above graph, the model ensemble simulation is
plotted (solid) vs. the validation datasets of of IRF9 mRNAc concen-
trations in response to IFN-α stimuli (circles). In A-D) the dynamical
time course behaviour of the datasets and the model ensemble for 24
hours is plotted. The doses are, in A) 500U and B) 2500U of IFN-α
dose from the publication Bolen et al. [161]. C) 15U and D) 30U of
IFN-α dose from the publication Jilg et al. [162]. In panel E) and F)
the 24th hour dose-response curves are shown for E) all datasets from
Bolen et al. [161]. The datasets used in the parameter estimation are
plotted as hollow circles. F) datasets from Jilg et al. [162].
3.4.5 Analysis of the intracellular hepatocyte model
Simulating the hepatocyte model with constant in vivo and in vitro doses As the
model ensemble was able to simulate the dose-response of IRF9 mRNAc, I used this
ensemble for further investigation. The hepatocyte model ensemble was simulated
with IFN-α doses applied in two different scenarios to investigate the differences in
the signalling dynamics. One was a typical intravenous injection IFN-α stimuli as a
constant dose (Cmax of 0.7 nmol/l in the liver). The second was the constant dose
of IFN-α for a typical in vitro assay or experiment setup (Cmax of 13 nmol/l). As
all models in the ensemble exhibit identical dynamics, for simplicity, I selected one
exemplary model from the model ensemble to represent the analysis. The represen-
tative model was simulated with the constant dose of 0.7 nmol/l, which is the typical
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in vivo dose of 36 U of IFN-α (but is non-linear in physiological conditions). The rep-
resentative model was also simulated with a constant dose of 13 nmol/l, which is
typical in vitro dose of 500 U of IFN-α in the petridish experiments. The important
response molecules of the pathway are plotted in Figure 3.9. As the doses were
constant (no physiological clearance of IFN-α), the in vitro behaviour is evidently
sustained for both the doses (36 U and 500 U) for all the models in the ensemble.
In addition, clearly, the shape of the temporal response profiles of the molecules is
similar for both the doses. However, the fold differences in the Cmax of the response
molecules in the model ensemble were approximately 1.8 fold higher for in vitro IFN-
α dose (500 U) as compared to the in vivo IFN-α dose (36 U) 3.10. The results show
that despite the high numerical difference in the doses, i.e., the in vitro dose of 500
U being 18 fold higher than the in vivo dose of 36 U. The simulation suggested sat-
uration at the IFN-α dose of 36 U. The activated receptor complex reached its peak
concentration 2 hours (Tmax) earlier for in vivo dose (36 U) than the in vitro dose (500
U). The time scale at which the peak of the SOCS1 concentration is reached for both
the doses is similar. Evidently, the moment the feedback protein SOCS1 starts to
decline from its Cmax, the activated receptor starts to slowly build up again until it
reaches its saturating Cmax at 22 hour.
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FIGURE 3.9: The hepatocyte model was simulated with a constant
low dose (36 U; typically administered dose in vivo) vs. the in vitro
dose (500 U; typically used in experimental setups). The (red lines),
hepatocyte culture simulation (green dashed lines). Simulation of
concentration time profiles in human and in human cell lines of A)
the non-linear IFN-α, B) activated receptor complex C) IRF9 mRNAc
and D) SOCS1 activated downstream in the models.
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FIGURE 3.10: Relative fold difference of A) activated receptor com-
plex and B) IRF9 mRNAc Cmax calculated by simulating the typical
administered dose of 36 U IFN-α (Cmax 0.7 nmol/l) and the exper-
imental dose of 500 U (Cmax 13 nmol/l) for the in vitro hepatocyte
model. These doses are constant doses for the hepatocyte model.
3.5 IFN-α PBPK/PD model
The PBPK model was coupled to the hepatocyte model in MoBi to establish a whole
body PBPK/PD model of IFN-α intravenous injection in humans. The integration of
the multi-scale PBPK/PD model was executed as follows:
1. Hepatocyte Model: The model ensemble of the hepatocyte model as set-up in
COPASI had to be transferred to MoBi. As there exists no bridging mark up
language to exchange models between SBML and PKML format coherently,
this was achieved manually. The reactions were carefully compartmentalised
replicating the anatomy of the organism and the dimensions. The units used
for the kinetic parameters were adjusted.
2. PBPK Model: The reactions connecting the pharmacokinetic model to the hep-
tocyte model (the receptor dynamics and the feedback inhibition on the recep-
tors by SOCS proteins) were defined in the interstitial compartment of the liver
of the organism PBPK model in order to include the complete dynamics of the
system.
3.5.1 Establishing the merged PBPK/PD model
The technical details to merge the models in MoBi are described in Appendix B,
subsection B.3.1. To replicate the hepatocyte model ensemble in MoBi, the IFN-α
drug dose was decoupled from the PBPK model. A constant IFN-α dose was defined
in the liver. The concurrency check of the inter-exchanged models was done by
comparing the simulation result of COPASI and the liver-restricted PBPK/PD model
in MoBi to replicate the in vitro condition in the liver of the organism. This was
executed using custom scripts written in MATLAB.
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During the integration two checks were important to validate the PBPK/PD
model. First, the congruence of the simulation of the hepatocyte model and the liver
restricted PBPK/PD organism model for identical structure was checked for (the
placement of the right molecules in the right compartments). Second, the PBPK/PD
model restricted in the liver compartment in MoBi was compared to the hepatocyte
model developed in COPASI to confirm that any differences seen solely arise from
the pharmacokinetic aspect (See Figure 3.11).
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FIGURE 3.11: The congruence between the multi-scale PBPK/PD
(blue lines) and hepatocyte model (orange dashed line) was tested
by defining the constant influx of IFN-α (experimental dose: 500 U,
model units: 13 nmol/l) in PBPK/PD model.
3.5.2 Human PBPK/PD model overview
The hepatocyte model was integrated into the PBPK organism model at the intersti-
tial space of the liver. The receptor binding to IFN-α at the target site is the point
of interaction of both models. The receptor concentrations and the kinetics were
kept identical to the PBPK organism model simulation after the hepatocyte model
integration. The reaction of the receptor binding and the feedback from SOCS on
the receptor complex were compartmentalised in the interstitial compartment of the
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liver of the PBPK model. The intracellular compartment and structure of the hepa-
tocyte model was preserved from the hepatocyte model in the PBPK/PD model. A
detailed description of the individual models is given in the section 3.3.1 and 3.4.1
respectively. The presented whole-body PBPK/PD IFN-α model in humans inte-
grates the whole body distribution model (data from Wills et al. [50] ) with activated
cellular signalling of IFN-α and represents changes in the signalling behaviour while
considering the in vivo context. Thereby, it captures the non-linear pharmacokinetic
behaviour (absorption, distribution, metabolism and elimination) of IFN-α and is
schematically described in Figure 3.12. The details of the kinetic rate laws for the
PBPK/PD model are described in Table 3.2 labelled by the reference: Multi-scale
compartment.
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FIGURE 3.12: The schematic representation of the whole-body PBP-
K/PD model for IFN-α i.v.application in human is shown above. The
IFN-α drug dose from the PBPK model arrives in the liver where it
interacts with the receptors defined at the interstitium in the PBPK
model (reactions M1-M5). The downstream JAK/STAT cascade was
introduced at the Activated receptor complex from the hepatocyte model
and the signalling pathway was implemented in the intracellular and
the nuclear compartment in the liver (reactions M6-M14).
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TABLE 3.2: Reaction List: The individual reactions for both models: the in vitro hepatocyte and the in vivo PBPK/PD model. The
column with R# and Cell Compartment depict the reactions that are present in the in vitro hepatocyte model and where. The columns
with M# and multi-scale compartment do the same for the in vivo PBPK/PD model. The column reactions describe the modelled
pathway along with the column kinetic rate law which gives insight on the kinetics used to model each step.
#
Cell
Compartment
multi-scale
Compartment
Reaction
Kinetic
rate law
R1 - Cell Intracellular - IFN→ ∅ k1 · S
R2 M1 Cell Intracellular Liver Interstitial IFNA + IFNAR2
 IFNA-IFNAR 2 Complex k1 · S1 · S2− P/keq
R3 M2 Cell Intracellular Liver Interstitial
IFNA R2 Complex + IFNAR1

 Activated Receptor Complex k1 · S1 · S2− P/keq
R4 M3 Cell Intracellular Liver Interstitial
Activated Receptor Complex

 SOCS1 IFNAR1 + IFNAR2
V·S·A
(Kms+S)(Ka+A)
- M4 - Liver Interstitial ∅ −→ IFNAR1 rel exp out× AF× f o× k t− S× k t
- M5 - Liver Interstitial ∅ −→ IFNAR2 rel exp out× AF× f o× k t− S× k t
R5 M6 Cell Intracellular Liver Intracellular Activated Receptor Complex + STAT2c→ Rec2 k1 · S
R6 M7 Cell Intracellular Liver Intracellular Rec2 + STAT1c −→ Rec21 k1 · S
R7 M8 Cell Intracellular Liver Intracellular Rec21 + IRF9c −→ ISGF−3c +
Activated Receptor Complex
k1 · S
R8 M9 Cell Intracellular Liver Intracellular ∅
Occupied ISGF−3n−−−−−−−−−−⇀↽ −
binding sites
mRNAc SOCS k1 ·M
R9 M10 Cell Intracellular Liver Intracellular mRNAc SOCS −→ ∅ k1 · S
R10 M11 Cell Intracellular Liver Intracellular ∅
Occupied ISGF−3n−−−−−−−−−−⇀↽ −
binding sites
mRNAc k1 ·M
R11 M12 Cell Intracellular Liver Intracellular mRNAc −→ ∅ k1 · S
R12 M13 Cell Intracellular Liver Intracellular ∅ mRNAc−−−−⇀↽ − IRF9c (kconst + kact)M− P · IRF9deg
R13 M14 Cell Intracellular Liver Intracellular ∅ mRNAc SOCS−−−−−−−⇀↽ − SOCS 1 kact ·M− K deg · P
R14 M15 Exchange Exchange STAT1n
 STAT1c k1 · S− P/keq
R15 M16 Exchange Exchange STAT2n
 STAT2c k1 · S− P/keq
R16 M17 Exchange Exchange IRF9n
 IRF9c k1 · S− P/keq
R17 M18 Exchange Exchange ISGF-3c
 ISGF-3n k1 · S
R18 M19 Cell Nucleus Liver Nucleus
Open ISGF-3n
binding sites
+ ISGF-3n
 Occupied ISGF-3n
binding sites
k1 · S1 · S2− P/keq
R19 M20 Cell Nucleus Liver Nucleus
Occupied ISGF-3n
binding sites
→ STAT 1n + STAT 2n + IRF 9n
+ Open ISGF-3n binding sites
k1 · S
R20 M21 Cell Nucleus Liver Nucleus IRF9n −→ ∅ k1 · S
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3.5.3 Analysis of the human PBPK/PD model
The pharmacokinetic behaviour of therapeutic proteins after their injection into an
organism is often influenced by binding to a specific target, i.e., for example an anti-
gen receptor. Therefore, their PK and PD relationship gives insight into the inter-
individual variability in response to a drug [204].
The presented IFN-α model integrated the whole body distribution PBPK model
(data from [50] ) with cellular signalling of IFN-α (a.k.a. the hepatocyte model).
The integrated whole-body PBPK/PD model of IFN-α in humans, allows for the si-
multaneous description of IFN-α pharmacokinetics at the whole-body level and the
resulting pharmacodynamics response in the JAK/STAT signalling cascade. Thus,
the simulation of the hepatocyte model within a whole-body context allowed to ex-
trapolate the cellular network to an in vivo situation. This is of particular relevance,
since the in vivo pharmacokinetics is highly dynamic while the in vitro assay used
for identification of the cellular network considered only stationary concentrations.
This was depicted in the analysis of the hepatocyte model. The whole-body PBP-
K/PD model thus allowed the analysis of the actual amount of IFN-α arriving at
the site of action, i.e., the liver and the dynamic profile of the induced intra-cellular
response.
in vitro - in vivo differences of IFN-α drug action Hereon, for clear understanding
the in vitro scenario will be referred to as petridish experiments.
Similar to the heptaocyte model (which represents the petridish scenario of the
JAK/STAT response to IFN-α stimulus), the simulated PBPK/PD model was further
analysed to extrapolate the differences of the dynamic behaviour of the responses in
the liver when comparing IFN-α doses applied i.v. to an organism or in petridish ex-
periments. To summarise, the in vivo dose of 36 U from Wills et al. [50] is non-linear
due to clearance processes in the body while the dose given in the petridish experi-
ments is a constant dose of 500 U [116]. One should also keep note, as mentioned in
the previous sections that an IFN-α stimulus 500 U is far above saturating levels at
least w.r.t. the readout used here, namely the mRNAc of IRF9.
The Cmax of the in vivo dose is 0.7 nmol/l while in the petridish experiments, the
dose was constant with a Cmax of 13 nmol/l. The PBPK/PD model was simulated
with the IFN-α dose on petridish experiments and compared to the i.v.-injected in
vivo dose. The simulation exhibited a 18-fold lower IFN-α amount reaching the liver
than was what was pipetted in petridish experiments (Figure 3.14). I further com-
pared the responses of the lower dose (in vivo) with the higher dose (petridish). The
activated the ternary receptor complex (a.k.a. activated receptor complex) reaches a
1.5 fold lower Cmax in comparison to petridish experiments (Figure 3.13 A and C).
The response of the followed biomarker, i.e., IRF9 mRNAc reached a Cmax which
was 4 fold lower (Figure 3.13 B and D).
3.5. IFN-α PBPK/PD model 51
1 2 3 4 5 6 7 8 9 10
0
1
2
3
4
IRF9 mRNAc Cmax 
Fo
ld
 d
iff
er
en
ce
 [R
at
io
]
Models
D)
0 240 480 720 960 1200 1440
10 -4
10 -3
10 -2
10 -1
10 0
IRF9 mRNAc
0
0.5
1
1.5
Act Rec Cmax 
1 2 3 4 5 6 7 8 9 10
C)
A) B)
0 240 480 720 960 1200 1440
10 -4
10 -3
10
10 -1
10 0
-2
Act Rec
Time [min]
D
os
e 
N
or
m
al
is
ed
 fo
ld
 d
iff
er
en
ce
 [R
at
io
] 
fit 1 fit 2 fit 3 fit 4 fit 5 fit 6 fit 7 fit 8 fit 9 fit 10
FIGURE 3.13: The difference in intracellular response when consid-
ering in vivo PBPK/PD model (36 U; injected dose) vs. the in vitro
model (500 U; constant dose). Fold difference is plotted of A) Acti-
vated receptor complex and B) IRF9 mRNAc simulation (solid lines)
as a concentration time profile for the top ten models. C) The cal-
culated fold difference Cmax achieved for activated receptor complex
(Act Rec) (bars for each model respectively) and D) fold difference in
the Cmax of IRF9 mRNAc.
Evidently, there are differences in the signalling response’s dynamics over time
to varying IFN-α doses for in vivo and petridish experiments. As the model en-
semble simulated identical behaviour of the response to IFN-α stimulus. For clear
understanding, I show the best fit of the model ensemble (referred to as fit 1) for this
analysis. In this model simulation, the differences are clearly seen at the commence-
ment of the signalling where the response in the petridish experiments was faster
(peak of the response achieved at 2 hours after IFN-α dose stimulus) than in in vivo
(Figure 3.14 B, C and D), but, the Cmax was attained faster in in vivo situations. Also,
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due to the non-linear dynamics, the in vivo response shunts faster than the response
in petridish (where the dose was constant, hence the dynamics last more prolonged).
The in vivo - in vitro difference was further compared to the analysis done on the
hepatocyte model in section 3.4 , subsection 3.4.5, Figure 3.9. In the case of the hep-
atocyte model, when the in vitro model was simulated with the constant dose of 0.7
nmol/l (typical in vivo injection dose) and 13 nmol/l (typical in vitro petridish ex-
periment dose), the signalling dynamics were sustained and the Cmax was attained
at an identical time scale for most of the molecules. However, Figure 3.10 depicts
that although there is a 18 fold difference between the dose pipetted on the petridish
experiments to the injected i.v. in vivo dose, the Cmax attained for the activated recep-
tor complex (Figure 3.10 A) and the response biomarker IRF9 mRNAc (Figure 3.10
B) were identical (≈ 1.8 fold). This shows that the intracellular signalling was not
only pronounced at a longer time-scale but was also notably higher for the petridish
experiments than the drug administration. In addition, saturation in the peak am-
plitude of the IRF9 mRNAc response was already achieved at the dose of 0.7 nmol/l
(36 U; in vivo) when it served as a constant stimulus for the petridish experiments.
The model ensemble quantitatively exhibited the same behaviour.
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FIGURE 3.14: The difference in signalling patterns in the in vivo (PBP-
K/PD) response vs. the in vitro (Hepatocyte) response when dose nor-
malised to the fixed in vitro dose (13 nmol/l). The PBPK/PD model
are plotted with red lines, the hepatocyte in vitro culture simulation
are plotted with green lines. Simulation of concentration time pro-
files in human and in human cell lines of A) the non-linear IFN-α, B)
activated receptor complex C) IRF9 mRNAc and D) SOCS1 activated
downstream in the models
.
To be able to compare the time-scale of the maximum activation of the intracel-
lular response biomarker (IRF9 mRNAc) to IFN-α stimuli in in vivo vs petridish ex-
periments, a simulation with using a dose of 0.7 nmol/l (36 U injection dose) IFN-α
for both in vivo and petridish experiment was executed. In this simulation, petridish
dose was constant (in vitro; seen in Figure 3.15 A) due to lack of clearance processes
while the in vivo dose was a non-linear process due to the clearance of the drug from
the body (in vivo; seen in Figure 3.15 B). With a similar IFN-α stimulus, as seen in
Figure 3.15, the model exhibits identical dynamical behaviour as discussed earlier,
i.e., the Cmax was achieved faster in vivo dose as compared to petridish experimental
setup. It is noteworthy that at the simulated in vivo constant dose, the response was
approximately 6 hours (Tmax) earlier as compared to the response in for the typical
petridish experiment dose (B.10). It can also be seen in Appendix B, Figure B.11 that
the activation of receptors was 0.6x higher (B.11 A) and the IRF9 mRNAc response
was 2x higher (B.11 B) in conditions when the exact same doses were administered in
both experiments. This is evidently the case ,because in vivo, the IFN-α levels rapidly
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decrease after the peak is reached due to clearance processes. The respective impact
on the in vitro hepatocyte is not witnessed as the dose of IFN-α was constant which
led to an add-on response over time. In summary, these results indicate that intracel-
lular signalling is strongly reduced in the context of drug administration compared
to the typical lab experiments.
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FIGURE 3.15: time course of species for the hepatocyte model and
the PBPK/PD model using the same IFN-α dose (that of in vivo situa-
tions; Cmax of 0.7 nmol/l) for the hepatocyte model and the PBPK/PD
model. Dose normalised temporal dynamics of A) IFN-α B) Activated
Receptor Complex C) IRF9 mRNAc D) SOCS calculated by simulat-
ing the in vivo dose ( 0.7 nmol/l in the liver from the injected dose of
36 U) of IFN-α for PBPK/PD and in vitro model.
Impact of IFNAR2 variability on the IFN-α drug action Finally, as described above,
this model used gene expression data from an average healthy European adult to es-
timate receptor abundance in the liver. Variations herein will strongly influence the
results. Variation in physiological parameters also influences the variability in the re-
sponse profile. This is specially true for receptors. The target-mediated drug dispo-
sition (TMDD) is determined by receptor-ligand binding and is one of the essential
steps that not only determines the clearance of IFN-α in liver but is also an essential
component to account for response in patient variability. The multi-scale PBPK/PD
model can help to analyse this influence by varying the concentrations of IFNAR2
(Receptor 2) using parameter scans. To this end, I mimicked differences in both re-
ceptor abundanceies as well as receptor binding (since in the model both parameters
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were correlated). The parameter scan of different concentrations of IFNAR2 led to
slightly different venous plasma distributions ( Figure 3.16 A) but relatively differ-
ent mRNAc profiles (Figure 3.16 B). The difference in plasma profiles highlights the
impact of IFN-α binding to the receptor on the clearance of IFN-α in liver as well as
the therapeutic outcome of an IFN-α treatment when considering IRF9 mRNAc as a
functional endpoint. It is to note that such a model can be further used to investigate
the differences in therapeutic responses (patient variability and disease states).
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FIGURE 3.16: THe influence of parameter scan of various concen-
trations of IFNAR2 on the A) IFN-α plasma concentration and B) the
corresponding PBPK/PD model response of IRF9 mRNAc in the liver
3.6 Discussion
The presented IFN-α model integrates the hepatocyte model into the whole-body
PBPK model and defines the changes in signalling behaviour when considering an
in vivo context. Thereby, it captures the non-linear pharmacokinetic behaviour (Ab-
sorption, Distribution, Metabolism and Elimination) of IFN− α. This is a significant
step. Establishing the PBPK/PD model to predict IFN − α receptor induced phar-
macodynamics during a single IFN − α intravenous administration highlights the
importance of ligand receptor binding to be of primary importance for amplification
in antiviral IFN − α signalling pathway.
Incontestably, IFN-α is the most extensively used cytokine in clinical medicine.
In the form of recombinant or (peg)IFN-α it has been used as an effective therapy
against HCV and HCB for the past 20 years. It is compelling that despite being a
clinical success, intriguingly little is known about its mode of action and the pharma-
codynamic effects. One hindrance for understanding the molecular effects of IFN-α
therapy on hepatocytes is that the experimental investigation requires liver biopsies
of patients undergoing IFN-α or recombinant/peg- IFN-α therapy. Due to its nature
of being clinically cumbersome, it hard to achieve this for a significant amount of
patients and for sufficient time-points.
In the past, genome scale network models have been integrated in PBPK models
[205], [206]. In addition, PBPK models have been coupled with simplistic or abstract
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dynamic cellular network models [168], [207], [208]. Semi-mechanistic PK/PD mod-
els were built using monkey, mouse and human data [55], [134], [146], [209]. Addi-
tionally, on the macro-scale, analysis of different routes of injections on IFN-α phar-
macokinetic were addressed by statistical modelling (a.k.a mixed effect models) [57],
[136], [210], [211]. Moreover, two-compartment PK/PD models on patient popula-
tions have been reported in the literature [47], [49], [50], [212], [213]. The multi-scale
PBPK/PD model established and analysed in this work is a unique example of link-
ing a detailed cellular signalling model to a whole-body PBPK model using the case
of therapeutic protein such as IFN-α.
In pre-clinical assessments of the drugs, in vitro assays are a routine. In addi-
tion, these assays are the basis of research in systems biology and such experiments
help understand cellular responses. Thus, most of the knowledge about the biolog-
ical mechanism of signalling elicited by IFN-α has been obtained through extensive
cell culture experiments and animal models [59], [214], [215]. It is clear, that the be-
haviour of proteins or molecules in isolated primary cell-cultures does not represent
the actual behaviour of cells in tissue and in vivo. Therefore, one must acknowl-
edge that the actual cellular response in vivo is stronger than what is estimated in
this study due to, e.g., paracrine signalling in response to IFN-α. Nonetheless, this
work elucidates that the intracellular signalling is four-fold reduced in physiological
conditions and the temporal dynamics are governed by the in vivo drug elimination
[216]–[218]. The results of such a PBPK/PD model approach can give insights to
improve in vitro assay design (this processes is termed as reverse dosimetry) such
that in future physiologically relevant doses of IFN-α are used in experiments [219].
This analysis is of relevance because in vitro assay concentrations are frequently
chosen at high and saturating levels as exhibited in the experimental datasets ob-
tained from the literature for IFN-α where the dose of 500 U is normally used for
experiments. Such doses neither reflect natural physiological endogenous concen-
trations of IFN-α nor doses which are used in clinical applications. As in this study,
such a saturating dose is used to establish the intracellular model, we are aware
that the model can be challenged and hence the model ensemble was used. It is to
note that in the publication of Maiwald et al. [116], there is a strong comparison
between Huh 7.5 an primary hepatocytes and depicts that the response behaviour
in the cell-line is quantitatively and dynamically comparable to the primary hepa-
tocytes. Clearly, this does not rule out the possibility that the response in isolated
primary hepatocytes is not consistent to their behaviour when they are responding
in a physiological context. However, in the absence of a methodology that allows to
follow IFN-α signalling in vivo in a time-dependent manner, the work in this chap-
ter exhibits quantitative differences between in vivo and in vitro scenarios. Such an
approach can contribute to in vitro-in vivo extrapolation as integrating pharmacoki-
netic behaviour with intracellular signalling is profoundly different from calculat-
ing the amount of IFN-α in the liver based on pharmacokinetic models followed
by separately calculating subsequent intracellular behaviour by administrating the
corresponding dose once to the virtual hepatocyte. In the integrated model, both
processes occur in parallel and any time-dependent change in the availability of the
drug at the site of action immediately influences the cellular behaviour.
Furthermore, PBPK/PD models contribute to the understanding of tissue dis-
tribution of drugs using a virtual whole-body model. Such studies in humans are
unfeasible. One can use the virtual prediction of tissue distribution in humans and
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compare them to the observed tissue distribution in animals, where such studies
are possible. Therefore, a PBPK/PD model will help to quantify the differences in
response between animal studies and human patients. The model highlighted the
impact of target mediated disposition of IFN-α treatments plays a major role in the
efficacy of the treatment. Hence such models can be applied to understand inter-
individual variability of response in patients.
The hepatocyte model was well established and validated for short-term be-
haviour with quantitative data. On short-time scale there was a variety of data
available in the study of Maiwald et al. [116]. The proteins in this study were quan-
titatively calibrated. However, the data implemented for the prediction of long-term
behaviour of the model was less and therefore the predictive power of the model is
also less reliable. However, the most significant intracellular analysis, namely the
peak amplitude and speed of activation occurs in a time range for which we have
much quantitative experiments and hence a high degree of confidence on it. In ad-
dition, for the amounts of IRF9 mRNAc simulated in this work, we did not have
qualitative experiments and the data were only described in relative arbitrary units,
therefore the model is currently only able to quantify relative changes.
A significant comparison between PBPK/PD approach and classical PKPD ap-
proach is how in classical PK models of disease state, one only infers on the dose
with simplistic models on the cellular side which are not comparable and do not
give away as much insight as the integration of the mechanistic details can. This
is truer for compounds like IFN-α as they are produced by most cells of our body
and function in both autocrine and paracrine manner. In cases like these, it is more
important to have multi-scale modelling approach to understand the efficacy, speci-
ficity and toxicity profile of the drug.
Finally, I would like to stress that the workflow presented in this chapter could be
applied to other drugs eliciting intracellular responses and is by no means restricted
to IFN-α signalling. Patient specific data can be integrated at the level of protein
abundancies, e.g. for the receptors. In the end, for an at least semi-automated set-
up of such integrated multi-scale models, it would be important to specify a com-
mon standard for model exchange between the systems biology and pharmacoki-
netic models, e.g., accepting SBML as the common standard to exchange cellular
models.
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Chapter 4
Multi-scale PBPK/PD model of
IFN-α dose in mice
4.1 Chapter summary
The use of animal models in drug discovery pipelines is common in preclinical
stages. Due to practical and ethical reasons, mice have been an important pillar
in biomedical research. They are frequently used to test for toxicity, efficacy and
safety of a potential drug or compound. In many instances, mathematical models
can reanalyse the data produced by such studies to quantitatively evaluate other as-
pects of the biological system. In this chapter, we aim to demonstrate a quantitative
understanding of IFN-α drug action in mice at both the cellular and whole-organism
levels by applying a computational QSP approach.
In this chapter, I focus on the implementation of a virtual mouse model as a
potential alternative to gain in-depth understanding of the factors associated with
variability of responses to the drug dose in humans. Moreover, as an organism,
mouse has been widely used in biomedical research and, thus, establishment of such
models is of relevance for cross-species extrapolation of dose predictions.
A mouse PBPK model for i.v. injected murine IFN-α was established. The model
simulations analyse the differences in plasma profiles (absorption, distribution, metabolism
and elimination (ADME)) of injected human and murine IFN-α. At the cellular level,
a signalling pathway model of the JAK/STAT pathway was established to describe
the dynamic response of the antiviral protein MX2 following the IFN-α stimulus in
mouse hepatocytes. Subsequently, the mouse PBPK/PD model was established by
integrating the previous two models. This can be used to facilitate cross-species ex-
trapolation of murine dynamics to humans.
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4.2 Motivation and open questions
It is commonly believed that IFN-α stimulates innate immune responses and helps
liver cells clear viruses [68], [71]. Yet, a significant fraction of patients does not re-
spond to IFN-α treatment against HCV (reviewed in [220]) and multiple sclerosis
[178] and, many experience severe, adverse side effects [33], [221]. This variability
in patient response remains a key challenge for effective IFN-α dosage, as noted in
chapter 3. In chapter 3, the key obstacles arose from the fact that it is ethically un-
feasible to conduct experiments in humans. For example, there are many challenges
in obtaining human tissue for biomendical research or in conducting cellular experi-
ments using human tissue (reviewed in [222]). Therefore, after in vitro assays, animal
models are employed for understanding the response of the human physiology to
the drug [223]. Due to their accessibility and resemblance to the human genome (97
%) [155], mice have been regularly used in preclinical research (59% of the animals
used). For practical and economic purposes, carrying out tissue distribution and
ADME profile studies in mice are not difficult [39], [160], [177]. Before proceeding
with first in human trials, experiments in mice are absolutely necessary. However,
these trials have a low success rate [223]–[226]. Moreover, recently, the study by
Seok et al. [227] reported ”poor correlation of immune responses between mouse
and humans”. Consequently, the establishment of PBPK/PD model of mouse can
help to understand the reasons to the failure of IFN-α treatments in patients. Such
QSP models can also assist in addressing principles of the 3R (reduction, replace-
ment and refinement) for animal studies.
The induction of ISGs such as Mx genes have been correlated to IFN-α’s antiviral
properties [228]. Myxovirus resistance (Mx) protein is an antiviral ISG that func-
tions like a GTPase and is highly conserved across species. Mouse and humans
have 2 forms of Mx proteins:MX1 and MX2 are found in mice, while MXA and MXB
proteins are the human homologs. Studies indicated that MX2 is non-functional in
most inbred mouse strains but is functional in wildtype strains [229], [230]. In this
work, the mouse PBPK/PD model consisting of a mouse PBPK model coupled to
an intracellular signaling model was developed. The PBPK model was informed by
quantitative data on the i.v. injected IFN-α plasma concentrations measured in mice
and the cellular model is parameterised to measurents of antiviral response of Mx2
in JAK/STAT pathway, in primary mouse hepatocytes, respectively.
4.3 Mouse PBPK model
4.3.1 Preliminary analysis for mouse PK data
Some sections of this analysis were performed by Rebekka Fendt in her master thesis. This
work was co-supervised by myself.
The datasets from the literature and collaboratory effort measure the murine IFN-
α venous plasma concentration for 2 hours [39], 3 hours [158] and for 20 minutes
[157] (dataset provided by Dr. Mario Koester1). The i.v. injection of murine IFN-α
in Bohoslawec et al. [39] was 8.7× 105 U, Rosztoczy et al. [158] was 1.9× 107 U
whilst, the i.v. injected IFN-α dose published in Pulverer et al. [157] was, 5000 U.
Moreover, the conversion factors for the dose units (U) varied significantly in these
publications. Hence, the calculations from U to amounts of injected IFN-α resulted
to 0.205 nmol, 0.162 nmol and 0.0016 nmol respectively and differed enormously.
1Department of Gene Regulation and Differentiation, HZI – Helmholtz Centre for Infection Re-
search, Inhoffenstr. 7, 38124, Braunschweig, Germany.
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As the time-scale of the datasets from Pulverer et al. [157] and Bohoslawec
et al. [39] range between 20 mins to 2 hours, a compartmental analysis2 on the
two datasets was performed. For an i.v. dose, the pharmacokinetics of a com-
pound can be represented by one-compartment (mono-exponential decay) or multi-
compartment (bi or tri-exponential decay) models that are fitted to plasma concen-
tration over time.
In the mono-exponential decay or one-compartment model, the compartment is
homogeneous for murine IFN-α and after the i.v. bolus administration, the plasma
concentration of murine IFN-α is (also see Figure 4.1 A):
C(t) = C0Kel×t (4.1)
Where C is the murine IFN-α plasma concentration at time t, Kel is the elimination
rate constant (represents the total clearance from kidney and liver). The semi loga-
rithmic plot of a mono-exponential decay would be a straight line.
A two-compartmental model (bi-exponential decay) describes the two-phase plasma
distribution of murine IFN-α. After i.v. administration, the murine IFN-α is instan-
taneously distributed to the highly perfused central compartment (which represents
the liver and/or kidney) where the elimination of murine IFN-α occurs. This model
is represented by bi-exponential decay of murine IFN-α (also see Figure 4.1 B) as
follows:
C(t) = A · e−α×t + B · e−β×t (4.2)
Where C is the murine IFN-α plasma concentration at time t, A is the distribution
phase (slope, α) and B is the elimination phase (slope, β).
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FIGURE 4.1: Fit of exponential models to the observed plasma con-
centration profile (semi-logarithmic plot). Exponential models were
fitted in MATLAB to observed IFN-α plasma concentrations in A) Pul-
verer et al. [157] B) Bohoslawec et al. [39]. The data are in black solid
dots. The mono-exponential fit is represented by a solid blue line and
the bi-exponential fit is represented by a solid orange line. ONote the
differences in dose and time scale of the datasets.
2One or several organs modelled as kinetically homogeneous.
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For Bohoslawec et al. [39], Rsquared was 0.9589 for the mono-exponential fit and
0.9889 for the bi-exponential fit and for Pulverer et al. [157], Rsquared was 0.5731
for the mono-exponential fit and 0.9970 for the bi-exponential fit indicating that a
two compartment model explains the data better. However, fitting Pulverer et al.
[157] data is tricky as the last datapoint is 20 mins after the administration, which
is potentially the distribution phase for murine IFN-α and there is no information
on the terminal phase for this experiment. In addition, the last data point is an
outlier as the plasma concentration of murine IFN-α is higher than the second last
data point leading to a positive slope for bi-exponential fit. The exclusion of the
last data point to fit the model is not possible as the data would be too sparse for
the variables fitted (3 data points and 4 variables). Therefore, the fits for Pulverer
et al. [157] lack biological explanation. In the data from Bohoslawec et al. [39], the
steep decline of murine IFN-α immediately after administration and the resulting
good bi-exponential fit is primarily due to rapid distribution of murine IFN-α from
plasma to well perfused organs. However, the data are not necessarily indicating
the shallower clearance due to insufficient measurements. From the data of Pulverer
et al. [157], no conclusion of the PK of murine IFN-α dose-dependent effects can be
drawn.
Although a two-compartment model is able to provide a good fit for the plasma
concentration of murine IFN-α, a PBPK model was considered to have a detailed
physiological understanding in predicting the target site concentrations of murine
IFN-α and is able to take mechanistic details into account. Therefore, the PBPK
model was solely fitted to the data from Bohoslawec et al. [39] and Roszotoczy et al.
[158].
4.4 Mouse IFN-α PBPK model
The goal of this work is to compare quantitative differences between in vitro- in
vivo scenarios and analyse cross-species extrapolation using QSP approach. For this
reason, in the following sections the workflow of the model development and the
structure of models (both, PBPK and intracellular model) are identical to that of the
human counterpart elaborated in chapter 3. Therefore, in the following sections,
wherever the human model approach is retained, I will refer to chapter 3.
A protein PBPK model of murine IFN-α distribution was established in PK-Sim
for an average mouse (Appendix C Table C.3), compound specific parameters (Ap-
pendix A, Table A.4). The route of administration is intravenous bolus. Mouse
IFANR1/2 tissue expressions were defined from the PK-Sim database. The recep-
tors were localised in the mouse liver interstitium. The clearance of murine IFN-α
via kidneys was inserted from the literature [39]. i.v. bolus injection of murine IFN-α
as reported by Bohoslawec et al. (1984) [39] and Rosztoczy et al. (1986) [158] were
used to fit the model.
4.4.1 Mouse PBPK model overview
The ADME profile of murine IFN-α was modelled as zero order input rate and first
order elimination rate. All the parameters for the pharmacokinetic modelling are
listed in Table 4.1. As stated in chapter 3, the liver was simplified as one big cell
and receptor amounts and concentrations were calculated as in the forthcoming
subsection 4.4.2, 4.4.2. The liver was divided into 3 compartments: the intersti-
tial, the cytoplasm and the nucleus. The defined volumes of each compartment is
described in the Appendix C, Table C.4. Similar to the human PBPK model, the
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IFN receptor dynamics were modelled in the interstitial compartment and consists
of the detailed receptor ligand interaction and turnover kinetics. Here, the murine
IFN-α drug dose arriving in the liver interstitiu binds to IFNAR2 to form a dimeric
ligand-receptor complex (IFNA-IFNAR2 Complex) (M1). The ligand-receptor com-
plex (IFNA-IFNAR2 Complex) binds to IFNAR1 to form the hetero-trimeric ligand
receptor complex (Activated Receptor Complex) (M2). The IFNAR2 and IFNAR1
basal turnover in the absence of the drug is modelled (M3 and M4). Finally, the
hetero-trimeric ligand receptor complex is internalised and degraded (M5). Illustra-
tion of the interactions can be found in chapter 3, Figure 3.1.
Reactions and rate laws used for the mouse PBPK model The reactions and the
rate laws used for the mouse PBPK model are the same as the ones used in the
human model. In summary, all the reactions are described by mass action kinetics.
For details of the kinetics, please refer to chapter 3, paragraph 3.3.1
4.4.2 Calculations for the PBPK model
Calculation of receptor concentration These calculations were performed by Rebbeka
Fendt in her master thesis.
The mean number of receptor IFN-α receptor per animal was assumed to be 1000
receptors per cell (inclusive of receptors: IFNAR1 and IFNAR2) and a cell mass of
10−12 kg was measured by others [191]–[193], [231]. The number of hepatocytes per
gram of mouse liver has been estimated as 135× 106 cells/g liver [188] which is close
to the human liver hepatocellularity. Different expression profiles of the receptors
were not taken into account.
Number o f Cells per animal =
Body weight
cell mass
=
0.021 kg
10−12 kg
= 2.1× 1010 cells (4.3)
Receptors per animal = number o f cells× receptors per cell
= 2.1× 1010 × 1000 receptors per cell
= 2.1× 1013 receptors
(4.4)
RecAmount Liver = (
number o f receptors
avogadro constant
) = (
2.1× 1013
6.02× 1023 ) = 3.5× 10
−11mol (4.5)
Receptor amount = 35pmol (4.6)
Calculation of the concentration of total receptors in the liver of the mouse
Receptor Concentration Liver = Receptor density per cell×
Mouse hepatocellularity number× liver density (4.7)
Recexp(
Receptor
ml
) = 1000(
Receptor
cell
)× 135× 106( Cells
gliver
)× 1.05( gliver
ml
) (4.8)
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Recconc(
mol
ml
) =
142× 109(Receptorml )
6.02× 1023 = 2.35× 10
−13(
mol
ml
) (4.9)
RecconcLiver = 0.235
pmol
ml
(4.10)
4.4.3 Parameter estimation strategy for the mouse PBPK model
The parameters of the simulated PBPK model were calibrated to plasma concentra-
tions (datasets from Bohoslawec et al. [39] and Roszotoczy et al. [158]). The esti-
mated parameters were- the plasma clearance, the individual receptor (IFNAR1 and
IFNAR2) and receptor complex dissociation rates and dissociation constants (Koff
and KD), the endocytosis rate of the receptor complex into the cells and the basal
turnover rates of the individual receptors (IFNAR1 and IFNAR2). In addition, it
was necessary to estimate the clearance as the total body clearance exhibited in the
literature was inclusive of the following three clearance rates: renal clearance, hep-
atic clearance and lung clearance. Furthermore, the total body clearance was given
per animal and the animal weight was not specified which makes the normalisa-
tion to the body weight required for the input parameter imprecise. However, the
clearance rate required for the mouse PBPK model was the renal clearance only as
the hepatic clearance rate was estimated for by the mechanistic receptor mediated
disposition. The mouse body weight was taken as the average mouse weight due to
the reported inconsistent weight.
The parameters of the established PBPK model were estimated by the Levenberg-
Marquardt algorithm and 150 parameter sets were obtained describing the venous
plasma concentration. The RMSD error (measure of the differences between values
predicted by the PBPK model and the values observed in the dataset) of all the fits
lay in the range of 1.28-1.30. The top five parameterisations of the simulation exhib-
ited similar plasma profile of murine IFN-α in the plasma, e.g., the similarity of the
of the simulations from first two parameter sets of the murine IFN-α plasma profile
for the datasets of Bohoslawec et al. [39] and Roszotoczy et al. [158] are shown in
Figure 4.2.
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FIGURE 4.2: Semi-logarithmic plot of the simulations of the first
two fits of the venous blood plasma profile of murine IFN-α for the
datasets of A) Bohoslawec et al. [39] and B) Roszotoczy et al. [158].
The simulations of the fit are plotted in solid line and the datasets are
plotted as circles. The y-axis is on a lograthmic scale and describes
the venous plasma concentration of murine IFN-α distribution while
the x-axis represents the time points in mins.
In some parameterisations, the reference concentrations values of the individual
receptors- IFNAR1 and IFNAR2 spanned in large range while presenting similarly
good simulation to the observed data, but the ratio of the concentrations of receptors
for some fits were not biologically relevant (e.g., the ratio of the concentration of IF-
NAR1 to IFNAR2 being 30:1, was a 30 order difference in magnitude while the ratio
reported in the literature is 2:1 [90]; see Appendix C, Figure C.1). The parameter for
clearance rate via kidneys was well defined, but the constants for receptor binding
(koff) and the constant for receptor turnover for the individual receptors ranged in
a span of 2 orders of magnitude. Since the top five PBPK model parameterisations
do not differ with regard to the simulation of murine IFN-α plasma or liver concen-
trations and are an input to the signalling model which will be integrated, Fit 1 is
a good representation of the fit ensemble as it has biologically relevant parameter
values (see Figure 4.3). The obtained simulations were not able to describe the ter-
minal points of the dataset. For Bohoslawec et al. [39], the simulation is not able
to describe the rapid terminal decline of the murine IFN-α plasma concentration for
the last sample measured at 160 mins. A similar difference can be noticed between
the PBPK model and the experimental data by Roszotoczy et al. [158], where the
last two samples at time points 325 mins and 660 mins show a slow decline in the
murine IFN-α plasma concentration.
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FIGURE 4.3: Physiologically based pharmacokinetic (PBPK) model fit
simulation and experimental blood plasma profile for Bohoslawec et
al. [39] and Roszotoczy et al. [158] of murine IFN-α in mouse. The
goodness of fit is plotted on the right (small plot) where the RMSE
and the Rsquared values are depicted.
4.4.4 Validation of the mouse PBPK model
The PBPK model simulation of murine IFN-α venous blood plasma concentration
was validated to the dataset of Kuichi et al. [159] where a 0.154 nmol dose of murine
IFN-α was intravenously injected into mice. The validation of the parameter set in-
creases confidence in the prediction of the PBPK model to different murine IFN-α
injection doses. Murine IFN-α concentrations in mouse plasma data was success-
fully simulated for a single i.v. injection (see Figure 4.4) representing the dataset.
A striking amount of murine IFN-α is cleared in a mono-exponential fashion, espe-
cially in the first 100 mins. (Figure 4.4 and Figure 4.3).
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FIGURE 4.4: Physiologically based pharmacokinetic (PBPK) model
simulation validated to the experimental blood plasma profile of
murine IFN-α from Kuichi et al. [159] in mouse. The goodness of fit
is plotted on the right (small plot) where the RMSE and the Rsquared
values are depicted.
The human IFN-α (hu-IFN-α) differs from murine IFN-α w.r.t. its kinetics of its
clearance from the plasma. In particular, studies reported inter-species IFNAR bind-
ing differences between hu-IFN-α and murine IFN-α for reasons that are not well un-
derstood [232]. After injection, murine IFN-α is cleared rapidly from the mice blood
(having a half-life of around 4.5 mins) but the clearance of corresponding doses are
reported for hu-IFN-α to be slow and with longer half life (15-20 mins) [159]. This
behaviour is not understood but hypothesised to result from the strong affinity of
murine IFN-α to homologous tissue (mouse tissue) [159]. The other reason is the
species-specific antigenicity against heterologous IFN-α (human IFN-α but in mouse
tissue) [233]. I tested the two hypotheses with the murine PBPK model. For the first
reason, the simulations exhibited no changes (results not shown). For the second
hypothesis, I compared model simulations with the measurements by Koyanagi et
al. [160] who injected hu-IFN-α in mice. The simulation suggested a more rapid
decline than reported of hu-IFN-α from the plasma of mouse. I analysed if the hu-
IFN-α plasma concentration could be simulated by changing the binding kinetics of
the receptors in the model. This was implemented by scanning the parameter values
of the binding kinetics of the receptors but they did not display any significant effect
on the clearance of hu-IFN-α in the simulation. I then explored the second reason
where, I varied the fraction unbound parameter value of hu-IFN-α to account for
varied antigenicity. This variation caused the simulation to slow down the clear-
ance of hu-IFN-α from the plasma (Figure 4.5). Thus, the simulation supported the
hypothesis of inter-species differences in the response to different IFN-α types.
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4.4.5 Analysis of the mouse PBPK model
Tissue distribution of murine IFN-α in mice IFN-α is used as an antiviral drug
in humans [6], [41], [234]. Ideally the data on tissue distribution of human interfer-
ons should be collected in experiments on humans but, as stated in chapter 3, tissue
distribution studies are not feasible in humans. However, its worthy to have data
on tissue distribution of IFN-α injection. Therefore, many studies for the same were
executed in mouse, rabbits and monkeys [36], [39]–[41], [235], [236]. Johns et al. [40]
measured the tissue distribution of murine IFN-α in different tissues of mice 30 mins
after the injection of a radioactive single dose of murine IFN-α. They reported the
highest amount of murine IFN-α in the liver and the kidneys and small amounts in
fat tissue of mice. The whole-body mouse PBPK model gives an opportunity to sim-
ulate and analyse the tissue distribution. The results of the simulation indicated that
the liver is the organ that contains the highest amount of murine IFN-α at 30 mins.
In contrast to the observation by Johns et al. [40], in the simulation the concentra-
tion of murine IFN-α in muscle is close to that of kidney, plasma and lungs at 30
mins and is significantly higher than in fat. Thus the model indicates the transfer of
murine IFN-α i to the muscle is stronger than in vivo experiment. This result should
be tested in experimental settings. However, there is congruence between the model
and the experiments as initially, the concentration of murine IFN-α in highly per-
fused organs like kidney, spleen and liver is close to the blood plasma concentration
of murine IFN-α but it decreases rapidly over time to be close to the poorly perfused
tissues.
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FIGURE 4.6: Simulation of the tissue distribution of murine IFN-α af-
ter i.v. administration of a single 2.35 nmol dose in the mouse PBPK
model. The vertical dashed line represents time=30 mins. murine
IFN-α tissue tissue concentrations in descending order after 30 min:
liver, (plasma), kidney, muscle and fat (with kidney and muscle con-
centrations being almost equal).
4.5 IFN-α mouse hepatocyte model
The hepatocyte model implemented in this study is the extension of the hepatocyte
model from in chapter 3. In summary, the model comprised of two compartments:
Nuclear and cytoplasmic, 23 species and 23 reactions. The details of the model struc-
ture are described in chapter 3, subsection 3.4.1. Due to the lack of data on interme-
diate pathway, the kinetic parameter values and the initial concentrations of the pro-
teins in the JAK/STAT pathway were kept identical to the human hepatocyte model
were kept identical because the molecules depict high homology between human
and mouse. Therefore, the existing hepatocyte model of the JAK/STAT pathway
was extended by three reactions to include the kinetics of Mx2, which is the followed
biomarker of this study. The initial concentrations of the molecules, their kinetic rate
law values and the scaling factors of the model were the same as the human hep-
atocyte model. However, the kinetics of the interaction of the receptors to murine
IFN-α, the activation of the ternary complex and the volume of the liver compart-
ment had the physiological parameters describing the mouse plasma concentration
from the mouse PBPK model.
4.5.1 Intracellular hepatocyte model overview
For the extension of the human hepatocyte model from chapter 3 I analysed the
homology and identity of the molecules for the pathway between the two species
(Appendix C, section C.2, TableC.7). The BLAST of the sequences had high homol-
ogy of the molecules of the JAK/STAT pathway of human and mouse. The details
of the upstream JAK/STAT pathway of the human hepatocyte model are found in
3, subsection 3.4.1. The human hepatocyte model of the JAK/STAT pathway was
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extended by three reactions. These reactions described the Mx2 mRNAc transcrip-
tion (R12), Mx2 mRNAc degradation (R13) and translation of the Mx2 protein (R16).
For this, the model had 2 different molecules introduced to it: The mRNA of Mx2
(mRNA Mx2) and the followed protein of interest MX2 (Mx2). The details of the
reactions and their kinetic rate laws are summarised in Table 4.1 and in Figure 4.7.
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FIGURE 4.7: The structure of the kinetic model of IFN-α signalling
pathway from the human hepatocyte model is depicted. It was fur-
ther extended to include the reaction kinetics of Mx2 transcription,
translation and degradation respectively (R12, R13 and R16). The
downstream cytoplasmic and nuclear reactions (solid black arrows)
and degradation reactions (red arrows with φ) are divided into the re-
spective model compartments (dashed yellow line). Finally, the feed-
back reactions were modelled (solid red line).
Reactions and rate laws Most reactions were modelled as mass action kinetics
(4.11).
vi = ki × [Substrate1]× [Substrate2]− 1keqi × [Product] (4.11)
Here the velocity of the reaction is determined by the ki and keqi and the transition
concentration of the [Substrate1], [Substrate2] and the [Product].
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Information on the nuclear binding sites of Mx2 The Mx2 gene has been reported
to be non-functional in all laboratory mouse strains due to mutations but expressed
in feral mice [237]. Mammals have structurally related nuclear and cytoplasmic Mx
proteins (collective of Mx1 and Mx2) [229], [238]. The human MxA promoter site was
reported to have three ISRE sites [239]. The mouse Mx2 promoter site was reported
to have two putative ISRE binding site and one IRF binding site, thus, allowing for
cooperativity [240].
The Mx2-luc expression dose response data on mouse primary hepatocyte in re-
sponse to mu-IFN-α were generated by Dr. Mario Koester at HZI, Braunschweig.
Initially, models with three different transcription rate law for Mx2 gene were eval-
uated as there is little knowledge on the mechanism of the gene transcription. The
models were also evaluated by including nuclear export reaction for Mx2 since the
transcription takes place in the nucleus and the protein is expressed in the cyto-
plasm. The evaluated models that included nuclear transport showed extreme delay
in the gene expression and therefore that process was discarded. Thenceforth, the
models with different transcription rate law for Mx2 and the cytosolic transcription
of Mx2 mRNA were analysed. The rate laws that were tested were Hill kinetics,
Michaelis Menten kinetics and mass action. Initial concentrations of the Mx2 pro-
tein and Mx2 mRNA were assumed to be zero because there is no constitutive Mx2
expression in vivo. The preliminary evaluation of the parameter estimation of the dif-
ferent rate laws showed that mass action kinetics could explain the Mx2 expression
data (Figure 4.8).
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FIGURE 4.8: Parameter estimation of the three rate laws of Mx2 tran-
scription for two doses of mu-IFN-α where the doses are 5 U (light
grey, six replicates) and 500 U (dark grey, six replicates) on mouse
primary hepatocytes A) Hill kinetics, B) Michaelis Menten kinetics
and c) mass action kinetics. The simulations of Mx2 response for the
two doses: 500 U (light blue) and 5 U (dark blue) are plotted as solid
lines. The y-axis depict the Mx2 luciferase light intensity in arbitrary
units and the x-axis define the time in mins (34 hours). Note that mass
action kinetics (C) is able to describe the Mx2 expression data.
4.5.2 Parameter estimation strategy for the mouse intracellular
hepatocyte model
Mapping of the model variables to the data As detailed in chapter 3, for the in-
tegration of the mouse hepatocyte model into the PBPK model, I need to ensure
consistencies at the receptor kinetics level. Thus, the receptor parameter values and
the equation was taken from the mouse PBPK model into the hepatocyte model (the
parameter values can be seen in appendix C, Table C.9). Scaling factors were added
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to the model to be able to represent the arbitrary units of the simulated Mx2 concen-
tration observed as light intensity of luciferin-luciferase reaction. The protein Mx2
of the model was mapped (4.12) to the dataset as follows:
Mx2†(ti) = ϕ1 ×
(
Mx2(ti)
)
(4.12)
where ϕ1 is the scaling factor.
Fitting the deterministic model Due to the size of the model and the lack of infor-
mation on the intermediate pathway molecules, the fitting of all the parameters was
a hard optimisation problem. Therefore, I extended the human hepatocyte model
ensemble of ten models from chapter 3, subsection 3.4.3 with the Mx2 transcription
(mass action kinetics), translation and degradation kinetics. The models in the en-
semble had identical structure and the parameterisations for the Mx2 reaction kinet-
ics were analysed using the parameter estimation strategy with random start values.
80 different parameterisations of each model in the model ensemble were executed
using the Particle Swarm algorithm. Therefore, in total 800 parameterisations were
obtained. In the distribution of parameter values of the model ensemble (see Figure
4.9), most parameters were evidently unidentifiable due to their broad distribution.
For example, some of the parameters were spread over the range of the parameter
variation, such as, the rate constant k1 for the transcription of MX2 mRNA and the
activation and degradation constants of the Mx2 protein synthesis, kact and kdeg.
Also, there is a correlation in the activation and degradation constants of the Mx2
protein.
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FIGURE 4.9: The parameter values of 800 fits are represented in the
box plot. The likely value of the fitted parameter is represented by the
box (green), the full range of the parameter variation is represented
by the dashed line (black) and the median is indicated by a solid line
(black).
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As the information on several parameters modelled was sparse, to deal with the
model uncertainty and scarcity of the data, further analysis was based on model en-
semble of ten models [203]. The ten models have identical model topology but dif-
ferent parameter values (see Appendix C, Table C.8) that described the experimental
data equally well and encompass the full range of possible biologically relevant pa-
rameter values. Simulations of the top ten models replicate the high and the low
murine IFN-α dose of the experimental data.
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FIGURE 4.10: Here, the parameter estimation results of the top ten
models in the model ensemble are shown. The experimental time
courses of the response of Mx2 for 500 U (black dots) and for 5 U
(grey dots) dose of murine IFN-α on primary mouse hepatocyte are
plotted. Corresponding to that the simulations (solid lines) of the
model ensemble are plotted. The x-axis of figures represent the time
scale at which the measurements were taken after the applied IFN-
α stimulus. The measurements of the protein expression are in light
intensity and arbitrary units are plotted on y-axis.
4.5.3 Validation of the intracellular mouse hepatocyte model
Further, I analyse the model ensemble against the dose response time points of the
dataset provided by Dr. Mario Koester. In the dataset primary mouse hepatocytes
were stimulated with murine IFN-α and the Mx2-Luciferase activity was determined
24 hours after stimulation. There are three replicates for each response measurement.
The simulations of the model ensemble reproduces the dose response experiments
(Figure 4.11). The maximum response of Mx2 was attained at doses between 25 to
100 U. The simulations of the model ensemble were spread between exhibiting sharp
peak response of Mx2 after 25 U (Fit 7-10) and exhibiting peak response of Mx2 at
100 U of murine IFN-α stimuli (Fit 1-6).
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FIGURE 4.11: In the above graph the model ensemble simulations are
plotted (solid) against the validation dataset where, the two different
doses of murine IFN-α stimuli trigger the response of Mx2 expression
(black circles). The 24th hour dose response curve is shown for the
datasets. The doses are 1 U, 5 U, 10 U, 25 U, 100 U, 500 U and 2500 U.
Semi-logarithmic y-axis represents the Mx2-Luciferase activity in ar-
bitrary units. The x-axis represents the aforementioned (3) interferon
doses in model units.
4.5.4 Analysis of the intracellular mouse hepatocyte model
The difference between 5 U and 500 U of murine IFN-α doses on primary mouse
hepatocyte response of Mx2 The intracellular mouse hepatocyte models in the en-
semble were simulated for the two murine IFN-α doses: 5 U and 500 U. The dynam-
ical behaviour of the ensemble was identical and hence I show the first model from
the ensemble as a representative example (Figure 4.12). For the propagation of the
signalling cascade, the simulations showed a time delay in reaching the peak con-
centrations. I.e., from the binding of STAT molecules to the receptors to have their
phosphorylated forms (Receptor + STAT1/2) to the expression of the proteins (Mx2
& SOCS1 ). Interestingly, the difference in the transcription sites on the DNA that
were bound to the transcription factor (occupied sites) differed by a factor of five
between the two doses of murine IFN-α while the doses differed by a factor of 100 (5
U and 500 U). This implies the dampening of the signal as it propogates to activate
the transcription. Also, the Mx2 expression consistently differed by a factor of four.
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FIGURE 4.12: The simulations of the representative model response
to high and low doses of murine IFN-α are shown. The receptor acti-
vation dynamics are plotted in the top panel (semi-logarithmic plot).
In the middle panel the dynamics of DNA-bound transcription factor
and the cytoplasmic mRNA of Mx2 are plotted. In the last panel the
dynamics of the proteins Mx2 and SOCS1 are plotted. The y-axis de-
pict the concentration of the molecules and the x-axis depicts the time
of the simulation in hours (up to 24 hours). SOCS.
4.6 IFN-α PBPK/PD mouse model
The PBPK model was coupled to the mouse hepatocyte model in MoBi to establish
whole body PBPK/PD model of IFN-α intravenous dose in mice. The integration
of the multi-scale PBPK/PD model was executed as instructed in chapter 3, Section
3.5.
4.6.1 Mouse PBPK/PD model overview
The hepatocyte model was integrated into the PBPK organism model in the intersti-
tial space of the liver. The point of interaction of both models is the receptor binding
of IFN-α at the target site. The receptor concentrations and the kinetics were kept
identical to the PBPK organism model simulation after the hepatocyte model in-
tegration and the kinetics for the same were present in the interstitium of the liver.
The intracellular compartment and structure of the hepatocyte model was preserved
from the mouse hepatocyte model in the PBPK/PD model. A detailed description
of the individual models are given in the section 4.3 and 4.5 respectively. The pre-
sented mouse PBPK/PD IFN-α model integrates the whole body distribution model
(data from Bohoslawec et al. [39] ) with activated cellular signalling of IFN-α and
represents changes in the signalling behaviour while considering the in vivo context.
Thereby, it captures the non-linear pharmacokinetic behaviour (absorption, distribu-
tion, metabolism and elimination) of IFN-α and is schematically described in Figure
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4.13. The details of the kinetic rate laws for the PBPK/PD model are described in
Table 3.2 with the reference of multiscale compartment.
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FIGURE 4.13: The diagram is a schematic representation of the struc-
ture of the mmouse PBPK/PD model. The murine IFN-α drug dose
from the mouse PBPK model arrives in the liver where, it interacts
with the receptors in the interstitium of the PBPK model (reactions
M1-M5). The downstream mouse JAK/STAT cascade was introduced
at the Activated receptor complex and the signalling pathway was com-
partmentalised in the intracellular and the nuclear compartment in
the liver (reactions M6-M17).
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TABLE 4.1: Collective reaction list: The individual reactions for both mouse models: the in vitro hepatocyte and the in vivo PBPK/PD
model. The column with R# and Cell Compartment depict the reactions that are present in the in vitro hepatocyte model. The columns
with M# and multi-scale compartment do the same for the in vivo PBPK/PD model. The column reactions describe the modelled
pathway along with the column kinetic rate law which gives insight on the kinetics used to model each step.
#
Cell
Compartment
Multiscale
Compartment
Reaction
Kinetic
rate law
R1 - Cell Intracellular - IFN→ ∅ k1 · S
R2 M1 Cell Intracellular Liver Interstitial IFNA + IFNAR2
 IFNA-IFNAR 2 Complex k1 · S1 · S2− P/keq
R3 M2 Cell Intracellular Liver Interstitial
IFNA R2 Complex + IFNAR1

 Activated Receptor Complex k1 · S1 · S2− P/keq
R4 M3 Cell Intracellular Liver Interstitial
Activated Receptor Complex

 [SOCS1] IFNAR1 + IFNAR2
V·S·A
(Kms+S)(Ka+A)
- M4 - Liver Interstitial ∅ −→ IFNAR1 rel exp out× AF× f o× k t− S× k t
- M5 - Liver Interstitial ∅ −→ IFNAR2 rel exp out× AF× f o× k t− S× k t
R5 M6 Cell Intracellular Liver Intracellular Activated Receptor Complex + STAT2c→ Rec2 k1 · S
R6 M7 Cell Intracellular Liver Intracellular Rec2 + STAT1c −→ Rec21 k1 · S
R7 M8 Cell Intracellular Liver Intracellular Rec21 + IRF9c −→ ISGF−3c +
Activated Receptor Complex
k1 · S
R8 M9 Cell Intracellular Liver Intracellular ∅
Occupied ISGF−3n−−−−−−−−−−⇀↽ −
binding sites
mRNAc SOCS k1 ·M
R9 M10 Cell Intracellular Liver Intracellular mRNAc SOCS −→ ∅ k1 · S
R10 M11 Cell Intracellular Liver Intracellular ∅
Occupied ISGF−3n−−−−−−−−−−⇀↽ −
binding sites
mRNAc k1 ·M
R11 M12 Cell Intracellular Liver Intracellular mRNAc −→ ∅ k1 · S
R12 M13 Cell Intracellular Liver Intracellular ∅
Occupied ISGF−3n−−−−−−−−−−⇀↽ −
binding sites
mRNAc Mx2 k1 ·M
R13 M14 Cell Intracellular Liver Intracellular mRNAc Mx2 −→ ∅ k1 · S
R14 M15 Cell Intracellular Liver Intracellular ∅ mRNAc−−−−⇀↽ − IRF9c (kconst + kact)M− P · IRF9deg
R15 M16 Cell Intracellular Liver Intracellular ∅ mRNAc SOCS−−−−−−−⇀↽ − SOCS 1 k act ·M− K deg · P
R16 M17 Cell Intracellular Liver Intracellular ∅ mRNAc Mx2−−−−−−−⇀↽ −Mx2 k act ·M− K deg · P
R17 M18 Exchange Exchange STAT1n
 STAT1c k1 · S− P/keq
R18 M19 Exchange Exchange STAT2n
 STAT2c k1 · S− P/keq
R19 M20 Exchange Exchange IRF9n
 IRF9c k1 · S− P/keq
R20 M21 Exchange Exchange ISGF-3c
 ISGF-3n k1 · S
R21 M22 Cell Nucleus Liver Nucleus
Open ISGF-3n
binding sites
+ ISGF-3n
 Occupied ISGF-3n
binding sites
k1 · S1 · S2− P/keq
R22 M23 Cell Nucleus Liver Nucleus
Occupied ISGF-3n
binding sites
→ STAT 1n + STAT 2n + IRF 9n
+ Open ISGF-3n binding sites
k1 · S
R23 M24 Cell Nucleus Liver Nucleus IRF9n −→ ∅ k1 · S
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4.7 Discussion
In this chapter, a whole-body mouse PBPK/PD model for murine IFN-α injection
is presented. By integrating a mouse hepatocyte model into a whole-body PBPK
model, this would improve the understanding of risks and toxicity profile of poten-
tial drug candidates and compounds, as well as help reduce costs and animal ex-
perimentation. Such QSP model would enable more comprehensive simulations on
dose-effect relationship between IFN-α injection and the response of the biomarker
Mx2 protein in the future. Ultimately, the PBPK/PD model can quantitatively show
the differences between preclinical knowledge of murine and human IFN-α sub-
types. This would, in turn, support an in depth understanding of cross-species ex-
trapolation and enable a quantitative understanding of the discrepancy between in
vitro in vivo IFN-α doses.
In general, the lack of quantitative data is a problem in systems pharmacology.
For many drugs, such as IFN-α, such data gets scantier as the dosage is commonly
quantified in international units resulting to difficulties in quantification. However,
the molar concentrations are crucial for mathematical modelling. As there is high
variability in the different batches of IFN-α preparations, the conversion factors tend
to differ in orders of magnitude. Moreover, the specific activity is not commonly re-
ported in the literature, thus leading to strong uncertainty about the injected dose.
The rapid initial drop (monoexponential decay) of the in vivo murine IFN-α plasma
concentration was explained by the current PBPK model. However, the model could
not explain the data of injected murine IFN-α by Pulverer et al. [157]. This is poten-
tially due to the short-time scale of the dataset (20 mins.) where it exhibits potential
distribution phase. Thus, no conclusion could be drawn from this dataset. Type
I interferons are reported to have species-selectivity, making it harder to interpret
cross-species experiments. The PBPK model was able to shed some light on the dif-
ferences between the pharmacokinetics of murine IFN-α 4 vs. human IFN-α 2 types,
although the simulation could not distinclty describe the termination phase in the
pharmacokinetics of human IFN-α 2. The model suggests that the inter-species vari-
ability seen in the differences in pharmacokinetics of the subtypes could be due to
either unspecific binding of IFN-α to cell-surface receptors or plasma proteins. The
measurements of unbound fraction of IFN-α (fu) could help to clarify this. Further-
more, there are various mouse and human IFN-α subtypes and further experiments
on them could help in the understanding of which subtype could be used in cross-
species experiments.
The mouse PBPK model is an effective tool to quantify and validate the tissue
distribution of murine and human IFN-α in mouse as an organism. Using this val-
idation analysis method, the pharmacokinetics and tissue distribution of IFN-α can
be well studied in preclinical stage and can therefore effectively reduce the failure
of IFN-α in the drug development process. Mouse is a very suitable organism to do
tissue or organ distribution analysis of IFN-α and would also contribute to under-
standing the influence of the distribution on the observed dose-effect relationship.
In literature, the murine Mx2 promoter site is reported to have two putative ISRE
binding sites and one IRF-E site, thus allowing for cooperativity [240]. In this work,
constitutive luciferase activity has been used as an in vitro assays on primary mouse
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hepatocytes for Mx2 expression. The mouse hepatocyte model was evaluated for
cooperativity in the transcription kinetics and it has been noted that the mass action
kinetics was able to describe the experimental data. Until now, the mouse hepato-
cyte model does not account for the constitutive activity of Mx2 baseline expression
hence the initial Mx2 mRNA and protein concentrations were fixed to zero. How-
ever, baseline expression of Mx2 have been reported in the literature [241]. Kariko
et al. [242] observed that the Mx2 endogenous expression can be caused by cellu-
lar stress response which triggers the IFN expression via the activation of the Toll
like receptor 3. High expression of Mx protein is the key marker of antiviral resis-
tance by the JAK/STAT pathway. Hence, the incorporation of the basal expression of
the ISG would help improve insights into the endogenous activity of the signalling
pathway. Most importantly, the model parameters are probable parameters as the
compartments are assumed to be well stirred and diffusion processes are not con-
sidered in the model, as the diffusion processes are not the focus of this work.
From the experiments, the Mx2 dynamics over time for IFN stimulation is not
well determined and hence would need to be repeated with more condensed mea-
surements during the time course. The information on the time at which Mx2 achieves
maximum response is missing and the current experiments do not explain whether
the maximum response attained by Mx2 is sustained or whether it decreases with
the later time-points. Lastly, the experiments on mouse cells for the molecules of the
JAK/STAT pathway would be beneficial to add value to the current mouse hepato-
cyte model.
Commonly, in the in vitro assays, the volume of the medium is considerably
larger than the volume of the seeded cells. Thus, the absolute amount of IFN-α is
commonly higher than the number of receptors present at the cell surface. In such
cases, where clearance is absent in in vitro assays, time resolved measurements of
IFN-α concentration in the medium, in order to analyse if the concentration of IFN-α
drops or stays constant over-time, would be most beneficial.
The current PBPK/PD models of human and mouse intentionally neglects the
direct binding of IFN-α to IFNAR1 (Interferon alpha receptor 1). This choice was
made based on the observation that only a small fraction of IFN-α binds to IFNAR1
due to its weaker binding constant for that receptor [185], [243]. Furthermore, the
affinities of IFN-α to the individual receptor subunits have been reported but there
is no information on the rate constants for the formation of the ternary complex.
Furthermore, the model could give insights on the influence of target mediated
disposition of murine IFN-α concentrations in tissue and blood. Lastly, such a model
could be employed in the future to analyse the impact of other biological effect of
the trigger of murine IFN-α on the induction of immune response and inflammation
hence understanding the tissue distribution of the drug in the light of other biologi-
cal implications.
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Chapter 5
Stochastic effects trigger
intracellular responses in IFN-α
signalling
5.1 Chapter summary
The work in this chapter is motivated by the response variability of the various
induced ISGs by IFN-α stimulation on human hepatocytes. Here we examine the
causes for variability between responding and non-responding cells in terms of IFN-
α stimulation. We analyse the intra-cellular biochemical noise that leads to the de-
cision of the responding / non-responding cells in an isogenic cell population. In
this work, for the first time, we analyse this aspect by using a mechanistically de-
tailed stochastic JAK/STAT pathway model. The model is calibrated to the single-
cell time-lapse responses of ISGs, Mx2 and ISG56 to IFN-α stimulation using flow
cytometry for Huh7.5 cells. Solving such detailed stochastic models can be time
consuming and intensive, thus in order to identify the model parameters we used
the recently developed algorithm by Dr. Luis Aguilera 1 [123] that fits the stochastic
model to single-cell data. Luis and myself established the project aim, the collabora-
tion and the model for this work.
In this chapter, I detail on establishment of the stochastic model of JAK/STAT
pathway which is based on the knowledge of previously developed deterministic
JAK/STAT models [114], [116]. I synopsize on the methodology of parameter esti-
mation where the model was calibrated to quantitatively immunoblotted population
data and single cell data produced by flow cytometry for various molecules in the
pathway in response to IFN-α dose stimulation. The results of this work have been
solely generated by Dr. Luis Aguilera and the basis of the text of the results and
figures of this chapter has been mostly taken from Aguilera et al. 2018 (in prepa-
ration)[244]. Parts of the text of this chapter were originally written by Dr. Luis
Aguilera, Prof. Dr. Ursula Kummer and myself. Figures used in this chapter are
adapted from Aguilera et al. [244] and were originally produced by Dr. Luis Aguil-
era. The experimental data used in this chapter is detailed in chapter 2, subsection
2.2.5.
1Research group of Brian Munsky, Department of Chemical and Biological Engineering, Colorado
State University, Fort Collins
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5.2 Motivation and open questions
IFN-α signalling activates the first line of defence against viral infections. On the
level of individual cells, the main function of this immune defence is to induce the
cell-intrinsic anti-pathogenic response in infected and neighbouring cells so as to
limit the spread of the infectious agents, specifically of viruses. Previous studies
demonstrated that only a fraction of cells in a cell population produce IFN-α [81],
[87], [121]. Both intrinsic and extrinsic noise were reasoned to be the source of this
stochastic variability in the inter-cellular response [81], [124], [245], [246]. It was
proposed that many functions are driven by biochemical noise within individual
cells, e.g., cell fate decision or mRNA and protein abundances [247]. In case of
IFN-α, neither the biochemical noise mechanism nor the function are understood.
Furthermore, IFIT1 (sometimes also referred to as ISG56) and MxA have been gold
standard mRNA/proteins which are expressed as part of the anti-viral response to
interferon induction [66], [69], [248]. MxA is one of the most well-studied ISGs. It is
the key anti-viral element induced by IFN-α and exerts its antiviral response during
the replication cycle of diverse viral families that include Orthomyxoviridae, Rhab-
doviridae, Paramyxoviridae among others [69]–[72]. On the other hand, IFIT1 was one
of the first ISGs to be discovered and is the most prominent member of human re-
sponse genes to viral stress. Both, MxA and ISG56 are strongly induced in response
to IFN and various viruses [66]–[68]. However, the stochastic behaviour of MxA and
IFIT1 gene induction remains a challenge as neither the mechanisms nor the func-
tion of intrinsic variability along the IFN-α activated JAK/STAT pathway are well
understood.
FIGURE 5.1: Molecular count of the JAK-STAT signalling pathway.
The molecular count of some of the most relevant elements in the
pathway is given at the right. A detailed list of the molecular count
used in the model is given in Appendix D, Table D.1
5.3. Stochastic model of JAK/STAT signalling upon IFN-α stimulation 83
Therefore, this work is motivated by the little explored impact of biochemical
noise on the transduced JAK/STAT pathway responses of the induced antiviral ISGs:
MxA and IFIT1. In order to have a detailed understanding on the stochastics of the
JAK/STAT pathway induced responses, our collaborators from the groups of Marco
Binder2 and Ralf Bartenschlager3 performed single-cell measurements of IFIT1 and
MxA. The Huh7.5 cells expressing bacterial artificial chromosome (BACs) based flu-
orescent reporters for MxA and ISG56 were stimulated by IFN-α. Single cell data
displaying IFIT1 and MxA expression differences in responding or non-responding
cells was collected by FACS in a time-lapse experiment. Complementary to the
noise assays conducted by our collaborators, we constructed a mechanistic stochas-
tic model and calibrated it to the data for MxA and IFIT1. This allowed us to in-
vestigate the influence of intrinsic and extrinsic noise in the JAK/STAT pathway at
single cell resolution. The results of this work show that the effects of noise are par-
ticularly strong at the receptor level, during the transcription of ISGs and during
the formation of the transcription factor ISGF3. Additionally, we concluded that the
JAK-STAT signalling pathway is a robust system that can filter extrinsic fluctuations.
5.3 Stochastic model of JAK/STAT signalling upon IFN-α
stimulation
To investigate the single-cell dynamic properties of IFN-α signalling, we developed
a mathematical model of the known key components, feedback responses and con-
stitutive regulatory mechanism. The model was developed from scratch to describe
the single-cell dynamics but was based on previously published deterministic mod-
els [114]–[117]. Since stochastic models are computationally expensive to solve, there
are constant endeavours on the implementation of new methods to fit single cell data
[123], [249], [250].
For the development of this model, the following assumptions were made:
1. The model comprises one compartment representing the cytosol and the nu-
cleus together.
2. The receptor mechanism is irreversible. At this point, the model can only de-
scribe a single stimulation without any reactivation of unbound receptors.
3. The variables representing gene activity, (e.g., socs / I socs) start fully activated.
The promoters can be simulated assuming a two state model.
4. The model does not start in steady state.
In the following sub-section I will describe the model structure and establish-
ment in details.
5.3.1 Mathematical model overview
The following conventions are used for the names of the species in the model:
1. Variables referring to mRNA are denoted by m prefix.
2Research Group ”Dynamics of early viral infection and the innate antiviral response”, Division
Virus-associated carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
3Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Ger-
many.
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2. Variables addressing the phosphorylated state use p prefix.
3. Gene promoters are represented by the gene’s name in lowercase.
The developed model consists of 28 species and 40 reactions (reactions (M1) to
(M40)). It comprises known key components and feedback mechanisms. The bind-
ing between free IFN-α and the IFNAR sub-unit 2 (R2) to form a pre-active complex
(RC) (M1) was modelled. The pre-active complex bound to the IFNAR sub-unit 1
(R1) to form the active complex (AR) (M2). The activated IFNARs relay the signal
inside the cytoplasm by phosphorylating STAT1 (M3) and STAT2 (M4). The phos-
phorylated STATs form the activated heterodimer STAT1-STAT2 (M6). The binding
of the hetero-dimer to IRF9 to form ISGF3 (M7) was modelled. Subsequently, ISGF3
binding to free DNA binding sites (ISRE) to induce transcriptional activity (M10-
M17) was modelled in the same compartment. The ISGF3-DNA complex leads to the
transcription of the mRNA for IRF9, MxA, ISG56 and SOCS (M18-M21). The tran-
scribed mRNAs are translated to: IRF9 as a positive feedback (M22), SOCS (M23)
as a negative feedback given by the SOCS1 degradation of active receptors (M5),
MxA and ISG56 (M24 & M25). Degradation of intermediary elements, such as cyto-
plasmic mRNAs and cytoplasmic proteins was considered (M26-M40). A graphical
representation of the interaction between species in the model is given in Fig 5.2 and
the model reactions are described in table 5.1.
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FIGURE 5.2: Figure adapted from Aguilera et al. [244]: Schematic rep-
resentation of the mechanistically detailed JAK/STAT pathway. The
model reactions are denoted by the variables in blue. The model de-
scribes the activation of the JAK-STAT signalling pathway by IFN-α.
Consequently, phosphorylation of STAT proteins cause a dimerisa-
tion of the same along with the formation of the ISGF3 complex by
binding to IRF9. Finally, the promoters of the ISGs are activated by
ISGF3. A positive feedback loop is exerted by IRF9. SOCS inactivates
the receptors, thus exerting a negative feedback on the pathway. In
the figure, arrows represent the reactions described in table 5.1.
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TABLE 5.1: The reactions following an IFN-α stimulation in the intracellular
JAK/STAT pathway for the stochastic model is detailed in this table. The column
# describes the reaction number followed by the column describing the reaction
and the kinetic rate law used to describe the kinetics of the model reactions.
# Reaction
Kinetic
rate law
M1 IFN + R2→ RC k1 · S1 · S2
M2 RC + R1→ AR k2 · S1 · S2
M3 AR + STAT1→ pSTAT1 + AR k3 · S1 · S2
M4 AR + STAT2→ pSTAT2 + AR k4 · S1 · S2
M5 AR + SOCS→ IR + SOCS k5 · S1 · S2
M6 pSTAT1 + pSTAT2→ dimerSTAT k6 · S1 · S2
M7 dimerSTAT + IRF9→ ISGF3 k7 · S1 · S2
M8 ∅→ STAT1 k8
M9 ∅→ STAT2 k9
M10 I ir f 9 + ISGF3→ ir f 9 + ISGF3 k10 · S1 · S2
M11 ir f 9→ I ir f 9 k11 · S1
M12 I socs + ISGF3→ socs + ISGF3 k12 · S1 · S2
M13 socs→ I socs k13 · S1
M14 I mxa + ISGF3→ mxa + ISGF3 k14 · S1 · S2
M15 mxa→ I mxa k15 · S1
M16 I isg56 + ISGF3→ isg56 + ISGF3 k16 · S1 · S2
M17 isg56→ I isg56 k17 · S1
M18 ir f 9→ ir f 9 + mIRF9 k18 · S1
M19 socs→ socs + mSOCS k19 · S1
M20 mxa→ mxa + mMXA k20 · S1
M21 isg56→ isg56 + mISG56 k21 · S1
M22 mIRF9→ mIRF9 + IRF9 k22 · S1
M23 mSOCS→ mSOCS + SOCS k23 · S1
M24 mMXA→ mMXA + MXA k24 · S1
M25 mISG56→ mISG56 + ISG56 k25 · S1
M26 mIRF9→ ∅ k26 · S1
M27 mSOCS→ ∅ k27 · S1
M28 mMXA→ ∅ k28 · S1
M29 mISG56→ ∅ k29 · S1
M30 IRF9→ ∅ k30 · S1
M31 SOCS→ ∅ k31 · S1
M32 MXA→ ∅ k32 · S1
M33 ISG56→ ∅ k33 · S1
M34 STAT1→ ∅ k34 · S1
M35 STAT2→ ∅ k35 · S1
M36 pSTAT1→ ∅ k36 · S1
M37 pSTAT2→ ∅ k37 · S1
M38 dimerSTAT→ ∅ k38 · S1
M39 ISGF3→ ∅ k39 · S1
M40 IFN→ ∅ k40 · S1
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Reactions and rate laws All reactions in the model are described by mass action kinetics 5.1.
vi = ki ∗ [Substrate1] ∗ [Substrate2] (5.1)
Here the velocity of the reaction is determined by ki and the transitional concentrations of
the Substrates are represented by [Substrate1] and [Substrate2].
5.3.2 Calculations for the model
Converting IFN-α units: From IU/m to molecules/cell Similar to Chapter 3, subsection 3.4.2,
the molecules/ cell were calculated for the stochastic model.
The model parameters were estimated based on data from the experiments of Bolen et al.,
Maiwald et al. and Bauhofer et al. [82], [116], [161]. In the experimental data, IFN-α stimulus
(IFNexp) activated the signalling pathway. Doses of IFNexp ranged from 10 IU/ml to 500 IU/ml
(1× 104 IU/L to 5× 105 IU/L). To map the model’s variable IFN to IFNexp, I transformed the
IFN doses (IU/L) to an effective molecular count (molecules/cell).
IFN-α doses (IU/L) were converted to molar concentration (M):
IFNexp(M) =
(
IFNexp(IU/L)/IFNsa(IU/g)
)
/IFNw(g/mol), (5.2)
where, IFNsa is the IFN-α specific activity. IFNsa = 1× 109 IU/g (R&D Systems, Minneapolis,
MN, USA). IFNw is the IFN molecular weight. IFNw = 1924.0 (g/mol).
Subsequently, I converted IFNexp(M) to total number of IFN-α molecules in the medium
(molecules/l), that is:
IFNexp(molecules/l) =
(
IFNexp(mol/l)/VM(l)
)
· NA(molecules/mol), (5.3)
where NA is the Avogrado’s constant, NA = 6.022× 1023(Molecules/mol). VM is the total vol-
ume in the medium, VM = 2× 10−3 L.
Finally, from the IFN-α molecules in the medium I calculated the effective number of molecules
that interact with each cell in the culture. To achieve this unit conversion I assumed that the
IFNexp is homogeneously distributed in the cell culture and every cell receives a small percent-
age of the total IFN-α molecules. This assumption is based on the dilution of the IFNexp in the
medium and their low probability of encounter with the cell receptors. This was accounted by
the parameter: IFN-α availability Av = 1%. The molecules of IFN-α available per cell is:
IFNexp(molecules/cell) =
(
IFNexp(molecules/l)/NC(cells/l)
)
× Av, (5.4)
where NC is the number of cells in the culture volume (NC = 1.2× 105 cells/l).
TABLE 5.2: From IFN-α (IU/ml) to molecules/cell
IFN (IU/ml) M molecules/cell
500 2.6 ×10−7 6.52 ×1012
100 5.19 ×10−8 1.3 ×1012
10 5.19 ×10−9 1.3 ×1011
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As mentioned previously in Chapter 3, subsection 3.4.2 can be affected by different factors
including: the IFN-α specific activity that can vary not only depend on the reagent supplier,
but also on storage and manipulation.
Promoter analysis for MxA and IFIT1 MxA promoter is reported to contain two functional
ISRE leading to cooperative binding of ISGF3 to the DNA sites [239]. Having a cooperative pro-
moter activation is commonly associated with differential gene regulation which determines
the systems decision making [247].
Most cell types do not express detectable levels of IFIT1 transcripts in the absence of IFN-α
stimuli. IRF3 is known to transactivate IFIT1 [251]. Two ISRE consensus sites are present in the
promoter of IFIT1, at positions -92 to -104 (ISRE I) and positions -105 to -117 (ISRE II) [252].
The MxA and IFIT1 promoter sequence was analysed using ENCODE and Jasper and is
found in Appendix D, subsection D.1.1.
The half life of the proteins and mRNAc for the model were fitted in the range of the bio-
logical values found in the literature as shown in Appendix D, Table D.1.
5.3.3 Parameter estimation
Mapping model variables to experimental data The data implemented for the fitting of the
model was not in absolute concentrations. Scaling factors were added to the model to represent
the quantitative immunoblotting data and the flow cytometry data.
Time course data The quantitative immunoblotting data was published in Maiwald et al.
[116]. The data described the temporal dynamics of different elements of the JAK-STAT sig-
nalling pathway. The dynamics of phosphorylated JAK1, pSTAT1 and nuclear IRF9 were mea-
sured in Huh7.5 cells after stimulation with 500 UI/ml of IFN-α for a total time of 180 min (total
8 measurements, an average of two replicates). The experimental measurements of phospho-
rylated JAK1 (pJAK1†) were mapped with active receptor (AR) in the model as follows:
pJAK1†(ti) = ϕ1 ∗ AR(ti), (5.5)
where ϕ1 is a scaling factor.
The experiment used the phosphorylation-state specific anitbodies to measure the dynamics of
phosphorylation of STAT1 in time. The experimental measurements of cytoplasmic phospho-
rylated STAT1 (pSTAT1†) were mapped to pSTAT1, dimerSTAT and ISGF3 molecules because
they collectively contain phosphorylated version of the STAT1 and were not differentiated ex-
perimentally. The assignment in the model is as follows:
pSTAT1†(ti) = ϕ2 ∗
(
pSTAT1(ti) + dimerSTAT(ti) + IRF3(ti)
)
, (5.6)
where ϕ2 is a scaling factor.
The experimental measurements of nuclear IRF9 (IRF9†) were mapped to ISGF3 and nuclear
IRF9 molecule because the experiment did not differentiate between individual IRF9 molecule
or the IRF9 bound to ISGF3. This was described in the model as follows:
IRF9†(ti) = ϕ3 ∗
(
ISGF3(ti) + IRF9(ti)
)
, (5.7)
where ϕ3 is a scaling factor.
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Flow cytometry data The data described expression of MxA and ISG56 after IFN-α stimula-
tion in a population of Huh7.5 cells. Huh7.5 cell culture was treated with various concentra-
tions of IFN-α (in the range of 10 to 1250 UI/ml) and single cell FACS measurements of MxA
and IFIT1 were performed (see data in Appendix D, section D.2). For the purpose of explaina-
tion, I selected the treatment with 250 UI/ml of IFN-α on the Huh7.5 cells. The measurements
of MxA and IFIT1 were reported as fluorescence intensity and does not give information on the
absolute concentrations, the scaling factor of the two proteins were implemented in the model:
The experimental measurements of MxA (MXA†) were mapped to MXA in the model as fol-
lows:
MXA†(ti) = ϕ4 ∗MXA(ti), (5.8)
where ϕ4 is a scaling factor.
The experimental measurements of IFIT1 (ISG56†) were mapped to ISG56 in the model as
follows:
ISG56†(ti) = ϕ5 ∗ ISG56(ti), (5.9)
where ϕ5 is a scaling factor.
Fitting the model The work in the following sections were devised and executed by Dr. Luis Aguil-
era.
The model was fitted to two different datasets obtained from different experimental proce-
dures and on different time-scales. The quantitative immunoblotting data was implemented
from the publication Maiwald et al. [116]. The flow cytometry dataset was analysed in MAT-
LAB using the function FCS datareader (Appendix D, Figures D.1, D.2 and Figure D.3). The
stochastic model was calibrated to datasets by implementing the parameter estimation method-
ology developed by Dr. Luis Aguilera consisted in the fitting of the stochastic version of the
model with experimental distributions [123]. In a nutshell, given the distinct resolutions and
time-scales of the datasets, the fitting strategy was divided into two steps:
1. A deterministic model was parameterised to the cell population data (time courses and
dose-response data) obtained by quantitative immunoblotting. The Genetic algorithm
was executed to obtain the parameter-set.
2. Once the parameterisation fulfilling the deterministic regime was found, the method fit-
ted the stochastic version of the model to experimental FACS distributions of MxA and
IFIT1. The Kolmogorov-Smirnov (KS) distances of the cumulative density function (CDF)
were calculated with respect to the experimental data distributions. This was based
on the Monte Carlo simulations of the single cell experimental data. Hence, the final
parameter-set of the stochastic model was obtained.
A diagram of the parameter estimation strategy is given in Figure 5.3 A.
Furthermore, the parameter space was narrowed down by parameter values determined
in the literature ( Appendix D, Table D.1). Notice that in Figure 5.3 B, with this algorithm Luis
was able to fit the temporal response of the IFN system and the stochastic dynamics in the final
ISG expression of MxA and IFIT1.
5.4 Results
In this section I recap the results that were generated by Dr. Luis Aguilera to lay insight into the
findings of this work.
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FIGURE 5.3: In the above figure the parameter estimation methodology as pub-
lished by Aguilera et al. [123] is illustrated. The parameter estimation strategy
involved A) First, solving the system for a parameterisation in the determinis-
tic regime. The genetic algorithm was executed to caliberate the model against
the time course data dose-response data produced by quantitative immunoblot-
ting as published in Maiwald et al. [116]. Once the deterministic solution was
achieved, the obtained parameter-set was implemented to calibrate the stochas-
tic model against flow cytometry data. B) Temporal distributions fitted to the
FACS dataset (solid colour distributions, blue for MxA and red for IFIT1). 1000
stochastic simulations of the temporal distribution are plotted as black lines. The
y-axis displays the normalised cell-count and the x-axis displays the fluorescence
intensities in arbitrary units (a.u.) for the expression of MxA and IFIT1 proteins.
Figure adapted from Aguilera et al. [244].
The model was simulated 4 using the Gillespie algorithm which is one of the stochastic
simulation algorithm (SSA). To account for the intrinsic noise, the model was solved using
Gillespie algorithm as implemented COPASI 4.21. The extrinsic noise was simulated as sug-
gested by Shahrezaei et al. [173] where the extrinsic noise is introduced on the SSA as a time
varying parameter and can simultaneously execute on many parameters of the model. This
work focuses on introduction of extrinsic noise only on the molecular count of the molecules
in the pathway where the noise is normally distributed over the following three values of σ: 0,
0.3, 0.6.
5.4.1 Heterogeneity in the response of MxA and IFIT1 to IFN-α
Previous studies [66], [253], [254] established the interference of MxA and IFIT1 proteins in
the viral infection, specifically Parainfluenza virus type 5. The single cell experiments executed
by our collaborators ( see chapter 2) successfully measured the distribution of the response of
4The mathematical calculation of the system dynamics over time
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MxA and IFIT1 in the Huh7.5 cell population, thereby capturing the cell-to-cell variability (Ap-
pendix D, Figures D.1 & D.2). The experiments exhibit unimodal distributions5 and sustained
responses of MxA and IFIT1. The shift in the unimodal distributions over time accounted for
the heterogeneity in the response (Figure 5.4). Here, the responding cells are in the ON sec-
tion of the curves in Figures 5.4 B & C while the non-responding cells are in the OFF section.
As the time elapses after the IFN-α stimulation, the fluorescence intensities of the response
biomarkers, MxA and IFIT1 increases, exhibiting the increase in responding cell population.
This observation is in contrast to the previous publication based on IRF7 as the reporter ISG
[81], where an all-or-none response (bimodal behaviour6) was observed, thus separating the
population into responding and non-responding cells. However, in our study we did not only
use different reporter ISGs (IFIT1 and MxA), but we also we also used data from a different cell
line (human hepatic cells instead of mouse fibroblastoid cells). This suggests that induction of
the ISGs is cell-type specific [255], [256].
FIGURE 5.4: Induction of response ISGs (MxA and IFIT1) after stimulation of
Huh7.5 cells with different dosages of IFN-α. A) schematic representation of the
experimental set-up, a threshold is defined on the basis of fluorescence intensi-
ties to differentiate the cells as responding or non-responding in a population.
B) Distributions of MxA expression at different time points after IFN-α stimu-
lation in the Huh7.5 cells. C) Distributions of IFIT1 expression at different time
points after IFN-α stimulation in the Huh7.5 cells. Data collected via FACS. Fig-
ure adapted from Aguilera et al. [244].
Furthermore, our experiments tested for temporal dose-response of MxA and IFIT1 to dif-
ferent doses of IFN-α (10, 50, 250, 1250 UI/mL) at time points 8, 12, 16, 20 and 32 hours after
respective dose induction. The measurements exhibited that 16 hrs post-induction, the cells
shift to higher intensities of signal response for MxA (see Appendix D, Figure D.1) and 12 hrs
post induction for IFIT1 (see Appendix D, Figure D.2). Moreover, the cells maintained the
graded increase in response of MxA and IFIT1 as the time elapsed for all IFN-α doses. The
5Continuum of expression of proteins within a population.
6Two distinct populations exhibiting expression of proteins as well as no expression of proteins within a popu-
lation.
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time dependence of the MxA and IFIT1 response were further observed by plotting the aver-
age fluorescence intensities (a.k.a mean fluorescence intensities (MFI). (See Appendix D, Figure
D.3). In conclusion, the experiments indicate dose-dependent responses of the reporting ISGs
which shifts the cell population towards an increased response as the time elapses, after IFN-α
stimuli.
5.4.2 Effect of noise on the induced MxA and IFIT1 responses
Effect of intrinsic noise on the pathway 1,000 repetitions of the simulations were run for 32
hours to gain a deeper understanding on the response heterogeneity landscape (of MxA and
IFIT1 respectively) in the population of trajectories (representing 1000 cells in a cell population
of 1000). The resulting simulation indicated differences in induced temporal responses. For
example, proteins activated after the association of IFN-α to the receptors showed fast and
transient dynamics, whereas the feedback proteins (positive feedback via IRF9 and negative
via SOCS) displayed slower and sustained dynamics. The simulation result indicated that the
pathway is sensitive to the IFN-α trigger but the feedback loops help to sustain the pathway
response for longer periods of time. Hence, keeping the pathway robust to the intrinsic noise
as seen in Figure 5.5 B. We observed that low concentrations of specific species in the signalling
pathway, especially, the number of phosphorylated STAT dimers and IRF9 proteins introduce
strong variability in the transient dynamics of ISGF3. This suggests that the fate of the response
may be determined by bottlenecks in the pathway when the receptors are not recycled.
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FIGURE 5.5: The temporal dynamics of the model and the cell population distri-
bution are represented in plot. A) Cell population data (obtained by quantitative
immunoblotting) describing the temporal dynamics of JAK1, pSTAT1 and nu-
clear IRF9 as published in Maiwald et al. [116]. Measurement error of 18 % is
represented in the figure as error bars. The measurements were done on Huh 7
cells after stimulating them with a dose of 500 U/ml of IFN-α. The induced tem-
poral response was measured using quantitative immunoblotting for 180 mins.
Each solid line represents the model trajectory, a total of 1,000 stochastic simula-
tions representing single cells. The histogram on the right side of plot represents
the final trajectory distribution of the population. B) The plots represent single
stochastic trajectory plotted in grey and the single blue line is the mean of the
stochastic trajectory. The plots describe the temporal dynamics of all the simu-
lated species in the induced JAK/STAT signalling pathway. The unit of the y-axis
is molecules per cell (M/C). Figure adapted from Aguilera et al. [244].
Effect of extrinsic noise on the pathway Extrinsic fluctuations can originate from different
external environmental sources. For example, during cell cycle or inheritance of variable copy
numbers of the proteins in different cells during cell division [257]. In this work, we explored
the effect of extrinsic variability on the pathway by introducing the noise as the variability in
the copy number. Hence, the initial molecular number of the species was varied by introduc-
ing random sampling using normal distributions N (µ, σ2) with values for µ ( Appendix D,
Table D.2 and one of three values of σ: 0, 0.3, 0.6. By introducing the σ as noise, we explored
the consequence of increased extrinsic noise on the molecule number of the system (Figure 5.6
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A). Thus we were able to quantify the variability in the JAK/STAT signalling pathway by per-
forming a variability analysis over initial molecule numbers. This was achieved by calculating
the coefficient of variation (ratio of the standard deviation, σs to the mean molecule number,
where the subindex s represents the species in the pathway). Considering the model can only
describe a single stimulation without any reactivation of unbound receptors, this analysis sug-
gests that the pathway shows minimal variability in the cytoplasmic components except for
ISGF3 complex. Contrasting that, the model results depict strong effect of noise in the nucleus
and on the cell membrane (Figure 5.6 B right column). This is an obvious observation, as the
ligand-receptor activation step is governed by complete activation of the receptors thus result-
ing to saturated activation and no further signal transfer. This shows that the extrinsic noise
governs the local dynamics of the cellular response (on molecules present in certain sections
of the pathway) but the global response (the induced response to IFN-α trigger) is rather ro-
bust to extrinsic noise. A quantification of this is observed in Figures 5.6 C and D where the
KS-distance was measured between distributions for MxA and IFIT1 under multiple values of
extrinsic variability at different time points. The model results depicts the JAK/STAT path-
way is affected by extrinsic noise at early time points (1 and 16 hours) however, the control of
extrinsic noise is lost on the pathway at later time point (32 hours).
5.4. Results 95
FIGURE 5.6: This figure recaps the introduction of biochemical noise in the JAK/-
STAT pathway. A) Introduction of extrinisc noise in the system as the variability
in the initial copy number of the molecules of the pathway. Wider distribution
or larger σs: 0, 0.3 and 0.6 were implemented to increase noise in the system. The
control, with σs= 0, only intrinsic noise accounts for variability. B) The variability
of the JAK/STAT pathway was measured at different time points and under dif-
ferent conditions of extrinsic noise (σs at the top of the panel) on the initial copy
number of the species in the pathway. The colour bar represents the coefficient
of variation between 0 to 1, the darker the colour, the higher the variability. C)
Stochastic simulation of MxA and IFIT1 expression after 32 hours of induction
with IFN-α. Note that the perturbations with extrinsic noise are also simulated
in the distribution. D) The distribution of MxA and IFIT1 expression at different
time points of the simulation to compare the strengths of intrinsic vs. the extrin-
sic noise using Kolmogorov-Smirnov distance. Figure adapted from Aguilera et
al. [244].
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5.5 Discussion
In the last two decades, many efforts have been made to increase the understanding of the
JAK/STAT signalling pathway that is triggered by IFN-α induction. With regards to biochem-
ical models, models describing the deterministic dynamics in cell populations already exist
[114]–[117]. On the single-cell side, stochastic models are slowly being explored to understand
how the analogue signal of IFN-α leads to cell specific decisions and variability in the molecule
reaction processes [121], [125]. Such variability in decision making arises from noise7 (intrin-
sic and extrinsic). Noise is a governing factor in cellular processes - almost all pathways are
impacted by noise. Such pathways have often evolved with a strong robustness against the
effect of noise in order to react to stress or infection. The lack of stochastic models describ-
ing the IFN-α system can be attributed to the scarcity of single cell data and efficient methods
to analyse and make use of this data. Promising high-throughput techniques to investigate
those mechanisms are flow cytometry [258], microarray analysis[259] and single molecule mi-
croscopy [260], which are increasingly being used in biomedical research to characterise in-
fectious diseases and to set therapeutic regimes. These techniques successfully capture the
intrinsic variability in the IFN-α responses by measuring the RNA or protein abundance in
single cells and the distribution of those molecules in cell populations. On the other hand,
incorporating single cell data and stochastic modelling is still a challenging task.
In the presented work, we used the high-throughput technique of FACS to examine the
temporal (for 32 hours) stochasticity of MxA and IFIT1 as the response biomarker after stim-
ulation of Huh7.5 cell-line by IFN-α. Simultaneously, we developed a detailed mathematical
model and calibrated it to the deterministic time course data of pJAK, pSTAT and SOCS as well
as single cell FACS data for MxA and IFIT1 in order to analyse the effect of noise on this sys-
tem. The novelty of this work is that the model is stochastic, mechanistic and incorporates the
major feedback system for a graded response that evolves over a long time span. Our model
differs from the other efforts which are made for the mechanistic stochastic model [125] by not
following the ISGs that induce an all-or-nothing response to the antiviral state. MxA and IFIT1
do not have any enzymatic control on the JAK/STAT pathway itself (unlike IRF1, IRF3, IRF7
and IRF9 which also act as transcriptional factors for the trigger of antiviral response). Thus,
we were able to establish graded (unimodal) temporal dynamics of MxA and IFIT1. There-
fore, this work shows a clear contrast to the reports based on single cell data for various IRFs,
where all-or-none response is commonly observed in the cell population [81], [125]. In our
understanding, this difference in response arises from two aspects:
1. The architecture of the ISG promoters. For example, the IRF7 promoter contains two
different transcriptional binding sites (ISRE and IRF-E), which can be activated not only
by ISGF3 but also by IRF7 dimer itself (thus applying a positive feedback to its own
production and hence the bimodality) [81]. Both MxA and IFIT1 do not possess any
enzymatic activity [67]. The lack of the co-operative behaviour explains the observed
graded response [202].
2. Cell-type specific and dose-dependent induction patterns of the MxA and IFIT1. Given
the simple architecture of their transcriptional sites (only ISREs), examples of their dose-
response expression being very similar in different individuals have been observed [261],
[262]. This suggests that the response to IFN-α, especially of MxA and IFIT1, is robust.
This explains the graded response that were consistently obtained for all IFN-α doses at
different time points.
7Random variability that arises in the molecule numbers per cell.
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This result is consistent with previous reports for MxA [83]. Higher organisms with intracellu-
lar signalling may benefit from such a robustness to be able to sustain signal propagation and
shape the anti-viral response in the cell populations.
Model limitations and future work Developing mathematical models to represent a bio-
logical system is a subjective task and often depends on the question one needs to ask [263].
In this work, we have focused on implementing the physiological molecule numbers and the
well-known mechanistic details which were described in previous works. However, important
aspects and intricacies of the signalling network were not considered in the evaluation of the
model. The promoters in this model were simulated assuming a two state model. More impor-
tantly, the overall idea in the model is that the activation of the pathway (dynamically) not only
increases the switching between states, but also the time the variable is in the ON state. The
same holds true for some activated compounds like pSTATs, STAT dimer and the transcription
factor where the concentrations of the phosphorylated forms are non-zero even without IFN-
α stimulation [116], [264], hence the model implements some ”basal level” of protein activity.
One important mechanistic detail that our model does not describe is receptor recycling, which
means the model can only describe a single stimulation without any reactivation of unbound
receptors as the receptor activation is irreversible.

99
Chapter 6
General discussion and concluding
remarks
6.1 Chapter summary
Throughout this dissertation, both in vitro hepatocyte data and in vivo data for mice and hu-
mans have been extensively integrated, modelled and analysed, including the response data
of the ISGs of the activated JAK/STAT pathway.
In this chapter, I would like to briefly bring together some of the key observations drawn
from the work described in the different chapters of my dissertation, modelling the response
of the JAK/STAT pathway to IFN-α. I will focus on the effects of dosage at the whole-body
level, including insights into the datasets as well as the implications of the use of in vitro assays
to help develop PBPK/PD models. The coupled PBPK/PD models will then provide insight
into the iterative experimental design of the in vitro assays and animal experiments. Finally, I
conclude with possible avenues and outlook for future work in investigating these important
points.
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Interferons are important components of the natural defence system found in mammals.
IFN-α was reported as an antiviral agent 40 years ago [1] but more than 25 years, since its first
clinical use, its potential as a drug for different ailments is still largely unexplored. In the past
20 years, IFN-α has been routinely used in treatment against HCV. In chronic HCV cases, the
treatment has been shown to be effective in eradicating viral markers in approximately 20%
of the patients. Currently, the FDA recommends a dose of 3 million international units (MIU)
IFN-α, 3 times a week for a period of 12 months for patients diagnosed with chronic HCV
and responding to the aforementioned therapy after 3 months [265]. After its first success
as an antiviral agent against HCV, many pharmacokinetic studies of IFN-α were undertaken
in volunteers and patients between 1986 to 1996 [266]. Currently, there is little knowledge
on the relationship between the drug dose and its mechanistic effect on the target organ, i.e.,
the induced intracellular responses within the liver. In the past decade, basic research has
provided mechanistic and dynamic understanding of the molecular and cellular responses to
IFN-α, reporting it as a double edged sword [267]–[269], as it mediates multifarious response
activities by induction or repression of thousands of interferon-stimulated genes (ISGs) [270],
[271]. Considering its efficacy in immunomodulation and angiogenesis in different cell-types
[9], [10], IFN-α therapy seems to have the potential to contribute as a remedy against many
diseases. Thus, it is important to have a quantitative systems understanding of the action of
IFN-α as a drug and the complex web of responses it activates at the target site.
In the past years, computational approaches have supported the experimental observations
to achieve an understanding of the IFN-α dose-effect relationships on different time-scales and
in different experimental set-ups [111]–[114], [116]–[120], as well as in different model organ-
isms (animal studies) [39], [40], [42]. The focus of the modelling approaches in the past years
was either on the kinetics of the intracellular reponse to explain in vitro cell studies (pharma-
codynamics) or on computing the distribution of the drug in the body (the pharmacokinetics).
An effort to combine the two different modelling aspects (kinetic models (PD) with pharma-
cokinetic models (PK)) is needed to establish a systems level understanding of the PK/PD
relationship- the quantitative systems pharmacology (QSP) approach [207], [216]–[218], [272],
[273]. In a publication in 2011, Van Der Graaf and Benson defined QSP as “the quantitative
analysis of the dynamic interactions between drug(s) and a biological system that aims to understand
the behaviour of the system as a whole. . . ” [274]. In other words, QSP aims to simultaneously
detail the description of pharmacokinetics (drug absorption, distribution, metabolism and ex-
cretion (ADME)) and the pharmacodynamics (intracellular response) of the drug action from a
whole-body perspective. In the area of biologicals, 1 PK/PD modelling has been more recently
applied for monoclonal antibodies [275], [276], where the use of the QSP approach is still in its
nascency. The implementation of PBPK/PD modelling is gaining recognition as an essential
step to allow for compliant translation from the pre-clinical to clinical stage while taking into
account the principles of the 3Rs (Replacement, Refinement and Reduction) for more humane
animal research.
The work in this thesis describes the workflow when applying the state-of-art QSP ap-
proach to establish an organism-level understanding of the therapeutic action of the biologic
IFN-α and its coupled response in the liver. The work in chapter 3 and chapter 4 uses the QSP
approach to establish mechanistically detailed the PBPK/PD model of two species: Mouse and
human. Most pre-clinical studies are conducted in mice, which are then translated to humans
by cross-species extrapolation. The development of mouse PBPK/PD model was undertaken
to aid for establishment of quantitative cross-species extrapolation in the future. A human
1are therapeutics originating from natural sources- humans, animal or microorganisms and are produced using
biological organisms.
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PBPK/PD model was developed because by implementing human cohort data and human
cell-line data, better estimations of the translational results from animals to humans can be
made. Furthermore, such models can be implemented in health-risk assessment of individu-
als. Thereby, contributing to personalised medicine. Ultimately, the differences between the
models of the two organisms would offer an in-depth understanding by providing insights into
inter-species differences. This would contribute to improved experimental designs for humane
animal research. The work in these chapters integrates the pharmacokinetic and pharmacody-
namic knowledge for humans and mice respectively. It describes a dose-response relationship
for IFN-α as well as concentration-effect relationships of the biomarkers IRF9 mRNAc and
Mx2. The presented PBPK/PD models and the knowledge generated from their analysis lay
the foundation for a rational design of experimental in vitro assays, dosing regimens and the
preclinical to clinical translation. In summary, the presented PBPK/PD approach allows for the
quantitative description of IFN-α-induced response modulations in the JAK/STAT signalling
pathway associated with the pharmacological action following the intravenous dose of IFN-α
in humans (chapter 3) and mice (chapter 4). The presented workflow in this dissertation pro-
vides the opportunity to link the JAK/STAT signalling pathway with IFN-α concentration-time
profiles, in order to gain more insights into the dynamics induced by target-mediated drug dis-
position (TMDD) as analysed in chapter 3, subsection 3.5.3.
To calibrate the PBPK/PD models for humans and mice, a high number of in vitro assays
were integrated from the literature [116], [157], [161], [162] and from collaborations that arose
during the course of this work (with Dr. Mario Koester2). These datasets sought to capture
the time course dynamics of the molecules in the JAK/STAT pathway in order to calibrate the
individual hepatocyte models for the human and mouse primary hepatocytes.
First, the presented PBPK models for humans and mice were developed based on results
digitised from the literature [39], [48]–[50], [159] in chapter 3 & 4. Although most parameter
values of these models lie within the range of reported literature values, there are some limi-
tations due to lack of information of the specific activity of IFN-α in the data sources. We do
realise this leads to uncertainty in the calculation of the injected dose.
The pharmacodynamic (kinetic) models presented in chapters 3 & 4 use the approach of
model ensembles [203]. In both the cases, the model parameters were not fully identifiable.
These model ensembles had different parameterisations for same model structure describing
the same behaviour of the cell-population quantitatively. This was done to counteract the
problem of non-identifiability of the parameters of the models. Robust predictions that do not
depend on the exact parametrisation of the model, but only on the fact that the model can re-
produce all known experimental data, still allow a meaningful interpretation. A difficulty for
parameter fitting was the complexity of the experimentally observed behaviour of the JAK/-
STAT pathway at multiple length and time scales. The amount of data available was limited
and comprised of multiple dimensions (some in arbitrary units, while others in relative mea-
surements). Moreover, the quantification of IFN-α is reported in international units (IU) which
introduces high variability in the calculation of the pipetted dose due to the high magnitude
of differences in the specific activity of batches of IFN-α in each experiment.
The PBPK model and the pharmacodynamic (kinetic) model were coupled to establish the
PBPK/PD QSP model. The results from chapter 3, subsection 3.5.3 depict relative differences
in in vitro vs. in vivo response of IRF9 mRNAc to IFN-α. Furthermore, the analysis reflects
2Department of Gene Regulation and Differentiation, HZI – Helmholtz Centre for Infection Research, Inhoffen-
str. 7, 38124, Braunschweig, Germany.
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an important point of the non-linearity in the signal propagation, where an 18-fold difference
in dose commonly used in in vitro assays relative to the i.v. injected IFN-α only induced a
4-fold difference in response. This is of relevance, as in vitro cell cultures are subjected to a
significantly different environment compared to that of the organ in the organism. Hence, the
implemented PBPK/PD QSP workflow is an important step to translate such in vitro calibrated
hepatocyte models by the approach of in vitro to in vivo extrapolation (IVIVE), into a clinically
relevant model. Finally, the clearance of IFN-α in the liver of the PBPK/PD model was strongly
governed by the variability in the expression of the receptors in the liver.
Mice are often used as animal models of various diseases which are treated with IFN-α.
However, performing these experiments is time consuming, expensive and a matter of ethical
concerns. In addition, potential differences in the physiological reaction to the drugs and side
effects can be missed due to differences between humans and mice. Thus, virtual computa-
tional models of the animal contribute to establishment of 3R approaches such as model-based
experimental planning as well as targeted and comprehensive analyses of experimental data.
In chapter 4, the computational model was expanded by using the PBPK/PD QSP approach
to establish and predict murine and human IFN-α concentrations in mouse for the preclinical
phase of the drug. The intention was to be able to establish such a complementary mouse
model for future in-silico-based predictions of IFN-α efficacy and to be able to extrapolate
cross-species differences in the JAK/STAT signalling response to IFN-α. Such a model might
help reduce animal testing by implementing the analysis of the same for proper designing,
conducting and reporting of experiments. In this chapter, the development of a mouse PBPK
model was based on in vitro data (e.g., plasma protein binding, signalling pathway experi-
ments) and physio-chemical properties of IFN-α reported in the literature [39], [157]–[160]. All
of human IFN-α subtypes and several mouse IFN-α subtypes are commercially available, but
there is little knowledge as to which one works best for cross-species extrapolation. Thus, the
established model supports quantification of those differences, preliminary work of which is
found in chapter 4, subsection 4.4.4.
Lastly, one of the major benefits of using the PBPK/PD approach is that the underlying
structure of PBPK/PD models applied in this thesis allows the simulation of reliable PK pro-
files in several compartments (organs) within the human and mouse body (e.g., the intracel-
lular space of the liver). In particular, PBPK modelling allows us to predict in vivo tissue con-
centrations from easily accessible samples in venous blood through the calculation of organ-
plasma partitioning. This feature of the model contributes to the understanding of tissue dis-
tribution by using a virtual whole-body model of the organisms which was achieved in the
chapters 3 & 4. The presented PBPK/PD QSP approach that utilises PBPK modelling is, thus,
applicable for extrapolating IFN-α concentrations at diverse sites of action besides the liver,
such as the heart or the kidney, assuming though, an inclusion of adequate signalling model is
mostly responsible for the respective mode of action. Furthermore, the analysis of tissue dis-
tribution is also useful in developing optimal strategies for the injection of therapeutic agents,
such that adequate concentrations would reach the site of action.
While establishing the pharmacodynamic (kinetic) models for chapters 3 & 4, variability in
the intracellular response was observed when simulating varying amounts of receptors. This is
certainly partially due to the small numbers of receptors reported to be present in both human
and mouse hepatoma cell lines (only around 1000 receptors/cell) [90], [277], [278]. Further-
more, important aspects of the response generated by the signal transduction are governed by
the stochasticity of the small numbers of signalling molecules present in a cell. This stochas-
ticity adds to the intrinsic noise of the system. Therefore, to explore the intra- and inter-cell
variability in the response of the JAK/STAT signalling pathway to IFN-α stimuli, a stochastic
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model was established. In the in vitro experiments done on mouse primary hepatocytes, the
observed dose response of Mx2 to the IFN-α does not necessarily account for individual cell
dynamics of high expression of Mx2. There could also be a possibility of all-or-none response
and only a fraction of cells could respond to IFN-α stimuli at different doses. These observa-
tions initiated the final chapter of this thesis- chapter 5. This work commenced a collaboration
with the group of Dr. Marco Binder at DKFZ, Heidelberg during which high-throughput tem-
poral (32 hours) data of MxA and IFIT1 after IFN-α induction in Huh 7.5 cells was obtained
at single-cell resolution. The mechanistically detailed stochastic model which followed was
calibrated to the deterministic time course data from Maiwald et al. [116] and the single cell
FACS data of MxA and IFIT1 from the experiments. Thus, the developed stochastic model
differed from previous efforts of other mechanistic stochastic models [125] by not following
ISGs which have enzymatic control on the JAK/STAT pathway itself (like IRF1, IRF3, IRF7
and IRF9, which also act as transcriptional factors for the trigger of antiviral response), which
would lead to an all-or-none response, but by following ISGs which show a graded response.
In addition, extrinsic noise was added to the model to account for the variability in the initial
copy numbers of the molecules in the pathway. The established model helped to explain the
robustness of the JAK/STAT signalling pathway in allowing a heterogeneous population of
cells to be able to have long and stable temporal responses of certain antiviral genes. Higher
organisms with intracellular signalling may benefit from such a endurance in order to sustain
signal propagation and shape the antiviral response in cell populations. The results obtained
in this chapter are also consistent with previous reports for MxA [83]. In this preliminary ver-
sion, however, one important mechanistic detail that is not yet covered in the stochastic model
is the receptor recycling, which implies that the model can only describe a single stimulation
without reactivation of unbound receptors. This will be included in the model in order to ad-
dress the impact of noise and the control of receptor variability on the non-linear propagation
of the JAK/STAT pathway. One final point is that in this work we have implemented discrete
stochastic methods [123] and have not taken the spatial processes in account.
Despite the improvement in computing time that our new fitting algorithms offer, there
is still room for improvements in this field. The stochastic simulation algorithms (SSA) and
methods are subjects of ongoing work as they are computationally demanding. One way to
make significant improvements would be to implement parallel computing to reduce the time
in solving models implementing SSA. There are many multi-scale models in the deterministic
domain of systems biology. However, as important such models are for real applications, there
is a high potential for the application of SSA in solving multi-scale biological problems which
include processes on different time-scales.
Apart from scientific challenges, a significant operational barrier in this work was the lack
of well-established model exchange standards for the models between the mark up language
SBML (systems biology mark up language) and PKML (pharmacokinetic mark up language).
However, the work-flow implemented in this thesis is universal for any protein molecule, mak-
ing this approach applicable for other drugs beyond IFN-α.
6.2 Concluding remarks
The motivation to integrate systems biology models and principles and the field of pharma-
cology is to not only to achieve a holistic understanding across different levels of biological
organisation. This would help to not only quantitatively understand the biological phenom-
ena in question, but also to establish a high success rate in bench to bedside translations of
drug development programs. In conclusion, the quantitative systems pharmacology approach
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aims to bridge the above-mentioned gaps such that it can support the prediction of the in vivo
drug-effects in humans in a quantitative manner by recycling the data produced from in vivo
animal studies and high-throughput in vitro assays. Also, there is a need of trained individuals
in both biological and quantitative sciences who can effectively bring this knowledge together
in order to develop such models, as well as the lack of computational tools that can integrate
diverse sets of data required to establish the QSP models. In spite of these hurdles, the work
described in this thesis is a sincere attempt to show the benefits of PBPK/PD QSP approaches
that can help to characterise dose-response relationships of translatable biomarkers in order to
determine the efficacy of the therapeutic compound.
Despite the increasing use of modelling approaches to support quantitative research in biol-
ogy, there is still a long way to go until the QSP approach would finally be able to significantly
increase the therapeutic succces rates, as such an approach is only as good as the data which
has been used for its establishment. In this regard, I hope this work describes some of the
challenges and the analyses one can do by implementing the sparse data available on IFN-α to
establish meaningful insights using the PBPK/PD QSP approach. I hope that in the near future
such an approach emerges as a corner-stone of quantitative drug discovery and development.
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A.1 Experimental data and conversions
A.1.1 Plasma pharmacokinetic data
Unit conversion IFN-α or mu-IFN-α 4 doses were calculated by using the molecular weight
of IFN-α as 19500 g/mol [165]. The doses were calculated as described in Chapter 2, 2.1 and
2.2. The specific activity was provided for human dataset from Wills et al. (1984) [50] as 1.7 X
10 8 U/mg. The resulting dose was 0.22 mg. For the validation human IFN-α datasets from
Shah et al. (1984) [48] and Radwanski et al. (1987) [49] the specific activity was used from
Radwanski et al. (1987) as 2.2 X 10 8 U/mg. The doses from Shah et al. (1984) [48] were: 30U
as a dose of 0.136 mg and 60U as a dose of 0.27 mg. The dose in mg for Radwanski et al. (1987)
[49] was 0.045 mg. The plasma concentration time profile of IFN-α PK used for fitting is further
described in Table A.1.1.
For the mu-IFN-α 4 no specific activity was provided in Bohoslawec et al. [39], hence the
assumption of the specific activity of 1.9 X 10 7 U/mg was made using the average of the
specific activity she came across during the work. Hence, the total dose was 0.045 mg or 2.35
nmol per animal. In the case of dataset from Dr. Mario Ko¨ster; the dose was 5000U with a
specific activity of 1.4 X 10 8 U/mg; hence to total dose/mouse was calculated to be 3.57 X 10
-5 mg or 1.83 pmol. The details of the parameters and the doses are recapped in Table C.1. The
final values of the concentration/time in plasma for each daaset are further described in
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TABLE A.1: This table contains the pharmacokinetic data of IFN-α published by
Wills et al. [50] that has been digitised and used for setting up the pharmacoki-
netic model.
Time [hours] Conc. [µmol/ml]
0.166 0.000194
0.33 0.000368
0.66 0.000686
0.83 0.0005
1 0.000379
1.5 0.000213
2 0.000133
3 6.9494E-05
4 1.7361E-05
5 1.2515E-05
6 8.7453E-06
7 6.6061E-06
8 5.7416E-06
12 3.487E-06
24 1.0668E-06
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TABLE A.2: This table contains the calculation for the pharmacokinetic data of
mu-IFN-α published by Pulverer et al [157], kindly provided by Mario Koester
, from Bohoslawec et al.[39],from Rosztoeczy et al.[158] and from Kiuchi et
al.[159]. The data from [39] and Rosztoeczy et al.[158] was used to fit the phar-
macokinetic model using PK-Sim. The data from Kiuchi et al.[159] was used to
validate the model.
Koester et al.
Time[hours] Cplasma IFN-α [pg/ml] Cplasma IFN-α[nmol/ml]
0.016 3047.152 0.000141
0.083 2258.690 0.0001049
0.166 1967.665 9.14173E-05
0.333 2042.735 9.4905E-05
Bohoslawec et al. (1986)
Time[hours] Serum Dose [%] Cplasma IFN-α[nmol/ml]
0.033 6.63 0.027436
0.083 3.97 0.016429
0.25 2.35 0.009725
0.5 1.2 0.004965
1 0.1 0.000413
3 0.01 4.13831E-05
Rosztoeczy et al. (1986)
Time [hours] Activity in plasma [U/ml] Cplasma IFN-α[nmol/ml]
0.19 13146.07 0.050896
1.44 65.40 0.000253
2.94 31.64 0.000122
5.82 20.34 7.87537E-05
11.36 6.10 2.3635E-05
Kiuchi et al. (1983)
Time[hours]
Serum dose [%]
Dataset 1
Cplasma IFN-α [nmol/ml]
Dataset 1
0.25 2.37 0.003685
0.5 0.71 0.001107
1 0.26 0.000405
2 0.10 0.000155
3 0.10 0.000168
Kiuchi et al. (1983)
Time[hours]
Serum dose [%]
Dataset 2
Cplasma IFN-α [nmol/ml]
Dataset 2
0.25 0.90 0.001397
0.5 0.57 0.000887
1 0.20 0.000313
2 0.03 6.01E-05
108 Appendix A. Appendix Chapter 2
A.1.2 Human hepatocyte dose response data
In the tables below, the experimental data provided by Bolen et al.[161] and digitised from Jilg
et al.
TABLE A.3: This table contains the dataset kindly provided by Steven H. Klein-
stein from Yale University. The data was normalised across different doses to be
comparable as it was fold change data.
hours 10U 100U 500U 2500U
0 0.016126431 0.016126431 0.016126431 0.016126431
1 0.016126431 0.025479761 0.016126431 0.043218836
4 0.107885825 0.524592808 0.220125786 0.816965006
6 0.149814546 0.592646347 0.278019674 1
12 0.197226254 0.421706176 0.232381874 0.466537655
24 0.130462829 0.277697146 0.173197871 0.36236091
A.1.3 Literature search
In the tables below, the information gathered from the literature and various databases for the
purpose of setting up the parameter or the parameter identification limits of the models for
each species.
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A.2 PBPK model parameterisation
TABLE A.4: This table contains the literature values of the pharmacokinetic pa-
rameters used in the PBPK human and mouse model. Wherever stated clearly
hu-IFN-α or mu-IFN-α the values were used for the respective model. The pa-
rameters which are not included under the respective species header were used
as values for both the models. The parameters were varied 50% for the parameter
estimation.
Parameter Literature Value Reference Unit
Lipophilicity (Log P) -0.366 [165] Log units
Fraction unbound (fu) 1 -
Solubility 100 [165] mg/ml (ref. pH is 7)
hu-IFN-α
Molecular Weight 19500 [165],
Drugbank (18.03.2014)
Accession number:
DB00034
g/mol
CLplasma (kidney) 2.7 [50][176][279][280] ml/min/kg
IFNAR1 concentration - - µmol/l
IFNAR2 concentration - - µmol/l
Koff IFNAR1 0.22 - 1/s
Koff IFNAR2 0.0077 [187][281] 1/s
KD IFNAR1 3.5 [282] nmol/l
KD IFNAR2 0.0077 [187][281] nmol/l
Kendocytosis - - 1/min
Kt IFNAR1 - - 1/min
Kt IFNAR2 - - 1/min
mu-IFN-α
Molecular Weight 21922 Uniprot (20.4.2017)
P01573
g/mol
IFNAR1 Concentration - - µmol/l
IFNAR2 Concentration - - µmol/l
CLplasma (Kidney) 10 -15.65 [39] ml/min/kg
Koff IFNAR1 1 [91] 1/s
Koff IFNAR2 0.015 [91][281] 1/s
KD IFNAR1 5 [91] µmol/l
KD IFNAR2 5 [91][281] nmol/l
Kendocytosis - - 1/min
Kt IFNAR1 - - 1/min
Kt IFNAR2 - - 1/min
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B.1 PBPK model parameterisation
TABLE B.1: This table contains the information about parameters used for ini-
tialising the individuals for PBPK model.
Biometrics
Species Human
Population European (ICPR, 2002)
Gender Male
Age 30 years
Weight 73 kg
Height 176 cm
BMI 23.57 kg/m2
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TABLE B.2: This table contains the literature values and the fitted values of the
pharmacokinetic parameters used in the PBPK human. The parameters were
varied 20% from the values reported in the literature for the parameter estima-
tion.
Parameter Fitted Value Literature Value Reference Unit
Lipophilicity (Log P) -0.366 [165] Log units
Fraction unbound (fu) 1
Solubility 100 [165] mg/ml (ref. pH is
7)
hu-IFN-α
Molecular weight 19500 [165],
Drugbank
(18.03.2014)
Accession num-
ber:
DB00034
g/mol
CLplasma (kidney) 3 2.7 [50][176][279][280] ml/min/kg
IFNAR1 concentration 0.26 - µmol/l
IFNAR2 concentration 0.5 - µmol/l
Koff IFNAR1 0.1 0.22 - 1/s
Koff IFNAR2 0.00022 0.0077 [187][281] 1/s
Keq IFNAR1 0.00077 0.0001-0.01 [187], [281], [282] l/nmol
Keq IFNAR2 1.5 0.002-0.1 [187][281] l/nmol
Kendocytosis 8.93226 - 1/min
Kt IFNAR1 0.02298 - - 1/min
Kt IFNAR2 0.074999 - - 1/min
TABLE B.3: The liver compartment is divided into the interstitial, cytoplasmic
and nuclear compartment. The volume of the interstitial and the cytoplasm is
borrowed from PK-sim organ values while the nuclear compartment was as-
signed the value 1:4 ratio of the cytoplasm as calculated from the experiments
done for Maiwald et al. [116] where the ratio of the nucleus to cytoplasm was
measured.
Volume in Litres
Compartment l
Interstitial 0.39
Cytoplasm 1.59
Nucleus 0.35
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TABLE B.4: The parameter values of the top 5 fits for the PBPK model of IFN-α
are listed. The values were well defined for many parameters and hence the first
top fit was evaluated further.
Parameter Name Unit Fit 1 Fit2 Fit3 Fit4 Fit5
K t IFNAR2 1/min 1.25E-03 1.25E-03 1.25E-03 1.25E-03 1.25E-03
K t IFNAR1 1/min 3.83E-04 7.71E-04 5.04E-04 9.99E-04 4.11E-04
R1 concentration µ mol/l 0.26 0.21 0.19 0.28 0.29
R2 concentration µ mol/l 0.5 0.5 0.5 0.5 0.5
Complex Koff 1/min 2.21E-04 1.04E-06 3.82E-05 1.00E-03 1.14E-04
IFNAR2 binding Keq l/nmol 1.00E-01 1.00E-01 1.00E-01 1.00E-01 9.81E-03
k endocytosis 1/min 8.93E-06 1.49E-06 2.41E-06 3.27E-05 4.62E-05
Complex Keq l/nmol 7.76E-04 3.72E-04 5.55E-04 2.56E-05 6.59E-04
IFNAR2 binding Koff 1/min 1.50E+00 1.50E+00 1.50E+00 1.50E+00 1.50E+00
Plasma Clearance ml/ min/mg 3.00E-03 3.00E-03 3.00E-03 3.00E-03 3.00E-03
0 5 10 15 20
10 -7
10 -6
10 -5
10 -4
10 -3
 data Fit 1 Fit 2
Fit 3 Fit 4 Fit 5
Time [hours]
µm
ol
/l
FIGURE B.1: The top 5 models have the RMSE of 0.7 and all the fits were equally
good. The plot represents the top 5 models simulating the IFN-α distribution in
the venous blood plasma (lines) vs the dataset of Wills et al. [50] (dots).
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B.2 Human hepatocyte model parameterisation
B.2.1 Literature search for the hepatocyte model
TABLE B.5: Values of kinetic parameters found in literature
Molecule Param Value References
ISGF3c kD [10nM(STAT2), 5µM(STAT1)] [283]
IFN-IFNR2 kD [2.2nM]* [284][285]
IFN-IFNR1 kD [2000nM] [284] [285]
STAT1-STAT2 kD [< 10nM, 5.5mM(STAT2mutant)] [286]
SOCS ** ki [1.5± 0.7µM(ForJAK2), 1.2± 0.3µM(ForATP)] [196]
*IFNAR2 binds IFN-α2 with an equilibrium dissociation constant of around 5 nM and a
complex lifetime of around 100 s, whereas the affinity toward IFNAR1 is three orders of
magnitude lower, and the complex dissociates about 100-fold faster.
** Non-competitive Inhibition
For COPASI please calculate keq = 1/kD
Publication Cells Dose  (U/ml) Response Control Time of stimulus 
Unit 
conversion 
Schlaak et al.
(2002) 
Fibrosar
coma 
cells 
10 100 1000 IRF9 GAPDH Treated for 8 hours 
Roche 
Molecular 
Biochemicals. 
Wolber et al.
(2002) HepG2 5 50 500 5000 IRF1 GAPDH 
Treated for 24 
hours Sigma. 
Jilg et al.
(2014) 
Huh7.5 30 mRNA 
STAT1, Mx1, 
IRF9 
GAPDH Treated for 0, 4, 8 and 24 hours 
Peginterferon 
alpha 2b from 
Schering. 
PHH 15 
Maiwald et al.
(2010) Huh 7.5 500 1000  
pSTAT  and 
pJAK 
Cells left 
untreated 
 
Treated for 0, 1, 
2, 3, 4, 8, 12 or 
24 hours 
PBL Labs
human 
leukocyte 
interferon. 
Bolen et al. 
(2014) 
PHH 500 
IRF9 and 
pSTAT1 
Cells left 
untreated 
Treated for 0.5, 
1, 2, 4, 6, 12 
and 24 hours 
Recombinant 
human 
interferon alpha 
2a. Huh 7 10 100 500 2500 
FIGURE B.2: The dose-response of IRF9 in human hepatoma cell lines or PHH
or Fibrosarcoma cells treatmented with IFN-α2 upto 24 hours found in various
publications [20], [22], [116], [161], [162].
B.2. Human hepatocyte model parameterisation 115
FIGURE B.3: This information is the evidence for TFBS marks. The TFBS for
IRF2, IRF1 and ISRE are found at the same position in the DNA of IRF9 gene in
HeLa and HepG2 cell-line. Hence this shows that IRF1/IRF2 or IRF7 (evidence
that this binds to ISRE) and ISGF3 complex (STAT1-STAT2-IRF9 and evidence
that this binds to ISRE) and STAT1/IRF9 (evidence that this binds to ISRE) can
all bind at these sites and induce transcription of IRF9.
FIGURE B.4: The sabioscience database reported chip experiments of IRF9 gene
showing the binding of ISGF3 at two sites- one on positive strand and one on
negative strand. Also, note that the most relevant transcription factor of IRF9
regulation is marked in blue. Various promoters of IRF1 are seen; one of which
overlaps with ISRE element.
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B.2.2 Hepatocyte model overview and parameterisation
IFN-α
R2
Ø R1 IFNAR2
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Activated Receptor Complex
Rec2
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FIGURE B.5: The architectural difference of adapted hepatocyte model to the
Maiwald et al. model [116] is described here. In the adapted hepatocyte model
the receptor concentrations and the kinetics are implemented from the PK model.
All parameters, except the receptor kinetics were fitted in the adapted hepatocyte
model.
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FIGURE B.6: The detailed count distribution of each parameter is plotted as a
histogram. The x-axis is the distribution of the parameter value from its lowest
to largest value. On the y-axis is the count distribution of that parameter found
in 1000 models.
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FIGURE B.7: The detailed count distribution of each parameter is plotted as a
histogram. The x-axis is the distribution of the parameter value from its least to
largest value. On the y-axis is the count distribution of that parameter found in
1000 models.
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FIGURE B.8: The top ten fits obtained from the fitting process for 20 datasets is
depicted. In the figure the time course profile for A) pStat cytoplasm in response
to 500 U B) pSTAT nucleus in response to 500 U C) pSTAT cytoplasm with overex-
pression of IRF9 protein D) pSTAT nucleus with overexpression of IRF9 protein
E) pStat cytoplasm in response to 500 U (second replicate) F) pSTAT nucleus in
response to 500U (second replicate) G) IRF9 mRNAc in response to 10U from
Bolen et al. [161] H) IRF9 mRNAc in response to 100U from Bolen et al. [161]
I) pSTAT total in nucleus in response to 500 U J) pSTAT total in cytoplasm in re-
sponse to 500U K) pSTAT total in nucleus in response to 1000 U L) pSTAT total in
cytoplasm in response to 1000U M) pJak in response to 500U (Activated receptor
complex)) N) pSTAT total in nucleus O) IRF9 protein total in nucleus P) mrna
socs in response to 500U Q) mrna socs with overexpression of IRF9 protein R)
pSTAT total in nucleus in response to 500U S) SOCS protein with overexpression
of IRF9 protein T) SOCS protein in response to 500U.
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TABLE B.6: The below table represents all the kinetic parameters obtained for the model ensemble. The receptor values were pre-
served from the PBPK model and the value of IFN efflux was also fitted and kept constant. These values can be found in B.7. Most of
the values are varied +- 50% or 75% as those used in Maiwald et al [116] or the literature values found for some parameters as stated
in D.1 and B.5.
Nr. Parameter fit 1 fit 2 fit 3 fit 4 fit 5 fit 6 fit 7 fit 8 fit 9 fit 10 Units
R4 & M3
Kms 6.13131 0.00180 1.48411e-05 0.00362991 0.0530483 9.56746e-07 0.122204 0.000124324 0.00012947 0.0026974 nmol/l
V 2.61285 1.90736 0.0424023 3.4103 8.79938 0.00792312 6.80457 0.227457 2.98461 9.97814 nmol/(l*s)
Ka 200 410.13 219.203 487.793 219.325 1383.79 291.406 200.873 879.986 3536.95 nmol/l
R5 & M6 k1 0.0035 0.0038 0.00212197 0.0020049 0.0440604 0.00118631 0.110752 0.112401 0.0683156 0.295528 l/(nmol*s)
R6 & M7 k1 0.000393 0.011137 0.00614481 0.000118306 0.116272 0.00733387 0.297544 0.301031 0.00480034 0.000385657 l/(nmol*s)
R7 & M8 k1 10 14.93 15 10 2.81244 2.90985 9.99396 9.91478 10 10 l/(nmol*s)
R8 & M9 k1 0.00697 0.00010 0.000214199 0.000100974 0.000248786 0.000248112 0.00095402 1e-06 1e-06 1.02804e-05 1/s
R9 & M10 k1 3.54e-05 3.66e-05 3.72397e-05 4.29623e-05 3.42033e-05 4.20262e-05 4.09684e-05 4.14782e-05 4.34948e-05 4.29233e-05 1/s
R10 & M11
k 5.879e-06 0.00656 0.145302 3.02119e-05 0.00329146 0.0826057 0.000524502 9.97918 4.77106 0.162675 nmol/(l*s)
Ka 0.333955 0.379743 0.150564 5.56749 9.75684 0.488633 7.22666 0.504096 0.3157 7.11777 nmol/l
R11 & M12 k1 1.17183e-05 1.47614e-05 1.48847e-05 4.4256e-05 1.41109e-05 4.45479e-05 4.3915e-05 4.29066e-05 4.3282e-05 4.35455e-05 1/s
R12 & M13
irf9deg 1e-07 0.0007188 0.000577945 1e-07 0.000511354 0.000399455 1e-06 0.10909 0.297425 0.00792213 1/s
k const 4.5e-06 0.032350 0.02600752002 4.5e-06 0.02301094365 0.01797546619 4.5e-05 4.90904 13.384125 0.35649 nmol/(l*s)
k act 10 2.113 0.356829 6.20201 8.15692 0.0548374 9.99988 0.125117 0.445746 10 1/s
R13 & M14
k act 5.70548 1.02536 4.60042 0.980916 1.81244 0.98304 1.00833 3.83025 4.68123 4.25086 1/s
k deg 0.16196 0.112138 0.150743 2.49471 2.17238 0.0466958 0.905009 0.0981067 0.495813 0.165271 1/s
R14 & M15
k1 0.0001 1.03093 4.33098 0.000169673 0.0109568 3.9328 0.000190079 9.99976 0.0697624 0.172737 l/s
keq 0.00697504 0.000145781 0.000174285 0.0182716 0.000110169 0.0001 0.0001 0.0001 0.00394036 3.91431 -
R15 & M16
k1 2.20533e-07 1e-06 1e-06 1e-05 1e-06 1e-05 1e-05 1e-05 1e-05 1e-05 l/s
keq 0.00197389 0.00875874 0.00887611 0.0726266 0.0085101 0.0747027 0.070818 0.0711071 0.0701783 0.0797429 -
R16 & M17
k1 9.92815e-07 0.000266464 0.00135527 9.75714e-07 0.00141323 0.006401 9.96322 0.231379 0.123091 0.000516299 l/s
keq 0.0297375 2.06451 3.71093 0.0289452 4.04655 4.24893 3.09838 9.41435 8.06671 1.8218 -
R17 & M18 k1 0.00774342 0.0355024 0.0174468 0.0041382 0.166535 0.00964032 0.813382 0.82559 0.505973 2.14223 l/s
R18 & M19
k1 0.123072 9.7025 6.42557e-06 1e-05 0.545132 0.0458358 9.98028 0.0089197 0.22289 0.0180208 l/(nmol*s)
keq 2.91162e-05 7.949e-06 5.86288 0.00141925 9.67627 0.000239805 9.9993 0.0163734 0.0437206 1.20463 l/nmol
R19 & M20 k1 0.10365 0.659215 4.04029 0.00978293 0.647071 0.0702393 1.98259 2.76704 1.27384 7.71511 1/s
R20 & M21 k1 1e-07 0.000718893 0.000577945 1e-07 0.000511354 0.000399455 1e-06 0.10909 0.297425 0.00792213 1/s
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TABLE B.7: The kinetic parameters whose values were fixed for the model en-
semble and were borrowed from the PBPK model.
Nr. Parameter Value Unit
R1 k1 0.0213795 1/s
R2
k1 0.1 l/(nmol*s)
keq 1.5 l/nmol
R3
k1 0.00022 l/(nmol*s)
keq 0.00077 l/nmol
B.3 Human PBPK/PD model establishment
B.3.1 Establishment of the PBPK/PD model in MoBi
To merge the models, the PK model was saved in pkml format and the cellular model the base
project file to work with. The integration of the models was executed manually in MoBi. The
heptocyte model was inserted in the liver compartment of the PBPK model and the coupling
was established for the intravenous dose of IFN-α simulated from the event of application in
MoBi building block. The cellular containers were structured in a way to match the PK-Sim
format in the way:
• Organism (logical)
• Liver (logical)
• Pericentral (logical) (New PK-Sim Model with zones needed to be taken into account)
• Intracellular (physical, tagged with cytoplasm)
• Nucleus (physical, tagged with nucleus)
After that the existing Molecules Start Values and the Parameter Start Values were updated by
adding liver and pericentral for all paths. Once the cellular model is following the structure
of PK-Sim. The spatial structure from PK model was imported and the nuclear compartment
was added (using add container and a saved cellular model spatial structure) and connection
to the existing Intracellular compartment. Next, the cellular model parameters were added
from cytoplasm to Intracellular compartment of PK model (using add Parameter and a saved
cellular model spatial structure). The molecules were merged from PK model to cellular model
molecules and whenever there was a conflict, new molecules were created for the same. The
molecules that were a part of the passive diffusion (like IRF9c, ISGF-3c, STAT1c and STAT2c
) were added to PK model molecules by loading from template provided by Mobi as cellu-
lar model. The values for fraction unbound, molecular weight, lipophilicity and solubility
were set at Reference point. The Simulation settings were set to similar start time, end time
and resolution as that from COPASI. The transport reactions were merged in the Passive trans-
ports building block from PK model to cellular model. Whenever they had conflict, they were
implemented manually. For the molecules like STAT1, IRF9, ISGF-3c, STAT1c and STAT2c
the PassiveDiffusion Pl2Int & PassiveDiffusion Int2Cell were added as they were excluded
molecules. Next, the reactions building block of PK model was merged with cellular model.
A new Molecule Start Value (MSV) block was created using the updated spatial structure and
the merged molecules and all the molecules were set to not present. This MSV was saved as
pkml and then merged with cellular model MSV. For this building block, on conflict the ex-
isting objects were chosen to be kept. This combined MSV was merged with an empty MSV.
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The merged MSV was opened and the following was taken care of for the molecules IRF9c,
ISGF-3c, STAT1 and STAT2 ; set up of is present = true in:
• Liver—Pericentral—Interstitial
• Liver—Pericentral—Plasma
• Liver—Periportal—Interstitial
• Liver—Periportal—Plasma
• Liver—Periportal—Intracellular
Finally, the Parameter Start Values (PSV) of PK model were merged with cellular model. The
final PBPK/PD model was ready and could be created by Create simulation in MoBi.
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FIGURE B.9: The model ensemble results w.r.t. to the readout, IRF9 mRNAc and
the effect of the PD on the IFN-α PK in venous blood is plotted here. It has to be
noted that the absolute differences for IRF9 mRNAc are huge. This is because we
do not have calibrated absolute measurements for IRF9 mRNAc, therefore, the
model ensemble is not able to predict and estimate the same. However, we can
work with the relative changes here and hence in the work, everything is dealt
with relative changes and normalised for the same. The dose normalised time
course of IRF9 mRNAc in A) in vivo PBPK/PD model and B) in vitro Hepatocyte
model is plotted. In C) the result of the model ensemble PD integration (with the
feedback SOCS to the receptors) on the IFN-α PK in venous blood for the in vivo
PBPK/PD model is plotted.
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IRF9 mRNAc Tmax
fit no. PBPK/PD  Liver Hepatocyte
1 3.034 8.93
2 2.85 8.68
3 2.83 8.71
4 2.26 7.21
5 2.84 8.58
6 2.2 7.41
7 2.21 7.34
8 2.23 7.61
9 2.22 7.62
10 2.23 7.43
FIGURE B.10: IRF9 mRNAc Tmax: In this table one sees the difference in time
scale of achieving the maximum concentrations in the top ten models for PBP-
K/PD model in the liver and in the hepatocyte (in vitro) conditions.
1 2 3 4 5 6 7 8 9 10
0
0.2
0.4
0.6
0.8
1 2 3 4 5 6 7 8 9 10
0
0.5
1
1.5
2
2.5 IRF9 mRNAc Cmax Act Rec Complex Cmax 
Fo
ld
 d
iff
er
en
ce
 [R
at
io
]
Models
fit 1 fit 2 fit 3 fit 4 fit 5 fit 6 fit 7 fit 8 fit 9 fit 10
A) B)
FIGURE B.11: Cmax of response for the model ensemble for identical doses in
PBPK/PD model vs. hepatocyte model: Relative fold difference calculated by
simulating the in vivo dose (0.7 nmol/l) at the liver from the dose of 36 U injected)
of IFN-α for PBPK/PD and in vitro model. The model ensemble relative fold
difference (bar for each model) in the Cmax for A) Activated receptor complex
and B) IRF9 mRNAc.
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C.1 PBPK model parameterisation
C.1.1 Literature values for the mouse PBPK model
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TABLE C.1: Pharmacokinetic data of mu-IFN-α published by different groups.
The data was used to fit and validate the pharmacokinetic model using PK-Sim.
Parameter M. Ko¨ster data Bohoslawec et al. (1986) Rosztoeczy et al. (1986) Kiuchi et al. (1983)
dose (IU per animal) 5000 870000 42000 100000
dose per body weight (mg/kg) 0.00170068 0.21080 0.1666 0.1587
plasma volume (ml) 0.497 0.497 0.497 0.497
molecular weight (IFN in g/mol) 21524 21524.12 21524.12 21524.12
specific activity (IU/mg) 140000000 196523713.5 120000000 30000000
specific activity (IU/nmol) - 4230000 258289.44 645723.6
body weight (kg) 0.021 0.021 0.021 0.021
C.1. PBPK model parameterisation 125
TABLE C.2: Molecular weight of mu-IFN-α found in UniProt of Drugbank.
Molecular weight of mu-IFN-α
mu-IFN-α subtype
UniProt identifier
Drugbank identifier
MW (g/mol)
some calculated from protein sequence
IFN-α2 (mouse) P01573 21921.55
IFN-α4 (mouse) P07351 21524.12
IFN-αb (mouse) P01575 22126.77
Roferon IFN-α2 (recombinant, human) 19241.1
IFN-αb (human) variant P01574 22293.88
Natural IFN-α DB05258 20700 (range 19300-22100)
peg IFN-α-2a DB00008 60000
C.1.2 Simulation values for the mouse PBPK model
TABLE C.3: This table contains the information about parameters used for ini-
tialising the mouse individuals for PBPK model.
Biometrics
Species Mouse
Population Mouse
Gender Unknown
Weight 0.021 kg
TABLE C.4: The mouse liver compartment is divided into the interstitial, cyto-
plasmic and nuclear compartment. The volume of the interstitial and the cyto-
plasm is borrowed from PK-sim organ values while the nuclear compartment
was assigned the value 1:4 ratio of the cytoplasm as calculated from the experi-
ments done for Maiwald et al. [116] where the ratio of the nucleus to cytoplasm
was measured.
Volume in Litres
Compartment l
Interstitial 0.0002119
Cytoplasm 0.000768
Nucleus 0.000171
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TABLE C.5: This table contains the literature values and the fitted values of the
pharmacokinetic parameters used in the PBPK human. The parameters were
varied 20% for the parameter estimation.
Parameter Fitted Value Literature Value Reference Unit
Lipophilicity (Log P) -0.366 [165] Log units
Fraction unbound (fu) 1
Solubility 100 [165] mg/ml (ref. pH is
7)
mu-IFN-α
Molecular weight 19500 21922 Uniprot
(20.4.2017)
P01573
g/mol
IFNAR1 concentration 0.26 - µmol/l
IFNAR2 concentration 0.5 - µmol/l
CLplasma (kidney) 9.26 10 -15.65 [39] ml/min/kg
Koff IFNAR1 1E-03 1 [91] 1/s
Koff IFNAR2 0.03 0.015 [91], [281] 1/s
KD IFNAR1 1.01E-05 5 [91] µmol/l
KD IFNAR2 3 0.002-0.1 [91], [281] nmol/l
Kendocytosis 1.00E-04 - 1/min
Kt IFNAR1 6.66E-09 - - 1/min
Kt IFNAR2 1.72E-06 - - 1/min
TABLE C.6: The parameter values of the top 5 fits for the PBPK model of mouse
IFN-α are listed.
Parameter Name Unit Fit 1 Fit2 Fit3 Fit4 Fit5
K t IFNAR2 1/min 1.72E-06 3.13E-06 2.74E-06 2.10E-07 1.98E-07
K t IFNAR1 1/min 6.66E-09 1.71E-09 2.36E-08 2.29E-07 8.51E-08
R1 concentration pmol/ml 0.17 0.02 0.02 0.23 0.04
R2 concentration pmol/ml 0.46 0.6 0.37 0.59 0.53
Complex Koff 1/min 1E-03 1.74E-06 5.74E-06 3.47E-06 1.14E-04
Complex binding KD µ mol/l 1.01E-05 8.4E-03 6.1E-03 6.62E-03 2.28E-07
k endocytosis 1/ min 1.00E-04 1.00E-04 1.27 9.3E-03 4.62E-05
IFNAR2 binding Koff 1/s 0.03 0.03 0.05 0.05 6.59E-04
IFNAR2 binding KD nmol/l 3 3 3 3 4.06
Plasma Clearance ml/min/kg 9.26 9.34 9.19 9.50 8.76
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FIGURE C.1: Semi-logarithmic plot of the simulations of fit 2 where the recep-
tor ratio were not realistic biologically. The model species concentrations in the
liver, receptor occupancy of R1 and R2 and murine IFN-α concentration in ve-
nous blood are plotted. The ratio of the receptor concentration for this fit was
30 : 1 when the observed ratio in the literature is 2 : 1 [90]. Therefore this fit was
not used for further evaluation. The y-axis show the concentration of the species
depicted in the title while the x-axis represents the time-course. The dataset in
the last plot is the dataset from Bohoslawec et al. [39] and is plotted as the orange
solid line.
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C.2 Hepatocyte model parameterisation
C.2.1 Literature values for the mouse hepatocyte model
TABLE C.7: This table contains the the sequence identities and the homology of
the proteins in the JAK/STAT pathway for the species human and mouse. In
BLASTP the Query was human and the subject was mouse.
Name Species UniProt ID Identities (%) Homology (%)
IFNA
Human IFNA2 P01563
57 75
Mouse IFNA4 P07351
IFNAR1
Human P17181
49 66
Mouse P33896
IFNAR2
Human P48551
47 63
Mouse O35664
JAK1
Human P23458
94 96
Mouse P52332
TYK2
Human P29597
80 86
Mouse Q9R117
STAT1
Human P42224
92 94
Mouse P42225
STAT2
Human P52630
73 82
Mouse Q9WVL2
IRF9
Human Q00978
70 79
Mouse Q61179
SOCS1
Human O15524
95 96
Mouse O35716
C.2.2 Mouse hepatocyte model parameterisation
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TABLE C.8: The below table represents parameterisations of the kinetic values obtained for the model ensemble. The receptor values
were preserved from the mouse PBPK model and the IFN efflux values have been maintained from the human hepatocyte model.
These values can be found in C.9. Most of the values were taken from the human hepatocyte model under the assumption that the
proteins in the cascade exhibit a high homology between mouse and humans.
Nr. Parameter fit 1 fit 2 fit 3 fit 4 fit 5 fit 6 fit 7 fit 8 fit 9 fit 10 Units
R4 & M3
Kms 6.13131 6.13131 6.13131 6.13131 6.13131 6.13131 6.13131 1.48411e-05 1.48411e-05 1.48411e-05 nmol/l
V 2.61285 2.61285 2.61285 2.61285 2.61285 2.61285 2.61285 0.0424023 0.0424023 0.0424023 nmol/(l*s)
Ka 200 200 200 200 200 200 200 219.203 219.203 219.203 nmol/l
R5 & M6 k1 0.0035 0.0035 0.0035 0.0035 0.0035 0.0035 0.0035 0.00212197 0.00212197 0.00212197 l/(nmol*s)
R6 & M7 k1 0.000393 0.000393 0.000393 0.000393 0.000393 0.000393 0.000393 0.00614481 0.00614481 0.00614481 l/(nmol*s)
R7 & M8 k1 10 10 10 10 10 10 10 15 15 15 l/(nmol*s)
R8 & M9 k1 0.00697 0.00697 0.00697 0.00697 0.00697 0.00697 0.00697 0.000214199 0.000214199 0.000214199 1/s
R9 & M10 k1 3.54e-05 3.54e-05 3.54e-05 3.54e-05 3.54e-05 3.54e-05 3.54e-05 3.72397e-05 3.72397e-05 3.72397e-05 1/s
R10 & M11
k 5.879e-06 5.879e-06 5.879e-06 5.879e-06 5.879e-06 5.879e-06 5.879e-06 nmol/(l*s)
Ka 0.333955 0.333955 0.150564 0.333955 0.333955 0.333955 0.333955 nmol/l
R11 & M12 k1 1.17183e-05 1.17183e-05 1.17183e-05 1.17183e-05 1.17183e-05 1.17183e-05 1.17183e-05 1/s
R12 & M13 k1 0.000124514 1e-06 2.42899e-05 1e-06 0.00381719 3.35844e-06 4.3915e-05 0.000128617 1.04454e-06 1e-06 1/s
R13 & M14 k1 8.95158e-06 0.000122594 0.000122763 0.000122986 8.67761e-06 8.25502e-06 4.3915e-05 0.000162536 7.10343e-05 7.09477e-05 1/s
R14 & M15
irf9deg 1e-07 1e-07 1e-07 1e-07 1e-07 1e-07 1e-07 0.000577 0.000577 0.000577 1/s
k const 4.5e-06 4.5e-06 4.5e-06 4.5e-06 4.5e-06 4.5e-06 4.5e-06 0.026 0.026 0.026 nmol/(l*s)
k act 10 10 10 10 10 10 10 0.356829 0.356829 0.356829 1/s
R15 & M16
k act 5.70548 5.70548 5.70548 5.70548 5.70548 5.70548 5.70548 4.60042 4.60042 4.60042 1/s
k deg 0.16196 0.16196 0.16196 0.16196 0.16196 0.16196 0.16196 0.150743 0.150743 0.150743 1/s
R16 & M17
k act 0.0039677 2.74342 0.00468499 0.0843807 1e-05 0.0145789 0.00767509 0.267533 2.40468 1/s
k deg 0.000122591 8.9514e-06 8.94144e-06 8.93296e-06 0.000129823 0.000144197 0.000139028 7.10296e-05 0.000162515 0.000162876 1/s
R17 & M18
k1 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.00209186 0.00209186 0.00209186 l/s
keq 0.00697504 0.00697504 0.00697504 0.00697504 0.00697504 0.00697504 0.00697504 0.000174285 0.000174285 0.000174285 -
R18 & M19
k1 2.20533e-07 2.20533e-07 2.20533e-07 2.20533e-07 2.20533e-07 2.20533e-07 2.20533e-07 4.83e-10 4.83e-10 4.83e-10 l/s
keq 0.00197389 0.00197389 0.00197389 0.00197389 0.00197389 0.00197389 0.070818 0.00887611 0.00887611 0.00887611 -
R19 & M20
k1 9.92815e-07 9.92815e-07 9.92815e-07 9.92815e-07 9.92815e-07 9.92815e-07 9.92815e-07 6.54595e-07 6.54595e-07 6.54595e-07 l/s
keq 0.0297375 0.0297375 0.0297375 0.0297375 0.0297375 0.0297375 0.0297375 3.71093 3.71093 3.71093 -
R20 & M21 k1 0.00774342 0.00774342 0.00774342 0.00774342 0.00774342 0.00774342 0.00774342 8.4268e-06 8.4268e-06 8.4268e-06 l/s
R21 & M22
k1 0.123072 0.123072 0.123072 0.123072 0.123072 0.123072 0.123072 6.42557e-06 6.42557e-06 6.42557e-06 l/(nmol*s)
keq 2.91162e-05 2.91162e-05 2.91162e-05 2.91162e-05 9.67627 2.91162e-05 2.91162e-05 5.86288 5.86288 5.86288 l/nmol
R22 & M23 k1 0.10365 0.10365 0.10365 0.10365 0.10365 0.10365 0.10365 4.04029 4.04029 4.04029 1/s
R23 & M24 k1 1e-07 1e-07 1e-07 1e-07 1e-07 1e-07 1e-07 0.000577 0.000577 0.000577 1/s
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TABLE C.9: The kinetic parameters whose values were fixed for the model en-
semble and were borrowed from the PBPK model.
Nr. Parameter Value Unit
R2
koff 0.001 1/s
kD 0.0100834 nmol/l
R3
koff 0.03 1/s
kD 3 nmol/l
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D.1 Literature search
TABLE D.1: Half life of the molecules found in literature.
Molecule Half-life (h) kd (min−1) References
mIRF9 [1, 10]* [1.16× 10−3, 1.16× 10−2] [287]
mSOCS [1, 10]* [1.16× 10−3, 1.16× 10−2] [287]
mMXA [1, 10]* [1.16× 10−3, 1.16× 10−2] [287]
IRF9 2 5.78× 10−3 [116]
SOCS1 [1.5, 3] [3.85× 10−3, 7.70× 10−3] [288], [289]
MXA 55* 2.1× 10−4 [261]
MXA+dGFP 4* 2.89× 10−3 [82]
STAT1 [16, 24] [3.1× 10−4, 4.81× 10−4] [288], [290]
STAT2 24 [3.1× 10−4, 4.81× 10−4] [290]
pSTAT1 2 5.78× 10−3 [290]
pSTAT2 2 5.78× 10−3 [290]
dimerSTAT 24** 4.81× 10−4 [290]
ISGF3 24** 4.81× 10−4 [290]
IFN [4, 10] [1.16× 10−3, 2.89× 10−3] [197], [198]
Inactive Receptor [1, 4] [1.25× 10−3, 5.02× 10−3] [291]
* Typical half life of human mRNAs [287].
** dimerSTAT and ISGF3 are reported to have large half-life.
Degradation rates were calculated as kd = ln(2)/τ, where τ is the species half-life.
D.1.1 Promoter analysis for MxA and IFIT1
MxA promoter sequence
TCATCAGTTAAGGCTGTTTTTACTTCTTTTGTGGATCTTCAGTTACTTTAGGCCATCTGGATGTATACCTGCAAGTCACAGGGGATGCGATGGCCTGGCCTGGGATG
CGATGGCCTGGCCTGACAACTATTACCTATGTTATGTTTATTATTTTAAGCTTTATTATTACTATTTTATTTATTTTATTTTATTTTCCTTCCACACACCCGTTTCCACC
CTGGAGAGGCCAGATGAGCCAGACTCCAGGGAGGCCTAGAAGTGGGCAAGGGGAAACGGGAAAGGAGGAAGATGGTATGGGTGTGCCTGGTTAGGGGTGGGA
GTGCTGGACGGAGTTCGGGACAAGAGGGGCTCTGCAGCCATTGGCACACAATGCCTGGGAGTCCCTGCTGGTGCTGGGATCATCCCAGTGAGCCCTGGGAGGGA
ACTGAAGACCCCCAATTACCAATGCATCTGTTTTCAAAACCGACGGGGGGAAGGACATGCCTAGGTTCAAGGATACGTGCAGGCTTGGATGACTCCGGGCCATT
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AGGGAGCCTCCGGAGCACCTTGATCCTCAGACGGGCCTGATGAAACGAGCATCTGATTCAGCAGGCCTGGGTTCGGGCCCGAGAACCTGCGTCTCCCGCGAGTT
CCCGCGAGGCAAGTGCTGCAGGTGCGGGGCCAGGAGCTAGGTTTCGTTTCTGCGCCCGGAGCCGCCCTCAGCACAGGGTCTGTGAGTTTCATTTCTTCGCGGCGC
GGGGCGGGGCTGGGCGCGGGGTGAAAGAGGCGAAGCGAGAGCGGA
IFIT1 promoter sequence
TTTTAGACGGAGTCTCGCTCTGTCACCAGACTGGAGTACAGTGGTGTGATCTCGGCTCACTGCAACCTCTGCCTCCCAGGTTCAAGCAATTCCCCTGCCTCAGCCT
CTCGAGTAGGTGGGACTACAGGTGCACACCACCACACCCAGCTAATTTTTTGTATTTTAGTAGAGAGGGGGTTTCACCATGTTGGCCACGATGGTCTCCATCTCCT
GACCTTGTCATCCGCCCACCTTGGCCTCCCAAAGTGCTGGGACTACAGGCATGAGCCACCGCACCCAGCCAAGAATCATTATTTTTAACTTGATGACTGAAAATA
ATAATAATAATAGTTACCACTTATTTGCATGCTTCTATGTGCCAGGTAGTTGCTAACTATTTAAACTCAAATTCCATGAACTGTAGTGGAGGTTGTACTGGAATTTG
ATTCAGAATGACAGTGTCCATGATGGAGCAATAGAGGGCTCTCTATTTCAAACCATACCTCCTTGCTTTTACCTCCTGCCTAAGTCATCAGGGGTTAGAAGGCTTT
CTAGGTATTGGTCTCTTTCCTTCATTCCTAAACCAGATTGGTTGCTTATTTCCGTCAAGCTGAAACCAAAAGTAAGCAACCAAAAAGCAACCAGCAACCAAAAGC
CTTGTTACTCAATTAATTAAGAGTAGATTTTTATATTTGATAGTAGGTTCCTTCTAAATATAGAAACTGAAAATAGAGCTATCTCCTTCAATTCTCCTTTTTCTGTGT
ATTCATCCAGAATCCAGCCACCAACTGCCACAATAGGCAGCAATGGACTGATGTTCTTTAGGGAGGACGTGAATCTCGTTCCAAATGCTGGCCAGTCATTGGGTT
TCTGCAGCACTAGAAACATCTATGGTTGCAGGTCTGCAGTTTATCTGTTTTAAAATAGAAACAAAGTTTCATTCCCCACCCCCCCCCGTCAGCAGGAATTCCGCTA
GCTTTAGTTTCACTTTCCCCTTTCGGTTTCCCTAGGTTTCCAACTT
D.2 Experimental data
The experimental data from flow cytometry was analysed using matlab funciton.
FIGURE D.1: Figure adapted from Aguilera et al. 2018[244] Single-cell data in
a population of Huh 7.5 cells expressing MxA when stimulated with different
doses of IFN-α. This was plotted using matlab function FCS data reader. The
distribution of the single-cell expression of MxA under different conditions is
plotted here(first column, control, without interferon stimulation), subsequent
columns represent the MxA expression after multiple IFN doses (from 10 to 1250
UI/mL of IFN-α).
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FIGURE D.2: Figure adapted from Aguilera et al. 2018[244] Single-cell data in
a population of Huh 7.5 cells expressing IFIT1 when stimulated with different
doses of IFN-α. This was plotted using matlab function FCS data reader. The
distribution of the single-cell expression of IFIT1 under different conditions is
plotted here(first column, control, without interferon stimulation), subsequent
columns represent the MxA expression after multiple IFN doses (from 10 to 1250
UI/mL of IFN-α).
FIGURE D.3: Figure adapted from Aguilera et al. 2018[244] The deterministic
average of the cell populations was calculated to plot the temporal dynamics of
the response of MxA from figure D.1 and IFIT1 from figure D.2 to IFN treatment.
The average values indicate that Tmax of IFIT1 is at 16 hours after IFN stimula-
tion, whereas the Tmax of MxA were obtained at 32 hours after IFN stimulation.
D.3 Stochastic model parameterisation
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TABLE D.2: System’s initial conditions (IC). Table adapted from Aguilera et al.
2018 [244]
Variable IC (Molecules/Cell) References
∗∗ IFN [5× 103 , 1× 104] Fitted
R2 1000 [116], [190], [198], [292]–[294]
RC 10 TS
R1 1000 TS
AR 10 TS
STAT1 1× 105 [115], [116], [295], [296]
STAT2 1× 104 [116], [295], [297]
SOCS 0 [113]
*dimerSTAT 100 [264]
IRF9 10 [116]
*ISGF3 100 TS
*pSTAT1 100 [264]
*pSTAT2 100 [264]
IR 0 TS
ir f 9 1 TS
socs 1 TS
isg56 1 TS
mxa 1 TS
mIRF9 10 TS
mSOCS 10 TS
mMXA 0 TS
mISG56 0 TS
MXA 0 TS
ISG56 0 TS
I ir f 9 0 TS
I socs 0 TS
I mxa 0 TS
I isg56 0 TS
* According to Chatterjee et al. [264] there is a very low phosphorylation of STAT proteins, for
that reason all forms and complex including phosphorylated STAT proteins are considered to
have basal initial concentrations. ** Values for the initial IFN concentration were estimated by
fitting the model to the experimental data. Obtaining that 500 U of IFN correspond to 10,000
IFN molecules and 250 U of IFN correspond to 5,000 molecules.
TABLE D.3: Scaling factors for the stochastic model
Scaling Factor Value
ϕ1 1.2× 10−3
ϕ2 1.17× 10−4
ϕ3 1.79× 10−4
ϕ4 0.1
ϕ5 0.05
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TABLE D.4: Parameter values for the JAK-STAT signalling pathway for the
stochastic model. Table adapted from Aguilera et al. 2018 [244]
Parameter Nominal Units References
k1 1.146× 10−5 Cell/(Molecules·min) Fitted
k2 1.136× 10−3 Cell/(Molecules·min) Fitted
k3 1.56× 10−5 Cell/(Molecules·min) Fitted
k4 1.96× 10−5 Cell/(Molecules·min) Fitted
k5 1× 10−4 Cell/(Molecules·min) Fitted
k6 1× 10−5 Cell/(Molecules·min) Fitted
k7 1.60× 10−3 Molecules/(Cell·min) Fitted
k8 3.15 Cell/min Fitted
k9 3.15 Cell/min Fitted
k10 1.12× 10−3 Molecules/(Cell·min) Fitted
k11 3.69 Cell/min Fitted
k12 1.11 Molecules/(Cell·min) Fitted
k13 5.06× 10−5 1/min Fitted
k14 1× 10−3 Molecules/(Cell·min) Fitted
k15 0.235 1/min Fitted
k16 0.0725 Molecules/(Cell·min) Fitted
k17 1.53× 10−5 1/min Fitted
‡k18 3.00 1/min [298]
‡k19 9.653× 10−2 1/min [298]
‡k20 2× 10−2 1/min [298]
‡k21 1.5× 10−3 1/min [298]
†k22 1.61 1/min [299]
†k23 0.1 1/min [299]
†k24 0.911 1/min [299]
†k25 27.09 1/min [299]
k26 5.02× 10−4 1/min [287]
k27 5.02× 10−3 1/min [287]
k28 1.7× 10−3 1/min [287]
k29 7.4× 10−3 1/min [287]
k30 6.08× 10−2 1/min TS
k31 3.34× 10−3 1/min [290]
k32 3.49× 10−4 1/min [116]
k33 1.6× 10−3 1/min [288], [289]
k34 2.70× 10−4 1/min [288], [290]
k35 2.09× 10−4 1/min [290]
k36 0.125 1/min [290]
k37 1.65× 10−5 1/min [290]
k38 1.05× 10−6 1/min [261]
k39 2.09× 10−2 1/min [290]
k40 2× 10−3 1/min [197], [198]
† Translations rates assumed to be close to reported averages times ≈ 16
Proteins/mRNA/min [299] . ‡ Transcription rates was assumed to be close to reported
averages times to produce a mRNA ≈ 20 min [298]. IFNR dissociation constant of 10−9,10−11
[292]. RNA half-life was assumed close to the average value reported by [287] This study (TS).
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